PCT
WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :

(21) International Application Number: PCT/US96/02641
(43) International Publication Number: WO 96/28427
(22) International Filing Date: 8 March 1996 (08.03.96)
(41) International Publication Date: 19 September 1996 (19.09.96)
(30) Priority Data:
08/401,829 10 March 1995 (10.03.95) US
08/473,385 7 June 1995 (07.06.95) US
(34) Priority Data:
08/473,385 (CIP) Filed on 7 June 1995 (07.06.95)

(71) Applicant (for all designated States except US):
BERLEX LABORATORIES, INC. [US/US]; 15409 San Pablo avenue, Richmond, CA 94804-0099 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only):
BUCKMAN, Brad, O. [US/US]; 2042 Leimert Boulevard, Oakland, CA 94602 (US).
DAVEY, David, D. [US/US]; 3813 Painted Pony Road, El Sobrante, CA 94803 (US).

(79) Agents:


Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS

(57) Abstract
This invention is directed to benzamidine derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity. Accordingly, in one aspect, this invention provides compounds selected from the group consisting of formulae (I), (II), (III), (IV), (V), (VI), (VII), and (VIII), wherein: A is -CR<sup>1</sup>- or -N-, Z<sup>1</sup> and Z<sup>2</sup> are independently -O-, -NR<sup>2</sup>-, -S-, or -OCH<sub>2</sub>-; R<sup>1</sup> and R<sup>2</sup> are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, -NR<sup>2</sup>R<sup>3</sup>, -C(O)R<sup>4</sup>, -C(O)NR<sup>5</sup>R<sup>6</sup>, -C(O)NR<sup>5</sup>(CH<sub>2</sub>)<sub>n</sub>C(O)NR<sup>5</sup>R<sup>6</sup>, -N(R)<sup>7</sup>)(C=O)NR<sup>5</sup>R<sup>6</sup>, -N(R)<sup>7</sup>(C=O)OH, -N(R)<sup>7</sup>)(C=O)OR<sup>8</sup>, -N(R)<sup>7</sup>)(C=O)O(R<sup>8</sup>)R<sup>9</sup>, -N(R)<sup>7</sup>)(C=O)OR<sup>8</sup>, -N(R)<sup>7</sup>)(C=O)O(R<sup>8</sup>)R<sup>9</sup>, -R<sup>2</sup> is hydrogen; halo; alkyl; haloalkoxy; -OR<sup>10</sup>, -C(O)OR<sup>11</sup>, -C(O)N(R)<sup>12</sup>R<sup>13</sup>, -N(R)<sup>12</sup>R<sup>13</sup>, -C(O)NR<sup>14</sup>(CH<sub>2</sub>)<sub>m</sub>C(O)NR<sup>14</sup>(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup> (where m is 0 to 3); -N(R)<sup>15</sup>)(C=O)OH (where n is 1 to 3); -N(H)<sup>2</sup>)(C=O)OR<sup>16</sup>(CH<sub>2</sub>)<sub>m</sub>C(O)OR<sup>8</sup> (where n is 1 to 3); -O(CH<sub>2</sub>)<sub>p</sub>C(O)OR<sup>10</sup> (where p is 1 to 6); -NR<sup>17</sup>(CH<sub>2</sub>)<sub>m</sub>C(O)OR<sup>8</sup>(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>(where each n is independently 1 to 3); morpholin-4-yl; 3-tetrahydrofuranonyl, etc.; R<sup>4</sup> and R<sup>7</sup> are independently hydrogen, halo, alkyl, nitro, -OR<sup>10</sup>, -C(O)OR<sup>11</sup>, -C(O)N(R)<sup>12</sup>R<sup>13</sup>, -N(R)<sup>12</sup>R<sup>13</sup>, -N(H)<sup>2</sup>)(C=O)OR<sup>16</sup>, or -N(H)<sup>2</sup>)(C=O)OR<sup>16</sup>; -R<sup>3</sup> is -CH<sub>2</sub>H<sub>2</sub>COOH(NH)(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>(where m is 0 to 3), -CH<sub>2</sub>H<sub>2</sub>COOH(NH)(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>(where m is 0 to 3), -CH<sub>2</sub>H<sub>2</sub>COOH(NH)(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>(where m is 0 to 3), -CH<sub>2</sub>H<sub>2</sub>COOH(NH)(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>(where m is 0 to 3), -N(H)<sup>2</sup>)(C=O)OR<sup>16</sup>(1,2)-tetrahydropropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolizinyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl); each R<sup>8</sup> and R<sup>9</sup> is independently hydrogen alkyl, aryl, or aralkyl; R<sup>8</sup> is hydrogen, alkyl, aryl, aralkyl, 1-pyridyl, 4-morpholinyl, 4-piperazinyl, 4-(N-methyl)piperazinyl, or piperedin-1-yl; R<sup>12</sup> is hydrogen, alkyl or halo; and R<sup>13</sup> is alkyl, aryl or aralkyl; or a pharmaceutically acceptable salt thereof.
### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>AM</th>
<th>Armenia</th>
<th>GB</th>
<th>United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
<td>GE</td>
<td>Georgia</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GN</td>
<td>Guinea</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GR</td>
<td>Greece</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>IE</td>
<td>Ireland</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>IT</td>
<td>Italy</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>KE</td>
<td>Kenya</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>KG</td>
<td>Kyrgyzstan</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>KR</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KZ</td>
<td>Kazakhstan</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>LK</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LR</td>
<td>Liberia</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>LT</td>
<td>Lithuania</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>MV</td>
<td>Malawi</td>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>NE</td>
<td>Niger</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>NO</td>
<td>Norway</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>PL</td>
<td>Poland</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>RO</td>
<td>Romania</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>SD</td>
<td>Sudan</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>SG</td>
<td>Singapore</td>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td>SK</td>
<td>Slovakia</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>SZ</td>
<td>Swaziland</td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>TT</td>
<td>Trinidad and Tobago</td>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td>UA</td>
<td>Uganda</td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>UZ</td>
<td>Uzbekistan</td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
</tbody>
</table>
BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS

Field of the Invention

The present invention is directed to benzamidine derivatives and their pharmaceutically acceptable salts, which inhibit the enzyme, factor Xa, thereby being useful as anti-coagulants. It also relates to pharmaceutical compositions containing the derivatives or their pharmaceutically acceptable salts, and methods of their use.

BACKGROUND OF THE INVENTION

Factor Xa is a member of the trypsin-like serine protease class of enzymes. A one-to-one binding of factors Xa and Va with calcium ions and phospholipid forms the prothrombinase complex which converts prothrombin to thrombin. Thrombin, in turn, converts fibrinogen to fibrin which polymerizes to form insoluble fibrin.

In the coagulation cascade, the prothrombinase complex is the convergent point of the intrinsic (surface activated) and extrinsic (vessel injury-tissue factor) pathways (Biochemistry (1991), Vol. 30, p. 10363; and Cell (1988), Vol. 53, pp. 505-518). The model of the coagulation cascade has been refined further with the discovery of the mode of action of tissue factor pathway inhibitor (TFPI) (Seminars in Hematology (1992), Vol. 29, pp. 159-161). TFPI is a circulating multi-domain serine protease inhibitor with three Kunitz-like serpin domains which competes with factor Va for free factor Xa. Once formed, the binary complex of factor Xa and TFPI becomes a potent inhibitor of the factor VIIa and tissue factor complex.

Factor Xa can be activated by two distinct complexes, by tissue factor-VIIa complex on the "Xa burst" pathway and by the factor IXa-VIIa complex (TENase) of the "sustained Xa" pathway in the coagulation cascade. After vessel injury, the "Xa burst" pathway is activated via tissue factor (TF). Up regulation of the coagulation cascade occurs via increased factor Xa production via the "sustained Xa" pathway. Down regulation of the coagulation cascade occurs with the formation of the factor Xa-TFPI complex, which not only removes factor Xa but also inhibits further factor formation via the "Xa burst" pathway. Therefore, the coagulation cascade is naturally regulated by factor Xa.

The primary advantage of inhibiting factor Xa over thrombin in order to prevent coagulation is the focal role of factor Xa versus the multiple functions of thrombin. Thrombin not only catalyzes the conversion of fibrinogen to fibrin, factor VIII to VIIa, factor V to Va, and factor XI to Xla, but also activates platelets, is a monocyte chemotactic factor, and mitogen for lymphocytes and smooth muscle cells. Thrombin activates protein C, the in vivo anti-coagulant inactivator of factors Va and VIIIa, when bound to thrombomodulin. In circulation, thrombin is rapidly inactivated by antithrombin III (ATIII) and heparin cofactor II (HCII) in a reaction which is catalyzed by heparin or other proteoglycan-associated glycosaminoglycans, whereas thrombin in tissues is inactivated by the
protease, nexin. Thrombin carries out its multiple cellular activation functions through a unique “tethered ligand” thrombin receptor (Cell (1991), Vol. 64, p. 1057), which requires the same anionic binding site and active site used in fibrinogen binding and cleavage and by thrombomodulin binding and protein C activation. Thus, a diverse group of in vivo molecular targets compete to bind thrombin and the subsequent proteolytic events will have very different physiological consequences depending upon which cell type and which receptor, modulator, substrate or inhibitor binds thrombin.

Published data with the proteins antistasin and tick anti-coagulant peptide (TAP) demonstrate that factor Xa inhibitors are efficacious anti-coagulants (Thrombosis and Haemostasis (1992), Vol. 67, pp. 371-376; and Science (1990), Vol. 248, pp. 593-596).

The active site of factor Xa can be blocked by either a mechanism-based or a tight binding inhibitor (a tight binding inhibitor differs from a mechanism-based inhibitor by the lack of a covalent link between the enzyme and the inhibitor). Two types of mechanism-based inhibitors are known, reversible and irreversible, which are distinguished by ease of hydrolysis of the enzyme-inhibitor link (Thrombosis Res (1992), Vol. 67, pp. 221-231; and Trends Pharmacol. Sci. (1987), Vol. 8, pp. 303-307). A series of guanidino compounds are examples of tight-binding inhibitors (Thrombosis Res. (1980), Vol. 19, pp. 339-349). Arylsulfonyl-arginine-piperidinecarboxylic acid derivatives have also been shown to be tight-binding inhibitors of thrombin (Biochem. (1984), Vol. 23, pp. 85-90), as well as a series of arylimidine-containing compounds, including 3-amidinophenylaryl derivatives (Thrombosis Res. (1983), Vol. 29, pp. 635-642) and bis(amidino)benzyl cycloketones (Thrombosis Res. (1980), Vol. 17, pp. 545-548). However, these compounds demonstrate poor selectivity for factor Xa.

Related Disclosures

European Published Patent Application 0 540 051 (Nagahara et al.) describes aromatic amidine derivatives which are stated to be capable of showing a strong anticoagulant effect through reversible inhibition of factor Xa.

The synthesis of α,α′-bis(aminobenzylidene)cycloalkanones and α,α′-bis(aminobenzyl)cycloalkanones is described in Pharmazie (1977), Vol. 32, No. 3, pp. 141-145. These compounds are disclosed as being serine protease inhibitors.

SUMMARY OF THE INVENTION

This invention is directed to compounds or their pharmaceutically acceptable salts which inhibit human factor Xa and are therefore useful as pharmacological agents for the treatment of disease-states characterized by thrombotic activity.

Accordingly, in one aspect, this invention provides compounds selected from the group consisting of the following formulae:
wherein

A is -C(R\textsuperscript{11})= or -N=;

Z\textdegree\textsuperscript{1} and Z\textsuperscript{2} are independently -O-, -N(R\textsuperscript{8})~, -S~, or -OCH\textsubscript{2}~;

R\textsuperscript{1} and R\textsuperscript{3} are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro,

\begin{align*}
-\text{N}(R\textsuperscript{8})R\textsuperscript{9}, & \quad -\text{C}(\text{O})\text{OR}\textsuperscript{8}, \\
-\text{C}(\text{O})\text{N}(R\textsuperscript{8})R\textsuperscript{9}, & \quad -\text{C}(\text{O})\text{N}(R\textsuperscript{8})\text{CH}_2\text{C}(\text{O})\text{N}(R\textsuperscript{8})R\textsuperscript{9}, \\
-\text{N}(R\textsuperscript{8})\text{C}(\text{O})\text{N}(R\textsuperscript{8})R\textsuperscript{9}, & \quad -\text{N}(R\textsuperscript{8})\text{C}(\text{O})\text{N}(R\textsuperscript{8})\text{CH}_2\text{C}(\text{O})\text{N}(R\textsuperscript{8})R\textsuperscript{9}, \\
-\text{N}(R\textsuperscript{8})\text{C}(\text{O})R\textsuperscript{8}, & \quad -\text{N}(R\textsuperscript{8})\text{C}(\text{O})\text{S}(\text{O})_2R\textsuperscript{12}, \\
& \quad \text{or } -\text{N}(R\textsuperscript{8})\text{C}(\text{O})\text{N}(R\textsuperscript{8})\text{CH}_2\text{C}(\text{O})\text{N}(R\textsuperscript{8})R\textsuperscript{9}, \\
-\text{N}(R\textsuperscript{8})\text{C}(\text{O})R\textsuperscript{8}, & \quad -\text{N}(R\textsuperscript{8})\text{C}(\text{O})\text{S}(\text{O})_2R\textsuperscript{12}, \\
& \quad \text{or } -\text{N}(R\textsuperscript{8})\text{C}(\text{O})\text{N}(R\textsuperscript{8})\text{CH}_2\text{C}(\text{O})\text{N}(R\textsuperscript{8})R\textsuperscript{9},
\end{align*}

R\textsuperscript{2} is hydrogen; halo; alkyl; haloalkoxy; -OR\textsuperscript{8}, -\text{C}(\text{O})\text{OR}\textsuperscript{8}, -\text{C}(\text{O})\text{N}(R\textsuperscript{8})R\textsuperscript{9};

\begin{align*}
-\text{N}(R\textsuperscript{8})\text{C}(\text{O})R\textsuperscript{8}, & \quad -\text{N}(R\textsuperscript{8})\text{C}(\text{O})\text{N}(R\textsuperscript{8})(\text{CH}_2)_m\text{C}(\text{O})\text{OR}\textsuperscript{8} \text{ (where m is 0 to 3)}, \\
& \quad -\text{N}(R\textsuperscript{8})\text{C}(\text{O})\text{N}(R\textsuperscript{8})(\text{CH}_2)_n\text{C}(\text{O})\text{OR}\textsuperscript{8} \text{ (where n is}
1 to 3): -N[(CH₂)nN(R⁶)R⁹](CH₂)nC(O)OR⁸ (where each n is 1 to 3); -O(CH₂)pC(O)OR⁸ (where p is 1 to 6); -N[(CH₂)nC(O)R⁸](CH₂)nC(O)OR⁸ (where each n is independently 1 to 3); morpholin-4-yl; 3-tetrahydrofuranoxy;

or R² is arylaxy (optionally substituted by one or more substituents independently selected from the group consisting of -OR⁸, -C(O)N(R⁶)R⁹, halo, alkyl, carboxy, alkoxy carbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxy carbonyl alkyl, carboxy alkyl, aminocarbonyl alkyl, (alkylamino) carbonyl alkyl, (dialkylamino) carbonyl alkyl, (aryl amino) carbonyl alkyl, (arylalkylamino) carbonyl alkyl, alkoxy carbonyl alkenyl, carboxy alkenyl, aminocarbonyl alkenyl, (alkylamino) carbonyl alkenyl, (dialkylamino) carbonyl alkenyl, (aryl amino) carbonyl alkenyl, (arylalkylamino) carbonyl alkenyl, (hydroxy alkoxycarbonyl) carbonyl, (alkoxy alkoxycarbonyl) carbonyl, (aryl alkoxycarbonyl) carbonyl, (arylalkylamino) carbonyl, tetrazo lyl, morpholin-4-yl alkyl, and (1,2)-imidazoliny1 (optionally substituted by alkyl));

or R² is piperazin-1-yl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, carboxy, -C(O)N(R⁶)R⁹, carboxy alkyl, alkoxy carbonyl, and alkoxy carbonyl alkyl);

or R² is 1-piperazinoyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, carboxy, -C(O)N(R⁶)R⁹, carboxy alkyl, alkoxy carbonyl, and alkoxy carbonyl alkyl);

or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from the group consisting of carboxy, -C(O)N(R⁶)R⁹, carboxy alkyl, alkoxy carbonyl, and alkoxy carbonyl alkyl);

or R² is (3,4)-piperidinol (optionally substituted by one or more substituents selected from the group consisting of alky carbonyl, carboxy, -C(O)N(R⁶)R⁹, alkoxy carboxyl, carboxy alkyl, alkoxy carbonyl alkyl, and tetrazolo lyl alkyl);

or R² is piperidin-4-yl amino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy carbonyl, -C(O)N(R⁶)R⁹, carboxy alkyl, alkoxy carbonyl alkyl and aralkyl);

or R² is 3-pyrrolidinyl oxy (optionally substituted by one or more substituents selected from the group consisting of alkyl, aralkyl, amidino, 1-imino ethyl, carboxy, -C(O)N(R⁶)R⁹, carboxy alkyl, alkoxy carbonyl and alkoxy carbonyl alkyl);

R⁴ and R⁷ are independently hydrogen, halo, alkyl, nitro, -OR⁸, -C(O)OR⁸, -C(O)N(R⁶)R⁹, -NR²R⁹, -N(H)C(O)R⁸, or -N(H)S(O)₂R¹²;

R⁵ is -C(NH)NH₂, -C(NH)NH(O)R⁸, -C(NH)N(H)C(O)OR¹², -C(NH)N(H)S(O)₂R¹², -C(NH)N(H)C(O)N(R⁶)R⁹, or -C(NH)N(H)C(O)R⁸;

R⁶ is halo, alkyl, haloalkyl, haloalkoxy, nitro, amino, ureido, guanidino, -OR⁸, -C(NH)NH₂, -C(NH)NHOH, -C(O)R¹⁰, -(CH₂)ₘC(O)N(R⁶)R⁹ (where m is 0 to
each R⁸ and R⁹ is independently hydrogen, alkyl, aryl, or aralkyl;
R¹⁰ is hydrogen, alkyl, aryl, aralkyl, 1-pyrroolidinyl, 4-morpolinyl,
4-piperazinyl, 4-(N-methyl)piperazinyl, or piperidin-1-yl;
R¹¹ is hydrogen, alkyl or halo; and
R¹² is alkyl, aryl or aralkyl;
or a pharmaceutically acceptable salt thereof.

In another aspect, this invention provides compositions useful in treating a human having a
disease-state characterized by thrombotic activity, which composition comprises a therapeutically
effective amount of a compound of the invention as described above, or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable excipient.

In another aspect, this invention provides a method of treating a human having a
disease-state characterized by thrombotic activity, which method comprises administering to a human in need thereof a therapeutically effective amount of a compound of the invention as described above.

In another aspect, this invention provides a method of inhibiting human factor Xa in vitro or
in vivo by the administration of a compound of the invention.

DETAILED DESCRIPTION OF THE INVENTION

Definitions
As used in the specification and appended claims, unless specified to the contrary, the
following terms have the meaning indicated:

"Halo" refers to bromo, chloro or fluoro.
"Aminocarbonyl" refers to the radical -C(O)NH₂.
"Amidino" refers to the radical -C(NH)NH₂.
"Benzamidine" refers to a phenyl radical substituted by an amidino radical.
"Carboxy" refers to the radical -COOH.
"Dimethylaminocarbonyl" refers to the radical -C(O)N(CH₃)₂.
"Alkyl" refers to a straight or branched chain monovalent or divalent radical consisting solely
of carbon and hydrogen, containing no unsaturation and having from one to six carbon atoms, e.g.,
methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), and
"Alkenyl" refers to a straight or branched chain monovalent or divalent radical consisting solely of carbon and hydrogen, containing at least one double bond and having from one to six carbon atoms, e.g., ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, pent-1,4-dienyl, and the like.

"Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like.

"Haloalkoxy" refers to a radical of the formula -OR\textsubscript{b} wherein R\textsubscript{b} is haloalkyl as defined above, e.g., trifluoromethoxy, difluoromethoxy, trichloromethoxy, 2-trifluoroethoxy, 1-fluoromethyl-2-fluoroethoxy, 3-bromo-2-fluoropropoxy, 1-bromomethyl-2-bromoethoxy, and the like.

"Aryl" refers to a phenyl or naphthyl radical optionally substituted by halo, alkyl, alkoxy, amino, nitro or carboxy.

"Aralky1" refers to a radical of the formula -R\textsubscript{a}R\textsubscript{c} where R\textsubscript{a} is alkyl as defined above and R\textsubscript{c} is aryl as defined above, e.g., benzyl.

"Aryloxy" refers to a radical of the formula -OR\textsubscript{c} where R\textsubscript{c} is phenyl or naphthyl, e.g., phenoxy and naphthoxy.

"Alkoxy" refers to a radical of the formula -OR\textsubscript{a} where R\textsubscript{a} is alkyl as defined above, e.g., methoxy, ethoxy, n-propoxy, 1-methylethoxy (iso-propoxy), n-butoxy, n-pentoxy, 1,1-dimethylethoxy (t-butoxy), and the like.

"Alkanol" refers to a branched or unbranched aliphatic hydrocarbon of 1 to 6 carbons wherein one hydroxyl radical is attached thereto, e.g., methanol, \text{-} \text{propanol}, and the like.

"Aminocarbonylalkyl" refers to a radical of the formula -R\textsubscript{a}C(O)NH\textsubscript{2} wherein R\textsubscript{a} is alkyl as defined above, e.g., aminocarbonylmethyl, 2-aminocarbonylethyl, 3-aminocarbonylpropyl, 1,1-dimethyl-2-aminocarbonylthethyl, and the like.

"(Alkylamino)carbonylalkyl" refers to a radical of the formula -R\textsubscript{a}C(O)NHR\textsubscript{a} wherein each R\textsubscript{a} is the same or different and is alkyl as defined above, e.g., (methylamino)carbonylmethyl, 2-(ethylamino)carbonylethyl, 3-(methylamino)carbonylpropyl, 1,1-dimethyl-2-(ethylamino)carbonylthethyl, and the like.

"(Dialkylamino)carbonylalkyl" refers to a radical of the formula -R\textsubscript{a}C(O)NHR\textsubscript{a} wherein each R\textsubscript{a} is the same or different and is alkyl as defined above, e.g., (dimethylamino)carbonylmethyl, 2-(diethylamino)carbonylethyl, 3-(dimethylamino)carbonylpropyl, 1,1-dimethyl-2-(diethylamino)carbonylthethyl, and the like.

"(Arylaminocarbonylalkyl" refers to a radical of the formula -R\textsubscript{a}C(O)NHRC\textsubscript{a} wherein R\textsubscript{a} is aryl as defined above and R\textsubscript{c} is aryl as defined above, e.g., phenylaminocarbonylmethyl, 2-phenylaminocarbonylethyl, 3-phenylaminocarbonylpropyl, 1,1-dimethyl-2-phenylaminocarbonylthethyl, and the like.

"(Arylaminocarbonylalkyl" refers to a radical of the formula -R\textsubscript{a}C(O)NHRC\textsubscript{a} wherein R\textsubscript{a} is
alkyl as defined above and \( R_d \) is aralkyl as defined above, *e.g.*, benzylaminocarboxylinethyl, 2-benzylaminocarbonylethyl, 3-benzylaminocarbonylpropyl, 1,1-dimethyl-2-benzylaminocarbonylthethyl, and the like.

"Alkoxy carbonylalkenyln" refers to a radical of the formula \(-R_e\text{C}(\text{O})\text{OR}_a\) wherein \( R_a \) is lower alkyl as defined above and \( R_e \) is alkenyl as defined above, *e.g.*, 2-methoxycarbonylenethyl, 3-methoxycarboxyprop-1-enyl, 2-ethoxycarbonylethlenyl, and the like.

"Carboxyalkenyln" refers to a radical of the formula \(-R_e\text{C}(\text{O})\text{OH}\) where \( R_e \) is alkenyl as defined above, *e.g.*, 2-carboxyethenyl, 3-carboxyprop-1-enyl, 4-carboxybut-1-enyl, and the like.

"Aminocarbonylalkenyln" refers to a radical of the formula \(-R_e\text{C}(\text{O})\text{NH}_2\) wherein \( R_e \) is alkenyl as defined above, *e.g.*, 2-aminocarboxylenethyl, 3-aminocarbonylprop-1-enyl, 1-methyl-2-aminocarbonylethlenyl, and the like.

"(Alkylamino)carbonylalkenyln" refers to a radical of the formula \(-R_e\text{C}(\text{O})\text{N}(\text{H})\text{R}_c\) wherein \( R_c \) is alkyl as defined above and \( R_e \) is alkenyl as defined above, *e.g.*, 2-(ethylamino)carbonylenethyl, 3-(methylamino)carbonylprop-1-enyl, 1-methyl-2-(ethylamino)carbonylethlenyl, and the like.

"(Dialkylamino)carbonylalkenyln" refers to a radical of the formula \(-R_e\text{C}(\text{O})\text{N}(\text{R}_a)_2\) wherein each \( R_a \) is the same or different and is alkyl as defined above and \( R_e \) is alkenyl as defined above, *e.g.*, 2-(diethylamino)carbonylenethyl, 3-(dimethylamino)carbonylprop-1-enyl, 1-methyl-2-(diethylamino)carbonylethlenyl, and the like.

"(Arylamino)carbonylalkenyln" refers to a radical of the formula \(-R_e\text{C}(\text{O})\text{N}(\text{H})\text{R}_c\) wherein \( R_c \) is aryl as defined above and \( R_e \) is alkenyl as defined above, *e.g.*, 2-(phenylamino)carbonylenethyl, 3-(phenylamino)carbonylprop-1-enyl, 1-methyl-2-(phenylamino)carbonylethlenyl, and the like.

"(Aralkylamino)carbonylalkenyln" refers to a radical of the formula \(-R_e\text{C}(\text{O})\text{N}(\text{H})\text{R}_d\) wherein \( R_d \) is aralkyl as defined above and \( R_e \) is alkenyl as defined above, *e.g.*, 2-(benzylamino)carbonylenethyl, 3-(benzylamino)carbonylprop-1-enyl, 1-methyl-2-(benzylamino)carbonylethlenyl, and the like.

"(Hydroxyalkoxy)carbonyln" refers to a radical of the formula \(-\text{C}(\text{O})\text{OR}_a\) wherein \( R_a \) is alkyl as defined above substituted by a hydroxy radical, *e.g.*, 2-(hydroxy)ethoxy carbonyln, 3-(hydroxy)propoxycarbonyln, 5-(hydroxy)pentoxycarbonyln, and the like.

"(Alkoxyalkoxy)carbonyln" refers to a radical of the formula \(-\text{C}(\text{O})\text{OR}_a\text{OR}_a\) wherein each \( R_a \) is the same or different and is alkyl as defined above, *e.g.*, 2-(methoxy)ethoxy carbonyln, 3-(methoxy)propoxycarbonyln, 5-(ethoxy)pentoxycarbonyln, and the like.

"(Hydroxyalkoxy)alkoxy carbonyln" refers to a radical of the formula \(-\text{C}(\text{O})\text{OR}_a\text{OR}_a\) wherein each \( R_a \) is the same or different and is alkyl as defined above, *e.g.*, 2-(2-(methoxy)ethoxy)ethoxy carbonyln, 2-(3-hydroxypropoxy)ethoxy carbonyln, and the like.
"Haloalkoxy carbonyl" refers to a radical of the formula \(-\text{C(O)}\text{OR}_b\) wherein \(R_b\) is haloalkyl as defined above, e.g., trifluoromethoxycarbonyl, difluoromethoxycarbonyl, trichloromethoxycarbonyl, 2,2-trifluoroethoxycarbonyl, 1-fluoromethyl-2-fluoro-ethoxycarbonyl, 3-bromo-2-fluoropropoxycarbonyl, 1-bromomethyl-2-bromoethoxy-carbonyl, and the like.

"Carboxyalkyl" refers to a radical of the formula \(-\text{R}_a\text{C(O)}\text{OH}\) where \(R_a\) is alkyl as defined above, e.g., carboxymethyl, 2-carboxyethyl, 3-carboxypropyl, and the like.

"Alkoxy carbonyl" refers to a radical of the formula \(-\text{C(O)}\text{OR}_a\) wherein \(R_a\) is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, \(n\)-propoxycarbonyl, and the like.

"Alkoxy carbonylalkyl" refers to a radical of the formula \(-\text{R}_a\text{C(O)}\text{OR}_b\) wherein each \(R_a\) is the same or different and is alkyl as defined above, e.g., methoxycarbonyl ethyl, ethoxycarbonyl ethyl, \(t\)-butoxycarbonyl ethyl, and the like.

"Morpholin-4-ylalkyl" refers to a radical of the formula \(-\text{R}_a\text{R}_b\) where \(R_a\) is alkyl as defined above and \(R_b\) is a morpholin-4-yl radical, e.g., morpholin-4-yl methyl, morpholin-4-yl ethyl, and the like.

"4-morpholinoxy" refers to a radical of the formula \(-\text{C(O)}\text{OR}_a\) where \(R_a\) is a morpholin-4-yl radical.

"(3,4)-Piperidinoxy" refers to a radical of the formula \(-\text{OR}_a\) where \(R_a\) is a piperidinyl radical attached to the oxygen atom at either the 3- or 4-position.

"3-Tetrahydrofuranoxy" refers to the radical of the formula \(-\text{OR}_a\) where \(R_a\) is a tetrahydrofuranyl radical attached to the oxygen atom at the 3-position.

"3-Pyrrolidinoxy" refers to the radical of the formula \(-\text{OR}_a\) where \(R_a\) is a pyrrolidinyl radical attached to the oxygen atom at the 3-position.

"1-Piperazinoyl" refers to the radical of the formula \(-\text{C(O)}\text{R}_a\) where \(R_a\) is piperazin-1-yl.

"1-Piperidinoyl" refers to the radical of the formula \(-\text{C(O)}\text{R}_a\) where \(R_a\) is piperidin-1-yl.

"1-Pyrrolidinoyl" refers to the radical of the formula \(-\text{C(O)}\text{R}_a\) where \(R_a\) is pyrrolidin-1-yl.

"(1,2)-imidazolyl" refers to an imidazolyl radical attached at either the 1- or 2-position.

"(1,2)-imidazolinyl" refers to a 4,5-dihydroimidazolyl radical attached at either the 1- or the 2-position.

"DMSO" refers to dimethyl sulfoxide.

"HPLC" refers to high performance liquid chromatography.

"Optional" or "optionally" means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.

"Pharmacaceutically acceptable salt" includes both acid and base addition salts.

"Pharmacaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

"Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.

Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanalamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydramamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanalamine, trimethamine, dicyclohexylamine, choline and caffeine.

"Therapeutically effective amount" refers to that amount of a compound of formula (I) which, when administered to a human in need thereof, is sufficient to effect treatment, as defined below, for disease-states characterized by thrombotic activity. The amount of a compound of formula (I) which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease-state and its severity, and the age of the human to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.

"Treating" or "treatment" as used herein cover the treatment of a disease-state in a human, which disease-state is characterized by thrombotic activity; and include:

(i) preventing the disease-state from occurring in a human, in particular, when such human is predisposed to the disease-state but has not yet been diagnosed as having it;

(ii) inhibiting the disease-state, i.e., arresting its development; or

(iii) relieving the disease-state, i.e., causing regression of the disease-state.

The yield of each of the reactions described herein is expressed as a percentage of the theoretical yield.

The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms in their structure. The compounds of the invention and their pharmaceutically acceptable salts may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of this invention.

The nomenclature used herein is a modified form of the I.U.P.A.C. system wherein the
compounds of the invention are named as derivatives of benzamidine. For example, a compound of the invention selected from formula (I), \textit{i.e.},

wherein A is \(-\text{N}=\), Z\(^1\) and Z\(^2\) are both \(-\text{O}-\), R\(^1\) and R\(^2\) are both fluoro, R\(^3\) is methyl, R\(^4\) is methoxy, R\(^5\) is \(-\text{C(NH)}\text{NH}_2\), R\(^6\) is dimethylamino, and R\(^7\) is hydrogen, that is, a compound of the following formula:

is named herein as 4-methoxy-3-\{3,5-difluoro-6-(3-dimethylaminophenoxy)\}-4-methyl(pyridin-2-yl)oxy]benzamidine.

Utility and Administration

A. Utility

The compounds of the invention are inhibitors of factor Xa and therefore useful in disease-states characterized by thrombotic activity based on factor Xa's role in the coagulation cascade (see Background of the Invention above). A primary indication for the compounds is prophylaxis for long term risk following myocardial infarction. Additional indications are prophylaxis of deep vein thrombosis (DVT) following orthopedic surgery or prophylaxis of selected patients following a transient ischemic attack. The compounds of the invention may also be useful for indications in which coumadin is currently used, such as for DVT or other types of surgical intervention such as coronary artery bypass graft and percutaneous transluminal coronary angioplasty. The compounds are also useful for the treatment of thrombotic complications associated
with acute promyelocytic leukemia, diabetes, multiple myelomas, disseminated intravascular coagulation associated with septic shock, purpura fulminans associated infection, adult respiratory distress syndrome, unstable angina, and thrombotic complications associated with aortic valve or vascular prosthesis. The compounds are also useful for prophylaxis for thrombotic diseases, in particular in patients who have a high risk of developing such disease.

In addition, the compounds of the invention are useful as in vitro diagnostic reagents for selectively inhibiting factor Xa without inhibiting other components of the coagulation cascade.

B. Testing

The primary bioassays used to demonstrate the inhibitory effect of the compounds of the invention on factor Xa are simple chromogenic assays involving only serine protease, the compound of the invention to be tested, substrate and buffer (see, e.g., *Thrombosis Res.* (1979), Vol. 16, pp. 245-254). For example, four tissue human serine proteases can be used in the primary bioassay, free factor Xa, prothrombinase, thrombin (IIa) and tissue plasminogen activator (tPA). The assay for tPA has been successfully used before to demonstrate undesired side effects in the inhibition of the fibrinolytic process (see, e.g., *J. Med. Chem.* (1993), Vol. 36, pp. 314-319). Another bioassay useful in demonstrating the utility of the compounds of the invention in inhibiting factor Xa demonstrates the potency of the compounds against free factor Xa in citrated plasma. For example, the anticoagulant efficacy of the compounds of the invention will be tested using either the prothrombin time (PT), or activated partial thromboplastin time (aPTT) while selectivity of the compounds is checked with the thrombin clotting time (TCT) assay. Correlation of the $K_i$ in the primary enzyme assay with the $K_i$ for free factor Xa in citrated plasma will screen against compounds which interact with or are inactivated by other plasma components. Correlation of the $K_i$ with the extension of the PT is a necessary in vitro demonstration that potency in the free factor Xa inhibition assay translates into potency in a clinical coagulation assay. In addition, extension of the PT in citrated plasma can be used to measure duration of action in subsequent pharmacodynamic studies.


C. General Administration

Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally, topically, transdermally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages. The
compositions will include a conventional pharmaceutical carrier or excipient and a compound of the invention as the active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. Preferably, the composition will be about 5% to 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.

The preferred route of administration is oral, using a convenient daily dosage regimen which can be adjusted according to the degree of severity of the disease-state to be treated. For such oral administration, a pharmaceutically acceptable composition containing a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.

Preferably such compositions will take the form of capsule, caplet or tablet and therefore will also contain a diluent such as lactose, sucrose, dicalcium phosphate, and the like; a disintegrant such as croscarmellose sodium or derivatives thereof; a lubricant such as magnesium stearate and the like; and a binder such as a starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose ether derivatives, and the like.

The compounds of the invention, or their pharmaceutically acceptable salts, may also be formulated into a suppository using, for example, about 0.5% to about 50% active ingredient disposed in a carrier that slowly dissolves within the body, e.g., polyoxyethylene glycols and polyethylene glycols (PEG), e.g., PEG 1000 (96%) and PEG 4000 (4%).

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., a compound(s) of the invention (about 0.5% to about 20%), or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension.

If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.

Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington’s Pharmaceutical Sciences*, 18th Ed., (Mack Publishing Company, Easton, Pennsylvania, 1990). The composition to be administered will, in any event,
contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically
acceptable salt thereof, for treatment of a disease-state alleviated by the inhibition of factor Xa in
accordance with the teachings of this invention.

The compounds of the invention, or their pharmaceutically acceptable salts, are administered
in a therapeutically effective amount which will vary depending upon a variety of factors including
the activity of the specific compound employed, the metabolic stability and length of action of the
compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of
excretion, drug combination, the severity of the particular disease-states, and the host undergoing
therapy. Generally, a therapeutically effective daily dose is from about 0.14 mg to about 14.3 mg/kg
of body weight per day of a compound of the invention, or a pharmaceutically acceptable salt
thereof; preferably, from about 0.7 mg to about 10 mg/kg of body weight per day; and most
preferably, from about 1.4 mg to about 7.2 mg/kg of body weight per day. For example, for
administration to a 70 kg person, the dosage range would be from about 10 mg to about 1.0 gram
per day of a compound of the invention, or a pharmaceutically acceptable salt thereof, preferably
from about 50 mg to about 700 mg per day, and most preferably from about 100 mg to about
500 mg per day.

Preferred Embodiments

Of the compounds of the invention as set forth above in the Summary of the Invention,
several groups of compounds are preferred.

One preferred group are those compounds selected from formula (I):

\[
\begin{align*}
\text{A is } &-\text{N} =; \\
\text{Z}^1 \text{ and } \text{Z}^2 \text{ are independently } &-\text{O}-, -\text{N}(\text{R}^8)- \text{ or } -\text{OCH}_2-; \\
\text{R}^1 \text{ and } \text{R}^3 \text{ are independently hydrogen, fluoro, chloro, haloalkyl, } -\text{N}(\text{R}^8)\text{R}^9, -\text{C}(\text{O})\text{OR}^8, \\
\text{-C}(\text{O})\text{N}(\text{R}^8)\text{R}^9, -\text{N}(\text{R}^8)\text{C}(\text{O})\text{N}(\text{R}^8)\text{R}^9, -\text{N}(\text{R}^8)\text{C}(\text{O})\text{R}^8, \text{ or } -\text{N}(\text{R}^8)\text{S}(\text{O})_2\text{R}^{12}; \\
\text{R}^2 \text{ is hydrogen; halo; alkyl; haloalkoxy; } &-\text{OR}^8, -\text{C}(\text{O})\text{OR}^8, -\text{C}(\text{O})\text{N}(\text{R}^8)\text{R}^8; \\
-\text{N}(\text{R}^8)\text{R}^9; -\text{C}(\text{O})\text{N}(\text{R}^8)(\text{CH}_2)\text{mC}(\text{O})\text{OR}^8 \text{ (where } m \text{ is } 0 \text{ to } 3); -\text{N}(\text{R}^8)(\text{CH}_2)\text{nC}(\text{O})\text{OR}^8 \text{ (where each } n \text{ is } 1 \text{ to } 3); -\text{N}(\text{CH}_2)\text{nN}(\text{R}^8)\text{R}^9(\text{CH}_2)\text{nC}(\text{O})\text{OR}^8 \text{ (where each } n \text{ is } 1 \text{ to } 3); -\text{O}(\text{CH}_2)\text{nC}(\text{O})\text{N}(\text{R}^8)\text{R}^9
\end{align*}
\]
(where n is 1 to 3); -O(CH_2)_pC(O)OR^8 (where p is 1 to 6); 
-N(R^8)(CH_2)_nC(O)N(R^8)(CH_2)_mC(O)OR^8 (where each n is independently 1 to 3); morpholin-4-yl; 
3-tetrahydrofuranoxy;

or R^2 is arylx (optionally substituted by one or more substituents independently

selected from the group consisting of -OR^8, -C(O)N(R^8)R^9, halo, alkyl, carboxy, 
alkoxycarbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxycarbonylalkyl, carboxyalkyl, 
aminocarboxylalkyl, (alkylamino)carboxylalkyl, (dialkylamino)carboxylalkyl, 
(arylaminocarbonylalkyl, (aralkylaminocarbonylalkyl, alkoxy carbonylalkenyl, carboxyalkenyl, 
aminocarboxylalkeny, (alkylamino)carboxylalkeny, (dialkylamino)carboxylalkeny, 
(arylaminocarbonylalkeny, (aralkylaminocarbonylalkeny, (hydroxyalkoxy)carbonyl, 
(alkoxy)alkoxycarbonyl, (hydroxyalkoxy)alkoxycarbonyl, (alkoxy)alkoxycarbonyl, tetracyclic, morpholin-4-ylalkyl, and (1,2)-imidazolinyl (optionally substituted by alkyl));

or R^2 is piperazin-1-yl (optionally substituted by one or more substituents independently

selected from the group consisting of alkyl, carboxy, -C(O)N(R^8)R^9, carboxyalkyl, 
alkoxycarbonyl, and alkoxycarbonylalkyl);

or R^2 is 1-piperazinoyl (optionally substituted by one or more substituents selected from

the group consisting of alkyl, carboxy, -C(O)N(R^8)R^9, carboxyalkyl, alkoxycarbonyl, and 
alcoholocarbonylalkyl);

or R^2 is piperidin-1-yl (optionally substituted by one or more substituents selected from

the group consisting of carboxy, -C(O)N(R^8)R^9, carboxyalkyl, alkoxycarbonyl, or 
alkoxycarbonylalkyl);

or R^2 is (3,4)-piperidinyloxy (optionally substituted by one or more substituents selected

from the group consisting of alkylcarbonyl, carboxy, -C(O)N(R^8)R^9, alkoxycarbonyl, 
karboxyalkyl, alkoxycarbonylalkyl, or tetracyclicalkyl);

or R^2 is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the

piperidinyl group is optionally substituted by one or more substituents selected from the group

consisting of alkyl, alkoxycarbonyl, carboxyalkyl, -C(O)N(R^8)R^9, alkoxycarbonylalkyl or 
aralkyl);

or R^2 is 3-pyridinloxy (optionally substituted by one or more substituents selected

from the group consisting of alkyl, aralkyl, amidino, 1-iminoethyl, carboxy, carboxyalkyl, 
alkoxycarbonyl, -C(O)N(R^8)R^9, or alkoxycarbonylalkyl);

R^4 is hydrogen, -OR^8 or -N(R^8)R^9;

R^5 is -CNHCONH_2;

R^6 is guanidino, -C(NHCONH_2, -C(O)N(R^8)R^9, -CH(OH)C(O)N(R^8)R^9, -(CH_2)_mN(R^8)R^9

(where m is 0 to 3), 1-piperidinoyl, 1-pyridolinoyl, (1,2)-imidazolyl (optionally substituted by

alkyl), or (1,2)-imidazoliny (optionally substituted by alkyl);

R^7 is hydrogen, halo, alkyl, -OR^8, -C(O)N(R^8)R^9;

R^8 and R^9 are independently hydrogen, methyl, ethyl or phenyl; and
$R^{12}$ is methyl, ethyl, phenyl or benzyl.

Of this group of compounds, a preferred subgroup of compounds is that subgroup wherein $Z^1$ and $Z^2$ are independently -O- or -NCH$_3$-

$R^1$ and $R^3$ are independently hydrogen, fluoro, chloro, trifluoromethyl, amino,

$\text{-C(O)(R^6)R^9, or -NH-C(O)NHR^9;}$

$R^2$ is hydrogen; alkyl; haloalkoxy; -OR$^8$, -C(O)OR$^8$, -N(R$^8$)R$^9$;

$\text{-N(R^8)(CH}_2)_n\text{C(O)OR}^8 \text{ (where } n \text{ is 1 to 3); -N(\text{CH}_2)_n\text{N(R}^8\text{)R}^9 \text{ (where each } n \text{ is 1 to 3); -O(\text{CH}_2)_p\text{C(O)OR}^8 \text{ (where } p \text{ is 1 to 6);}}$

$\text{-N(R}^8\text{)(CH}_2)_n\text{C(O)(R}^6\text{)(CH}_2)_n\text{C(O)OR}^8 \text{ (where each } n \text{ is independently 1 to 3); morpholin-4-yl;}$

3-tetrahydrofuranoxy;

or $R^2$ is aryloxy (optionally substituted by one or more substituents independently

selected from the group consisting of -OR$^6$, -C(O)(R$^6$)R$^9$, halo, alkyl, carboxy, alkoxy carbonyl, alkoxy carbonylalkyl, carboxy alkyl, alkoxy carbonylkenyl, carboxy alkenyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazoliny (optionally substituted by alkyl));

or $R^2$ is piperazin-1-yl (optionally substituted by one or more substituents independently

selected from the group consisting of alkyl, carboxy alkyl, and alkoxy carbonyl alkyl);

or $R^2$ is piperidin-1-yl (optionally substituted by one or more substituents selected from

the group consisting of carboxy alkyl and alkoxy carbonyl alkyl);

or $R^2$ is (3,4)-piperidinolxy (optionally substituted by one or more substituents selected

from the group consisting of carboxy alkyl and alkoxy carbonyl alkyl); or

or $R^2$ is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the

piperidinyl group is optionally substituted by one or more substituents selected from the group

consisting of carboxy alkyl, alkoxy carbonyl alkyl and aralkyl); or

or $R^2$ is 3-pyrrolidinolxy (optionally substituted by one or more substituents selected

from the group consisting of 1-imino ethyl, carboxy alkyl, alkoxy carbonyl and

alkoxy carbonyl alkyl);

$R^4$ is hydrogen, amino, hydroxy, or methoxy;

$R^5$ is -C(NH)NH$_2$;

$R^6$ is guanidino, -C(NH)NH$_2$, -C(O)(R$^6$)R$^9$, -(CH$_2$)$_m$N(R$^8$)R$^9$ (where $m$ is 0 to 1),

(1,2)-imidazolyl substituted by alkyl, or 2-imidazoliny substituted by alkyl;

$R^7$ is hydrogen, methoxy, or hydroxy; and

$R^8$ and $R^9$ are independently hydrogen, methyl, ethyl, or phenyl.

Of this subgroup of compounds, a preferred class of compounds is that class wherein $Z^1$ and $Z^2$ are both -O-; $R^1$ and $R^3$ are independently hydrogen, fluoro, or chloro; $R^4$ is amino, hydrogen, hydroxy or methoxy; $R^6$ is guanidino, -C(NH)NH$_2$, -C(O)(R$^6$)R$^9$, -(CH$_2$)$_m$N(R$^8$)R$^9$ (where $m$ is 0 or 1), (1,2)-imidazoliny substituted by methyl, or 2-imidazoliny optionally substituted by methyl; and $R^7$ is hydrogen or hydroxy.

Of this class of compounds, a preferred subclass of compounds is that subclass wherein $R^4$
is hydroxy; \( R^6 \) is dimethylamino or dimethylaminocarbonyl; and \( R^7 \) is hydrogen.

Of this subclass of compounds, preferred compounds are selected from the following:

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2-methoxy-4-carboxyphenoxy)pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1-ethoxycarbonyl-methyl)pyrrolidin-3-yl\}oxy\}pyridin-2-yl\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-propoxy-pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-pyridin-2-yl\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-carboxypiperidin-1-yl)pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-dimethylaminopyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1,3-difluoroprop-2-oxo)pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1-bromo-3-fluoro-prop-2-oxo)pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-methylpyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-((methyl)(carboxymethyl)amino)pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-carboxymethylpiperazin-1-yl)pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(piperidin-1-yl)-pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-methylpiperazin-1-yl)pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(morpholin-4-yl)-pyridin-2-yl\}oxy\}benzamidine;

- 4-hydroxy-3-\{(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-carboxymethylpiperazinyl)pyridin-2-yl\}oxy\}benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-ethoxycarbonylmethyl)piperazinyl]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxo)-4-(4-carboxy-2-methoxyphenoxy)pyridin-2-yl]oxygen]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-carboxy-2-(morpholin-4-ylmethyl)phenoxy)pyridin-2-yl]oxygen]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-((methyl)-(carboxymethyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(aminocarbonylmethoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxy-4-piperidinyl)oxy)pyridin-2-yl]oxy]benzamidine;

Of this class of compounds, another preferred subclass of compounds is that subclass wherein R6 is hydroxy; R6 is (1,2-imidazolyl substituted by methyl or 2-imidazolyl substituted by methyl; and R7 is hydrogen.

Of this subclass, preferred compounds are selected from the following:

4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazolyl-2-yl)phenoxy)-4-(2-methoxy)carbonyl(piperidin-1-yl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazolyl-2-yl)phenoxy)-4-(2-methoxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxy]-4-[(methyl)-(carboxymethyl)amino]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxy]-4-[(methyl)-(ethoxycarbonylmethyl)amino]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxy]-4-[(1-[(methoxy-carbonyl)ethyl]piperidin-4-yl)aminopyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxy]-4-[(2,6-dimethoxy-4-(2-ethoxycarbonyl)ethenyl]phenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[2,6-dimethoxy-4-(2-carboxyethenyl)phenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(5-carboxyprrolidin-3-yloxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[4-(1-ethoxycarbonyl)ethyl]piperazin-1-yl]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxy]-4-[(2-methoxy-4-ethoxy-carbonylphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(2-methoxy-4-carboxyphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(2-hydroxy-4-carboxyphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(2-carboxyphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(2-methoxy-5-ethoxy-carbonylphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(2-methoxy-5-carboxyphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(2,3-dimethoxy-5-ethoxy-carbonylphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(2,3-dimethoxy-5-carboxyphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(3-aminocarbonyl-5-ethoxy-carbonylphenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(3-1-methylimidazolin-2-yl)phenoxo)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-1-methylimidazolin-2-yl)phenoxo]-4-[(3-ethoxycarbonylphenoxo)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(2,6-dimethoxy-4-methoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(2,6-dimethoxy-4-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(3-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(3,5-dicarboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-4-[3-(1-methylimidazolin-2-yl)phenoxy]-
6-[3,5-dicarboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(3-carboxy-5-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(2,6-dimethoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(2-hydroxy-4-methoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(2-chloro-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(2,6-dimethyl-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(4-ethoxycarbonylmethyl)piprazin-1-yl]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(5-ethoxycarbonylpyrrolidin-3-yl)oxy]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-
4-(3-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(3-carboxypiperidin-1-yl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(3-(2-ethoxy-carbonyl)ethyl(phenoxoy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-ethoxycarbonyl)methyl(phenoxoy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-carboxymethyl)phenoxy]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-5-tetrazol-5-yl)phenoxy]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-dimethylaminoethyl)(carboxymethyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-carboxy-methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-carboxy-methyl)piperidin-4-yl)(amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-benzyl-piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-benzyl-piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-benzyl-piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-benzyl-piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-benzyl-piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-benzyl-piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((1-benzyl-piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;

Of this class of compound, another preferred subclass of compounds is that subclass wherein R^4 is hydroxy; R^6 is guanidino; and R^7 is hydrogen.

Of this subclass of compounds, preferred compounds are selected from the following:

4-hydroxy-3-[[3,5-difluoro-6-(3-(guanidino)phenoxy)-4-((1-ethoxycarbonylmethyl)
piperidin-4-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxyl]-4-{1-carboxymethylpiperidin-
4-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxyl]-4-{(5-ethoxycarbonylpyrrolidin-3-yl-
3-yl-oxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxyl]-4-{(2,6-dimethoxy-4-methoxy-
carbonylphenoxyl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxyl]-4-{(2,6-dimethoxy-
4-ethoxycarbonylphenoxyl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxyl]-4-{(2,6-dimethoxy-
4-carboxyphenoxyl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxyl]-4-{(methyl)(phenyl)amino-
carbonylpyridin-2-yl]oxy]benzamidine; and
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxyl]-4-{(4-carboxy-
methylpiperazin-1-yl)pyridin-2-yl]oxy]benzamidine.

Another preferred group of compounds are selected from formula (VII):

![Chemical structure diagram](image)

wherein

30 $Z^1$ and $Z^2$ are independently -O-, -N(R^8)- or -OCH_2-;
R^1 and R^3 are independently hydrogen, fluoro, chloro, haloalkyl, -N(R^8)R^9, -C(O)OR^8,
-C(O)N(R^8)R^9, -N(R^8)C(O)N(R^8)R^9, -N(R^8)C(O)R^8, or -N(R^8)S(O)_2R^{12};
R^2 is hydrogen; halo; alkyl; haloalkoxy; -OR^8; -C(O)OR^8; -C(O)N(R^8)R^9;
-N(R^8)R^9, -N(C(H)CH_2)nC(O)OR^8 (where m is 0 to 3); -N(R^8)(CH_2)nC(O)OR^8 (where n is 1 to 3); -N[(CH_2)_{n-p}C(O)OR^8 (where each n is 1 to 3); -O(CH_2)nC(O)N(R^8)R^9 (where n is 1 to 3); -O(CH_2)nC(O)OR^8 (where p is 1 to 6);
-N(R^8)(CH_2)nC(O)N(R^8)(CH_2)nC(O)OR^8 (where each n is independently 1 to 3); morpholin-4-yl;
3-tetrahydrofuranoxy;
or \( R^2 \) is aryloxy (optionally substituted by one or more substituents independently
selected from the group consisting of -OR\(^8\), -C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), halo, alkyl, carboxy, alkoxy carbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxy carbonylalkyl, carboxyalkyl, aminocarbonylalkyl, (alkylamino) carbonylalkyl, (dialkylamino) carbonylalkyl, (aryl amino) carbonylalkyl, (aralkylamino) carbonylalkyl, alkoxy carbonylalkeny, carboxyalkeny, aminocarbonylalkeny, (alkylamino) carbonylalkeny, (dialkylamino) carbonylalkeny, (aryl amino) carbonylalkeny, (aralkylamino) carbonylalkeny, (hydroxyalkoxy) carbonyl, alkoxy carbonyl, (hydroxyalkoxy) alkoxy carbonyl, (alkoxy) alkoxy carbonyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazoliny (optionally substituted by alkyl));

or \( R^2 \) is piperazin-1-yl (optionally substituted by one or more substituents independently
selected from the group consisting of alkyl, carboxy, -C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), carboxy alkyl, alkoxy carbonyl, and alkoxy carbonylalkyl);

or \( R^2 \) is 1-piperazinonyl (optionally substituted by one or more substituents selected from
the group consisting of alkyl, carboxy, -C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), carboxyalkyl, alkoxy carbonyl, and
alkoxy carbonylalkyl);

or \( R^2 \) is piperidin-1-yl (optionally substituted by one or more substituents selected from
the group consisting of carboxy, -C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), carboxy alkyl, alkoxy carbonyl, or
alkoxy carbonylalkyl);

or \( R^2 \) is (3,4)-piperidinyloxy (optionally substituted by one or more substituents selected
from the group consisting of alkylcarbonyl, carboxy, -C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), alkoxy carbonyl, carboxy alkyl, alkoxy carbonylalkyl, or tetrazolylalkyl);

or \( R^2 \) is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the
piperidinyl group is optionally substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy carbonyl, carboxy alkyl, -C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), alkoxy carbonylalkyl or
aralkyl);

or \( R^2 \) is 3-pyrolidinylloxy (optionally substituted by one or more substituents selected
from the group consisting of alkyl, aralkyl, amidino, 1-iminoethyl, carboxy, carboxy alkyl,
-C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), alkoxy carbonyl or alkoxy carbonylalkyl);

\( R^4 \) is hydrogen, -OR\(^8\) or -N(\(R^\text{B}\))R\(^9\);

\( R^5 \) is -C(\(\text{N}\))NH\(_2\);

\( R^6 \) is guanidino, -C(\(\text{N}\))NH\(_2\), -C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), -CH(\(\text{OH}\))C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\), -(CH\(_2\))\(_m\)N(\(R^\text{B}\))R\(^9\)
(where \( m \) is 0 to 3), 1-piperidinonyl, 1-pyrrolidinonyl, (1,2)-imidazoliny (optionally substituted by
alkyl), or (1,2)-imidazoliny (optionally substituted by alkyl);

\( R^7 \) is hydrogen, halo, alkyl, -OR\(^8\), -C(\(\text{O}\))N(\(R^\text{B}\))R\(^9\);

\( R^8 \) and \( R^9 \) are independently hydrogen, methyl, ethyl or phenyl;

\( R^{12} \) is methyl, ethyl, phenyl or benzyl.

Of this group of compounds, a preferred subgroup of compounds is that subgroup wherein
\( Z^1 \) and \( Z^2 \) are independently -O- or -NCH\(_3\)-;
R¹ and R³ are independently hydrogen, fluoro, chloro, trifluoromethyl, amino,
-C(O)N(R²)R⁹, or -NHC(O)NHR⁹;

R² is hydrogen; alkyl; halalkoxy; -OR⁸; -C(O)OR⁸; -N(R³)R⁹;
-N(R¹)(CH₂)ₙC(O)OR⁸ (where n is 1 to 3); -N((CH₂)₂R⁸(NR²)R⁹)(CH₂)ₙC(O)OR⁸ (where each n
is 1 to 3); -O(CH₂)ₚC(O)OR⁸ (where p is 1 to 6); -N((CH₂)₂R⁸C(O)N(R⁹)R⁸)(CH₂)ₙC(O)OR⁸ (where each n is independently 1 to 3); morpholin-4-yl;
3-tetrahydrofuranoxide;
or R² is aryloxy (optionally substituted by one or more substituents independently
selected from the group consisting of -OR⁸, -C(O)N(R⁸)R⁹, halo, alkyl, carboxy,
alkoxy carbonyl, alkoxy carbonylalkyl, carboxyalkyl, alkoxy carbonylalkenyl, carboxyalkenyl,
tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazoliny1 (optionally substituted by alkyl);
or R² is piperazin-1-yl (optionally substituted by one or more substituents independently
selected from the group consisting of alkyl, carboxyalkyl, and alkoxy carbonylalkyl);
or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from
the group consisting of carboxy and alkoxy carbonyl);
or R² is (3,4)-piperidinloxy (optionally substituted by one or more substituents selected
from the group consisting of carboxyalkyl and alkoxy carbonylalkyl);
or R² is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the
piperidinyl group is optionally substituted by one or more substituents selected from the group
consisting of carboxyalkyl, alkoxy carbonylalkyl and aralkyl);
or R² is 3-pyrrolidinloxy (optionally substituted by one or more substituents selected
from the group consisting of 1-imin-3-thyl, carboxy, carboxyalkyl, alkoxy carbonyl and
alkoxy carbonylalkyl);

R⁴ is hydrogen, amino, hydroxy, or methoxy;

R⁵ is -C(NH)NH₂;

R⁶ is guanidino, -C(NH)NH₂, -C(O)N(R⁸)R⁹, -(CH₂)₂mN(R⁸)R⁹ (where m is 0 to 1),
(1,2)-imidazolyl substituted by alkyl, or 2-imidazoliny1 substituted by alkyl;

R⁷ is hydrogen, methoxy, or hydroxy; and

R⁸ and R⁹ are independently hydrogen, methyl, ethyl, or phenyl.

Of this subgroup of compounds, a preferred subclass of compounds is that class wherein Z¹ and
Z² are both -O--; R¹ and R³ are independently hydrogen, fluoro, or chloro; R⁴ is amino, hydrogen,
hydroxy or methoxy; R⁶ is guanidino, -C(NH)NH₂, -C(O)N(R⁸)R⁹, -(CH₂)₂mN(R⁸)R⁹ (where m is 0 or
1), (1,2)-imidazolyl substituted by methyl, or 2-imidazoliny1 optionally substituted by methyl; and R⁷
is hydrogen or hydroxy.

Of this class of compounds, a preferred subclass of compounds is that subclass wherein R⁴
is hydroxy; R⁶ is dimethylamino or dimethylaminocarbonyl; and R⁷ is hydrogen.

Of this subclass of compounds, preferred compounds are 4-hydroxy-3-[(3,5-difluoro-
6-(3-dimethylaminocarbonylphenoxy)-2-methoxypyridin-4-yl)-oxy]benzamidine; and
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonyl-phenoxy)-2-(2-methoxy-5-ethoxycarbonylphenoxy)pyridin-4-yl)oxy]benzamidine.

Preparation of Compounds of The Invention

As a matter of convenience, the following description of the preparation of the compounds of the invention is directed to the preparation of compounds of formula (I). It is understood, however, that similar synthetic processes may be used to prepare the compounds of formula (II), (III), (IV), (V), (VI), (VII) and (VIII). It is also understood that in the following description, combinations of substituents and/or variables (e.g., $R^4$ and $R^5$) on the depicted formulae are permissible only if such combinations result in stable compounds.

A. Preparation of Intermediates

1. Compounds of formula (C)

Compounds of formula (C), as shown below, are intermediates in the preparation of the compounds of the invention. As illustrated below in Reaction Scheme 1, compounds of formula (C) are prepared from compounds of formulae (A) and (B) wherein X is chloro or fluoro and $R^{2a}$ is $-N(R^8)R^9$, $-N(R^8)(CHO)Cl$ or $OR^8$ (where $m$ is 0 to 3) or piperazinyl optionally substituted by alkyl, carboxy, carboxyalkyl, alkoxy carbonyl or alkoxy carbonylalkyl; and each $R^8$ and $R^9$ is independently hydrogen, alkyl, aryl or aralkyl:

![Reaction Scheme 1](image)

Compounds of formula (A) and (B) can be prepared according to methods known to those of ordinary skill in the art or are commercially available, for example, from Aldrich Chemical Company, Inc. or from Maybridge Co.

In general, compounds of formula (C) are prepared by reacting a compound of formula (A) with an equimolar amount of a compound of formula (B) at 0°C to 40°C, preferably at ambient temperature, in the presence of a base, e.g., triethylamine, or in the presence of a second equivalent of the compounds of formula (B). The compounds of formula (C) are isolated from the resulting reaction mixture by conventional methods.
2. Compounds of formula (F)

Compounds of formula (F), as shown below, are also intermediates in the preparation of the compounds of the invention. As illustrated below in Reaction Scheme 2, compounds of formula (F) are prepared from compounds of formulae (D) and (E) where each X is independently chloro or fluoro; and R\(^2\) is alkoxy, haloalkoxy, \(-\text{O}(\text{CH})_p\text{C(O)}\text{OR}\) \(^\text{B}\) (where \(p\) is 1 to 6), \(-\text{N}(\text{R})(\text{R})\) \(^\text{B}\), \(-\text{N}(\text{R})(\text{CH}_2)_{n}\text{C(O)}\text{OR}\) \(^\text{B}\) (where \(n\) is 1 to 3), \(-\text{N}(\text{R})(\text{CH}_2)_{n}\text{C(O)}\text{N}(\text{R})(\text{CH}_2)_{n}\text{C(O)}\text{OR}\) \(^\text{B}\) (where each \(n\) is independently 1 to 3), morpholin-4-yl, 3-tetrahydrofuranyloxy; or \(R^2\) is aryloxy (optionally substituted by one or more substituents independently selected from the group consisting of \(-\text{OR}\) \(^\text{B}\), \(-\text{C(O)}\text{N}(\text{R})(\text{R})\) \(^\text{B}\), halo, alkyl, alkoxy, haloalkoxy, haloalkoxy, alkoxycarbonyl, alkoxy, haloalkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkyl, (alkylamino)carbonylalkyl, (dialkylamino)carbonylalkyl, (aryl amino) carbonylalkyl, (aralkylaminocarbonylalkenyl, aminocarbonylalkenyl, (alkylamino)carbonylalkenyl, (dialkylamino)carbonylalkenyl, (arylamine)carbonylalkenyl, (aralkylamine)carbonylalkenyl, (hydroxylalkoxy)carbonyl, (alkoxylalkoxy)carbonyl, (hydroxyalkoxy)alkoxycarbonyl, (alkoxyalkoxy) alkoxycarbonyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazolinyl (optionally substituted by alkyl); or \(R^2\) is 1-piperidinyl (optionally substituted by alkoxycarbonyl or alkoxycarbonylalkyl); or \(R^2\) is 1-piperazinyl (optionally substituted by alkyl, alkoxycarbonyl, or alkoxycarbonylalkyl); or \(R^2\) is (3,4)-piperidinoxy (optionally substituted by alky carbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, or tetrazolylalkyl); or \(R^2\) is piperidin-4-yaminol (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by alkyl, alkoxycarbonyl, alkoxy carbonylalkyl or aralkyl); or \(R^2\) is 3-pyrrolidinoxy (optionally substituted by alkyl, aralkyl or alkoxy carbonylalkyl); and each \(R^8\) and \(R^9\) is independently hydrogen, alkyl, aryl or aralkyl:

![Reaction Scheme 2](image)

Compounds of formulae (D) and (E) are commercially available, for example, from Aldrich Chemical Company, Inc., or may be prepared according to methods known to those skilled in the art.

In general, compounds of formula (F) are prepared by treating a compound of formula (E) with a compound of formula (E) in an aprotic solvent, for example, methylene chloride, at between about 0°C and 50°C, preferably at ambient temperature, and, if the hydrogen in the compound of formula (E) is an hydroxyl hydrogen, in the presence of a base, for example, cesium carbonate. The compound of formula (F) is isolated from the reaction mixture by standard techniques.
3. Compounds of formulae (J) and (K)

Compounds of formulae (J) and (K), as shown below, are also intermediates in the preparation of the compounds of the invention. As illustrated below in Reaction Scheme 3, compounds of formula (J) and (K) are prepared from compounds of formula (G) and formula (H) where A is -N= or -C(R11)= (where R11 is hydrogen, alkyl or halo); X is fluoro of chloro; R1 and R3 are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, -NR(R8)R9, -C(O)OR8, -C(O)NR(R8)R9, -C(O)N(R8)CH2C(O)NR(R8)R9, -N(R8)C(O)NR(R8)R9, -N(R8)C(O)R8, -N(R8)S(O)2R12, or -N(R8)C(O)NR(R8)CH2C(O)NR(R8)R9; R2 is hydrogen, alkyl, haloalkoxy, OR12, -C(O)OR8, -C(O)NR(R8)R9, -NR(R8)R9, -C(O)NR(R8)CH2mC(O)OR8 (where m is 0 to 3), -N(R8)(CH2)nC(O)OR8 (where n is 1 to 3), -N(CH2)pC(O)NR(R8)R9 (where n is 1 to 3), -O(CH2)nC(O)NR(R8)OR8 (where n is 1 to 3), -NR(R8)(CH2)nC(O)NR(R8)OR8 (where n is independently 1 to 3), morpholin-4-yl, 3-tetrahydrofuranox; or R2 is aryloxy (optionally substituted by one or more substituents independently selected from the group consisting of -OR12, -C(O)NR(R8)R9, halo, alkyl, alkoxycarbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonylalkyl, (alkylamino)carbonylalkyl, (dialkylamino)carbonylalkyl, (arylamino)carbonylalkyl, (arylalkylamino)carbonylalkyl, alkoxycarbonylalkyl, aminocarbonylalkenyl, alkoxycarbonylalkenyl, (alkylamino)carbonylalkenyl, (arylalkylamino)carbonylalkenyl, (arylalkylamino)carbonylalkenyl, (hydroxyalkylalkoxy)carbonyl, (alkoxy)alkoxycarbonyl, (hydroxyalkoxy)alkoxycarbonyl, (alkoxy)alkoxycarbonyl, tetracyclo, morpholin-4-ylalkyl, and (1,2)-imidazolinyl (optionally substituted by alkyl); or R2 is pipеразин-1-ил (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxycarbonyl, and alkoxycarbonylalkyl); or R2 is 1-piperazinoïl (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxycarbonyl, and alkoxycarbonylalkyl); or R2 is piperidin-1-ил (optionally substituted by one or more substituents selected from the group consisting of alkoxycarbonyl, and alkoxycarbonylalkyl); or R2 is 3,4-piperidinoloxî (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxycarbonyl, and alkoxycarbonylalkyl); or R2 is pipеразин-1-ил (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxycarbonyl, and alkoxycarbonylalkyl); or R2 is piperedin-4-ylmino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxycarbonyl, and alkoxycarbonylalkyl and aralkyl); or R2 is 3-pyrrrolidinoloxî (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxycarbonyl and alkoxycarbonylalkyl); R4 is independently hydrogen, halo, alkyl, nitro, -OR12, -C(O)OR8, -C(O)NR(R8)R9, -NR(R8)R9, or -N(H)C(O)R8; each R8 and R9 is independently hydrogen, alkyl, aryl or aralkyl; and R12 is alkyl, aryl or aralkyl;
Compounds of formula (G) include compounds of formulae (C) and (F) as described above, or may be prepared by methods described herein or by methods known to one of ordinary skill in the art. They may also be commercially available, for example, from Aldrich Chemical Co., Inc. or from Maybridge Co. Compounds of formula (H) may be prepared by methods known to one of ordinary skill in the art or may be commercially available, for example, from Aldrich Chemical Co., Inc.

In general, the compounds of formulae (J) and (K) are prepared by reacting a compound of formula (G) with a compound of formula (H) (in an equimolar amount for a compound of formula (K) and with two or more equivalents of a compound of formula (H) for a compound of formula (J)) in the presence of a base, *e.g.*, sodium hydride or cesium carbonate, at temperatures between about 20°C and 120°C, preferably, for compounds of formula (J), at temperatures of around 50°C, in an aprotic solvent, for example, dimethylformamide, DMSO or acetonitrile, for a period of time sufficient to complete the desired reaction as monitored by thin layer chromatography (TLC). Compounds of formulae (J) and (K) are then isolated from the reaction mixture by standard isolation techniques.

In a similar manner, compounds of formula (G) may be treated with compounds of formula (H) wherein the hydroxy group is replaced by an amino group to produce compounds of formulae (J) and (K) wherein the ether connecting group is replaced by an amino connecting group. The amino group can then be alkylated by standard procedures.
Compounds of formulae (J) and (K) wherein R⁴ is an amino group may be further treated with an alkylsulfonyl halide, e.g., methylsulfonylchloride, under basic conditions at ambient temperature to produce compounds of formulae (J) and (K) wherein R⁴ is -N(H)S(O)₂R¹².

4. Compounds of formula (M)

Compounds of formula (M), as shown below, are also intermediates in the preparation of the compounds of the invention. As illustrated below in Reaction Scheme 4, compounds of formula (M) are prepared from compounds of formula (K) and formula (L) where A is -N = or -C(R¹¹) = (where R¹¹ is hydrogen, alkyl or halo); X is fluoro of chloro; R¹ and R³ are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, -N[R⁸]R⁹, -C(O)OR⁸, -C(O)N[R⁸]R⁹, -C(O)N[R⁸]CH₂C(O)N[R⁸]R⁹, or -N[R⁸]C(O)N[R⁸]CH₂C(O)N[R⁸]R⁹; R² is hydrogen, alkyl, haloalkoxy, -OR¹², -C(O)OR⁸, -C(O)N[R⁸]R⁹, -N[R⁸]R³⁹, -C(O)N[R⁸]CH₂ₙC(O)OR⁸ (where n is 1 to 3), -N[(CH₂)ₚN[R⁸]R⁹]CH₂ₙC(O)OR⁸ (where each n is 1 to 3), -O(CH₂)ₚC(O)N[R⁸]R⁹ (where n is 1 to 3), -(CH₂)ₚC(O)OR⁸ (where p is 1 to 6), -N[R⁸]CH₂ₙC(O)N[R⁸]CH₂ₚC(O)OR⁸ (where each n is independently 1 to 3), morpholin-4-yl, 3-tetrahydrofuranoyl; or R² is aryl (optionally substituted by one or more substituents independently selected from the group consisting of -OR¹², -C(O)N[R⁸]R⁹, halo, alkyl, alkoxy carbonyl, haloalkoxy, haloalkoxy carbonyl, alkoxy carbonyl alkyl, aminocarbonylalkyl, (alkylamino) carbonylalkyl, (dialkylamino) carbonylalkyl, (arylamino) carbonylalkyl, (aralkylamino) carbonylalkyl, alkoxy carbonylalkenyl, aminocarbonylalkenyl, (alkylamino) carbonylalkenyl, (dialkylamino) carbonylalkenyl, (arylamino) carbonylalkenyl, (aralkylamino) carbonylalkenyl, (hydroxylalkoxy) carbonyl, (alkoxy) alkoxy carbonyl, (hydroxyalkoxy) alkoxy carbonyl, (alkoxy) alkoxy carbonyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazolinyl (optionally substituted by alkyl)); or R³ is piperazin-1-yl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy carbonyl, and alkoxy carbonylalkyl); or R² is 1-piperazinoyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy carbonyl, and alkoxy carbonylalkyl); or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy carbonyl, and alkoxy carbonylalkyl); or R² is (3,4)-piperidinoxy (optionally substituted by one or more substituents selected from the group consisting of alky carbonyl, alkoxy carbonyl, alkoxy carbonylalkyl, and tetrazolylalkyl); or R² is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy carbonyl, alkoxy carbonylalkyl and aralkyl); or R² is 3-pyrrolidinoxy (optionally substituted by one or more substituents selected from the group consisting of alkyl, aralkyl, alkoxy carbonyl and alkoxy carbonylalkyl); R⁴ and R⁷ are independently hydrogen, halo, alkyl, nitro, -OR¹², -C(O)OR⁸, -C(O)N[R⁸]R⁹, -N[R⁸]R⁹, or -N(H)C(O)R⁸; R⁶ is halo, alkyl, haloalkyl, haloalkoxy, nitro, amino, ureido, guanidino, -OR¹², -C(NH)NH₂, -C(NH)NOH, -C(O)R¹⁰, -(CH₂)ₚC(O)N[R⁸]R⁹ (where m is 0 to 3), -(CH₂)ₚC(O)N[R⁸]R⁹, -(CH₂)ₚC(O)N[R⁸]R⁹ (where m is 0 to 3), -(CH₂)ₚC(O)OR⁸ (where m is 0 to 3), -N(H)C(O)R⁸, (1,2)-tetrahydropropimidinyl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy carbonyl, and alkoxy carbonylalkyl); or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy carbonyl, alkoxy carbonylalkyl and aralkyl).
substituted by alkyl, (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl); each R^8 and R^9 is independently hydrogen, alkyl, aryl, or aralkyl; and R^{12} is alkyl, aryl or aralkyl:

![Reaction Scheme 4](image)

Compounds of formula (K) are prepared according to the methods described herein (see Reaction Scheme 3 above). Compounds of formula (L) are commercially available, for example, from Aldrich Chemical Co., or from Maybridge Co., or may be prepared according to methods known to those of ordinary skill in the art.

In general, the compounds of formula (M) are prepared in a manner similar to that described above for compounds of formula (J) and (K).

Compounds of formula (M) where R^4 or R^7 is hydroxy may be reacted with a haloalkane, such as iodomethane, under standard conditions to produce the corresponding compounds of formula (M) where R^4 or R^7 is alkoxy.

Compounds of formula (M) where R^6 or R^7 contains -C(O)OR^8 where R^8 is alkyl or aryl may be hydrolyzed under basic conditions (for example, in the presence of sodium hydroxide) to produce compounds of formula (M) where R^6 or R^7 contains -C(O)OR^8 where R^8 is hydrogen.

Compounds of formula (M) where the ether connecting group has been replaced by an unsubstituted amino connecting group may be treated with an alkylating agent, such as iodomethane, in the presence of a base, to produce compounds of formula (M) wherein the amino connecting group is substituted by alkyl, aryl, or aralkyl. In addition, compounds of formula (K) can be treated with a compound of formula (L) wherein the hydroxy group is replaced by a hydroxymethyl (-CH_2OH) group to produce the corresponding compounds of formula (M).

Compounds of formula (M) where each R^6 and R^7 independently contains -C(O)OR^8 where R^8 is hydrogen may be amidated or esterified under standard conditions to produce compounds of formula (M) where R^6 or R^7 contains -C(O)OR^8 where R^8 is alkyl, aryl or aralkyl, or compounds of formula (M) where R^6 or R^7 contains -C(O)NR^8R^9 where R^8 and R^9 are independently hydrogen, alkyl, aryl or aralkyl.
Compounds of formula (M) where R² is nitro may be reduced under standard conditions to produce compounds of formula (M) where R³ is amino; which can then be reacted with the appropriate acid halide or aryl- or alkylsulfonyl halide to produce compounds of formula (M) where R³ is \( -N(R^8)C(O)R^8 \) or \( -N(R^8)S(O)_{2}R^8 \) where R⁸ and R¹² are as defined above. In addition, compounds of formula (M) where R³ is amino can be reacted with an isocyanate or chloroformate to produce compounds of formula (M) where R³ is \( -N(R^8)C(O)N(R^8)R^8 \) or \( -N(R^8)C(O)OR^8 \).

5. Compounds of formula (P)

Compounds of formula (P), as shown below, are also intermediates in the preparation of the compounds of the invention, particularly those compounds of formula (I) wherein A is \(-C(R^{11})=\). As illustrated below in Reaction Scheme 5, compounds of formula (P) are prepared from compounds of formulae (N) and (O) where X is fluoro or chloro; R¹ and R² are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, \(-N(R^8)R^8\), \(-Cl(O)OR^8\), \(-C(O)N(R^8)R^8\), \(-C(O)NR^8\)CH₂C(O)N(R⁸)R⁸, \(-N(R^8)C(O)NR^8\), \(-N(R^8)C(O)\)R⁸, \(-N(R^8)S(O)_{2}R^8\), or \(-N(R^8)C(O)NR^8\)CH₂C(O)N(R⁸)R⁸; R² is hydrogen, alkyl, haloalkyl, \(-OR^8\), \(-Cl(O)OR^8\), \(-C(O)NR^8\)R⁸, \(-N(R^8)R^8\), \(-C(O)NR^8\)C(O)OR⁸ (where m is 0 to 3), \(-N(R^8)(CH_2)_nNR^8\)C(O)OR⁸ (where n is 1 to 3), \(-N(CH_2)_nNR^8\)R⁸, \(-O(CH_2)_nC(O)NR^8\)R⁸ (where n is 1 to 3), \(-O(CH_2)_nC(O)OR^8\) (where p is 1 to 6), \(-N(R^8)(CH_2)_nC(O)NR^8\)CH₂C(O)N(R⁸)R⁸ (where each n is independently 1 to 3), morpholin-4-yl, 3-tetrahydrofuranox; or R² is arylxyloxy (optionally substituted by one or more substituents independently selected from the group consisting of \(-OR^8\), \(-Cl(O)NR^8\)R⁸, halo, alkyl, carboxy, alkoxy carbonyl, haloalkoxy, haloalkoxy carbonyl, alkoxy carbonylalkyl, carboxyalkyl, aminocarbonylalkyl, \((\text{dialkylamino})\)carbonylalkyl, (arylaminocarbonyl)alkyl, (arylaminocarbonyl)alkyl, (alkylaminocarbonyl)alkyl, alkoxy carbonylalkenyl, carboxyalkenyl, aminocarbonylalkenyl, (alkylaminocarbonyl)alkenyl, (arylaminocarbonyl)alkenyl, (alkylaminocarbonyl)alkenyl, (arylaminocarbonyl)alkenyl, (hydroxylalkoxy)carbonyl, (alkoxy)alkoxy carbonyl, (hydroxyalkoxy)alkoxy carbonyl, (alkoxy)alkoxy carbonylalkyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazolinyl (optionally substituted by alkyl)); or R² is piperazin-1-yl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, carboxy, carboxyalkyl, alkoxy carbonyl, and alkoxy carbonylalkyl); or R² is 1-piperazinyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, carboxy, carboxyalkyl, alkoxy carbonyl, and alkoxy carbonylalkyl); or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from the group consisting of carboxy, carboxyalkyl, alkoxy carbonyl, and alkoxy carbonylalkyl); or R² is (3,4)-piperidinyl (optionally substituted by one or more substituents selected from the group consisting of alkylcarbonyl, carboxy, alkoxy carbonyl, carboxyalkyl, alkoxy carbonylalkyl, alkoxy carbonylalkyl, and tetrazolylalkyl); or R² is piperidin-4-yl (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy carbonyl, carboxyalkyl, alkoxy carbonylalkyl and aralkyl); or R² is 3-pyrrolidinyl (optionally substituted by one or more substituents selected from...
the group consisting of alkyl, aralkyl, amidino, 1-iminoethyl, carboxy, carboxyalkyl, alkoxycarbonyl and alkoxycarbonylalkyl; each $R^8$ and $R^9$ is independently hydrogen, alkyl, aryl, or aralkyl; $R^{11}$ is hydrogen, alkyl or halo; and $R^{12}$ is alkyl, aryl or aralkyl:

**REACTION SCHEME 5**

Compounds of formulae (N) and (O) may be prepared according to ordinary skill in the art, or by methods described herein, or may be commercially available, for example, from Aldrich Chemical Co., Inc.

In general, compounds of formula (P) are prepared in the same manner as described above for compounds of formula (J), except the temperatures at which the reaction is run are elevated to between about 50°C and 130°C. The compounds of formula (P) are isolated from the reaction mixture by conventional techniques.

B. Preparation of the Compounds of the Invention

In the following Reaction Scheme 6, compounds of formula (la) are compounds of formula (I) as described above in the Summary of the Invention wherein $Z^1$ and $Z^2$ are -O-. As illustrated below in Reaction Scheme 6, wherein A is -N= or -C(R^{11})= (where $R^{11}$ is hydrogen, alkyl or halo); $R^1$ and $R^3$ is hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, -N(R^{8})R^{9}, -C(O)OR^{13}, -C(O)N(R^{8})R^{9}, -C(O)N(R^{8})CH_{2}C(O)N(R^{8})R^{9}, -N(R^{8})C(O)N(R^{8})R^{9}, -N(R^{8})C(O)R^{8}, -N(R^{8})SO_{2}R^{12}, or -N(R^{8})C(O)N(R^{8})CH_{2}C(O)N(R^{8})R^{9}; $R^2$ is hydrogen, alkyl, haloalcohol, -OR^{8}, -C(O)OR^{13}, -C(O)N(R^{8})R^{9}, -N(R^{8})R^{9}, -C(O)N(R^{8})CH_{2}nC(O)OR^{13} (where $n$ is 0 to 3), -N(CH_{2})_{n}C(O)N(R^{8})R^{9} (where $n$ is 1 to 3), -N(CH_{2})_{n}C(O)N(R^{8})R^{9} (where $n$ is 1 to 3), -N(CH_{2})_{p}C(O)OR^{13} (where $p$ is 1 to 6), -N(R^{8})C(O)C(O)N(R^{8})CH_{2}nC(O)OR^{13} (where $n$ is independently 1 to 3), morpholin-4-yl, 3-tetrahydrofuranoxy; or $R^2$ is aryloxy (optionally substituted by one or more substituents independently selected from the group consisting of -OR^{8}, -C(O)N(R^{8})R^{9}, halo, alkyl, carboxy, alkoxyxcarbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxyxcarbonylalkyl, carboxyalkyl, aminocarbonylalkyl, (alkylamino)carbonylalkyl, (dialkylamino)carbonylalkyl, (arylamino)carbonylalkyl, (arylamino)carbonylalkyl, alkoxyxcarbonylalkenyl, carboxyalkenyl,
aminocarbonylalkenyl, (alkylamino)carbonylalkenyl, (dialkylamino)carbonylalkenyl, (arylamino)carbonylalkenyl, (aralkylamino)carbonylalkenyl, (hydroxyalkoxy)carbonyl, (alkoxy)alkoxycarbonyl, (hydroxyalkoxy)alkoxycarbonyl, (alkoxy)alkoxycarbonyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazoliny1 (optionally substituted by alkyl)); or R² is piperazin-1-yl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, carboxy, carboxyalkyl, alkoxyalkyl, and alkoxycarboxylalkyl); or R² is 1-piperazinoyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, carboxy, carboxyalkyl, alkoxyalkyl, and alkoxycarboxylalkyl); or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from the group consisting of carboxy, carboxyalkyl, alkoxyalkyl, and alkoxycarboxylalkyl); or R² is (3,4)-piperidinyloxoy (optionally substituted by one or more substituents selected from the group consisting of alkylcarbonyl, carboxy, alkoxyalkyl, carboxyalkyl, alkoxyalkylalkyl, and tetrazolylalkyl); or R² is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxyalkyl, carboxyalkyl, alkoxyalkylalkyl and aralkyl); or R² is 3-pyrrolidinyloxy (optionally substituted by one or more substituents selected from the group consisting of alkyl, aralkyl, amidino, 1-inoethoxy, carboxy, carboxyalkyl, alkoxyalkyl and alkoxycarboxylalkyl); R⁴ and R⁷ are independently hydrogen, halo, alkyl, nitro, -OR⁸, -C(O)OR¹³, -C(O)N(R⁸)R⁹, -N(R⁸)R⁹, or -N(H)C(O)R⁸; R⁶ is halo, alkyl, haloalkyl, haloalkoxy, nitro, amino, guanidino, -OR⁸, -C(NH)NH₂, -C(NH)NOH, -C(O)R¹⁰, -(CH₂)ₘC(O)N(R⁸)R⁹ (where m is 0 to 3), -(CH₂)ₘC(O)N(R⁸)R⁹ (where m is 0 to 3), -(CH₂)ₘC(O)OR¹³ (where m is 0 to 3), -N(H)C(O)R⁸, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazoliny1 (optionally substituted by alkyl), or (1,2)-imidazoliny1 (optionally substituted by alkyl); each R⁸ and R⁹ is independently hydrogen, alkyl, aryl, or aralkyl; R¹⁰ is hydrogen, alkyl, aryl, aralkyl, 4-morpholiny1, 4-piperaziny1, 4-(N-methyl)piperaziny1, or 1-piperidinyl; R¹² is alkyl, aryl or aralkyl; and R¹³ is hydrogen, alkyl or aralkyl; compounds of formula (Ia) are prepared from compounds of formula (Q) as follows:
Compounds of formula (Q) are prepared as described herein above for compounds of formulae (J), (M), and (P).

In general, compounds of formula (la) are prepared from compounds of formula (Q) by dissolving the compound of formula (Q) in an anhydrous alkanol, preferably ethanol and then treating the solution with an anhydrous mineral acid, preferably HCl, while maintaining the reaction temperatures between about -78°C and ambient temperature for between 2 hours and 24 hours, allowing the temperature to rise to ambient temperature while monitoring for reaction completion, for example, through thin layer chromatography. The solvent is then removed and the resulting residue dissolved in fresh anhydrous alkanol, preferably ethanol. The resulting solution was then treated with anhydrous ammonia at ambient pressure or in a sealed flask, at temperatures from between ambient temperature and 100°C for about 1 to about 5 hours. The compounds of formula (la) are then isolated from the reaction mixture by standard techniques.

Compounds of formula (la) wherein \( R^6 \) is \(-\text{CNH})\text{NH}_2 \) or \(-\text{CNH})\text{NHOH} \) are produced from the corresponding cyano compounds.

Alternatively, instead of treating the resulting residue above with anhydrous ammonia, the resulting residue may be treated with a compound of the formula \( \text{NH}_2\text{OR}^8 \) to afford the corresponding compound of formula (la) wherein \( R^5 \) is \(-\text{CNH})\text{NH}\text{OR}^8 \).

In addition, compounds of formula (la) which contain a \(-\text{C(O})\text{OR}^{13} \) group may be treated under standard transesterification conditions with an phenol or a naphthol (either optionally substituted by halo, alkyl, alkoxy, amino, nitro or carboxyl) to produce compounds of the invention which contain a \(-\text{C(O})\text{OR}^8 \) group where \( R^8 \) is aryl.

Compounds of formula (la) wherein \( R^6 \) is \(-\text{CNH})\text{NH}_2 \) or \(-\text{CNH})\text{NHOH} \) are produced from the corresponding cyano compounds in a similar manner as that described above for the compounds of formula (la).

In addition, compounds of formula (la) where \( R^1 \), \( R^2 \), \( R^3 \), \( R^4 \), and \( R^7 \) contains a \(-\text{N}(\text{R}^8)\text{R}^9 \) group where \( R^8 \) and \( R^9 \) are hydrogen, can be treated with the appropriate alkylating agents to afford the corresponding compounds of formula (la) where \( R^1 \), \( R^2 \), \( R^3 \), \( R^4 \), and \( R^7 \) contains \(-\text{N}(\text{R}^8)\text{R}^9 \), \(-\text{N}(\text{R}^8)\text{S(O)}\text{R}^{12} \), \(-\text{N}(\text{R}^8)\text{C(O)}\text{N}(\text{R}^8)\text{R}^9 \), \(-\text{N}(\text{R}^8)\text{C(O)}\text{N}(\text{R}^8)\text{CH}_2\text{C(O)}\text{N}(\text{R}^8)\text{R}^9 \), or \(-\text{N}(\text{R}^8)\text{C(O)}\text{R}^8 \) where each \( R^8 \) and \( R^9 \) is independently hydrogen, alkyl, aryl or aralkyl.

Compounds of formula (la) may be further treated with the appropriate acid halide, preferably acid chloride, or with the appropriate acid anhydride or an equivalent, to yield compounds of the invention wherein \( R^5 \) is \(-\text{CNH})\text{NH}\text{C(O})\text{R}^8 \) where \( R^8 \) is hydrogen, alkyl, aryl or aralkyl.

Alternatively, compounds of formula (la) may be further treated with carbamoyl chlorides or their equivalents to yield compounds of the invention where \( R^5 \) is \(-\text{CNH})\text{NH}\text{C(O})\text{R}^{12} \) where \( R^{12} \) is alkyl, aryl or aralkyl.

Alternatively, compounds of formula (la) may be further treated with compounds of the formula \( \text{R}^{12}\text{S(O)}\text{R}^{16} \) is described in the Summary of the Invention in a polar solvent, such as methylene chloride, at ambient temperature to afford compounds of the invention.
where R\(^6\) is \(-C(\text{NH})\text{N}(\text{H})\text{S}(\text{O})_2R^{12}\).

Alternatively, compounds of formula (la) may be further treated with an appropriately \(N\)-R\(^9\)-substituted phenylcarbamate in a polar solvent, preferably methylene chloride, at ambient temperature, for about 6 to 24 hours, preferably for about 12 hours, to afford compounds of the invention where R\(^5\) is \(-C(\text{NH})\text{N}(\text{H})\text{C}(\text{O})\text{N}(\text{R})_2\text{R}\(^9\))\(^9\).

Compounds of formula (la) wherein R\(^1\), R\(^2\) or R\(^3\) contains \(-\text{C}(\text{O})\text{N}(\text{R})_2\text{R}\(^9\)) or \(-\text{C}(\text{O})\text{OR}\(^1\)) where each R\(^8\) and R\(^9\) are independently alkyl, haloalkyl, aryl or aralkyl, and R\(^1\) is alkyl or aralkyl may be hydrolyzed under acidic conditions to prepare compounds of formula (la) where R\(^1\), R\(^2\) or R\(^3\) contains \(-\text{C}(\text{O})\text{OR}\(^8\)) where R\(^8\) is hydrogen.

Under the same conditions as previously described, compounds of formula (la) where R\(^1\), R\(^2\) or R\(^3\) contains \(-\text{C}(\text{O})\text{OR}\(^1\)) where R\(^1\) is hydrogen, alkyl, or aralkyl, may be amidated to form compounds of formula (la) where R\(^1\), R\(^2\) or R\(^3\) contains \(-\text{C}(\text{O})\text{N}(\text{R})_2\text{R}\(^9\)) where R\(^8\) and R\(^9\) are independently hydrogen, alkyl, aryl or aralkyl.

Compounds of formula (la) where R\(^4\) is \(-\text{OR}\(^8\)) where R\(^8\) is alkyl, aryl or aralkyl, may be converted to compounds of formula (la) where R\(^4\) is \(-\text{OR}\(^8\)) where R\(^8\) is hydrogen by treatment with boron tribromide in an aprotic solvent, for example, methylene chloride, at temperatures at first between -80°C and 0°C, then at ambient temperature, for about 4 hours to about 16 hours.

Alternatively, compounds of formula (la) where R\(^4\) is \(-\text{OR}\(^8\)) where R\(^8\) is arylmethyl, preferably, benzyl, may be treated with hydrogen and the appropriate catalyst, for example, palladium on carbon, to give compounds of formula (la) where R\(^4\) is \(-\text{OR}\(^8\)) where R\(^8\) is hydrogen.

Compounds of formula (la) where R\(^2\) is 3-pyrollidinylxox substituted by arylmethyl on the nitrogen may be treated under standard hydrogenolysis conditions to remove the arylmethyl group to produce compounds of formula (la) where R\(^2\) is unsubstituted 3-pyrollidinylxox, which can then be reacted with the appropriate imidate to produce the compounds of formula (la) where R\(^2\) is 3-pyrollidinylxox substituted by 1-iminoethyl, or with the appropriate haloalkyl esters to produce the compounds of formula (la) where R\(^2\) is 3-pyrollidinylxox substituted by alkoxyacarbonylalkyl.

In summary, compounds of the invention, are prepared by:

1) reacting a compound of formula (A) as described above with a compound of formula (B) as described above under the conditions as described above to produce a compound of formula (C) as described above, which is an intermediate in the preparation of the compounds of the invention; or

2) reacting a compound of formula (D) as described above with a compound of formula (E) as described above under conditions as described above to produce a compound of formula (F) as described above, which is an intermediate in the preparation of the compounds of the invention; or

3) reacting a compound of formula (G) as described above, which can be a compound of formula (C) as described above or a compound of formula (F) as described above, with a compound of formula (H) as described above under conditions as described above to produce a
compound of formula (J) or a compound of formula (K) as described above, which are intermediates in the preparation of the compounds of the invention; then

4) reacting a compound of formula (K) as described above with a compound of formula (L) as described above under conditions as described above to produce a compound of formula (M) as described above, which is an intermediate in the preparation of the compounds of the invention; or

5) reacting a compound of formula (N) as described above with a compound of formula (O) as described above under conditions as described above to produce a compound of formula (P) as described above, which is an intermediate in the preparation of the compounds of the invention; then

6) reacting a compound of formula (Q) as described above, which can be a compound of formula (J), a compound of formula (M) or a compound of formula (P) as described above, with the appropriate reagent under the conditions as described above to form compounds of formula (Ia) as described above.

Similar reactions may be performed on similar starting materials and intermediates to produce the corresponding compounds of the inventions not depicted in the Reaction Schemes above.

In addition, all compounds of the invention that exist in free base form or free acid form may be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic acid, or by the appropriate inorganic or organic base. Salts of the compounds of the invention can also be converted to the free base form or to the free acid form or to another salt.

The following specific preparations and examples are provided as a guide to assist in the practice of the invention, and are not intended as a limitation on the scope of the invention.

**PREPARATION 1**

4-Methoxy-2,3,5,6-tetrafluoropyridine

A. To pentafluoropyridine (1.0 g, 5.9 mmol) in petroleum ether (60 mL) at 0°C was added sodium methoxide (0.32 mg, 5.9 mmol). After stirring for 12 hours at ambient temperature, the reaction was washed with water, dried (MgSO₄), and the solvent was removed *in vacuo* to give 4-methoxy-2,3,5,6-tetrafluoropyridine; NMR (CDCl₃) 4.3 ppm.

B. In a similar manner, the following compounds were made:

- 2,3,5,6-tetrafluoro-4-(2,2,2-trifluoroethoxy)pyridine; and
- 2,3,5,6-tetrafluoro-4-(1,3-difluoroprop-2-oxy)pyridine.

**PREPARATION 2**

4-Dimethylamino-2,3,5,6-tetrafluoropyridine

A. To methylene chloride (50 mL) cooled in an ice bath was added pentafluoropyridine (2.0 g, 11.8 mmol) and dimethylamine (2.97 mL of a 40% solution in water, 24 mmol). After stirring
for 30 minutes the solution was washed with water, and dried over basic alumina. The solvent was removed in vacuo to give 4-dimethylamino-2,3,5,6-tetrafluoropyridine; NMR (CDCl₃) 3.13 (m, 6) ppm.

B. In a similar manner, the following compounds were made:

1-(2,3,5,6-tetrafluoropyridin-4-yl)piperidine-4-carboxylic acid, ethyl ester; NMR (CDCl₃) 4.15 (q, 2), 3.7 (m, 2), 3.25 (m, 2), 2.55 (m, 1), 2.05 (m, 2), 1.9 (m, 2), 1.15 (t, 3) ppm;

1-(2,3,5,6-tetrafluoropyridin-4-yl)piperidine-3-carboxylic acid, ethyl ester; NMR (CDCl₃) 4.15 (q, 2), 3.8 (m, 1), 3.55 (m, 1), 3.4 (m, 1), 3.25 (m, 1), 2.7 (m, 1), 2.15 (m, 1), 1.8 (m, 3), 1.15 (t, 3) ppm;

4-(piperidin-1-yl)-2,3,5,6-tetrafluoropyridine; NMR (CDCl₃) 3.4 (m, 4), 1.7 (m, 6) ppm;

4-(4-methylpiperazin-1-yl)-2,3,5,6-tetrafluoropyridine; NMR (CDCl₃) 3.45 (m, 4), 2.5 (m, 4), 2.3 (s, 3) ppm;

4-(2,3,5,6-tetrafluoropyridin-4-yl)piperazine-1-acetic acid, ethyl ester; NMR (CDCl₃) 4.2 (q, 2), 3.55 (m, 4), 3.3 (s, 2), 2.7 (m, 4), 1.3 (t, 3) ppm;

N-methyl-N-(2,3,5,6-tetrafluoropyridin-4-yl)glycine, ethyl ester; and

4-(morpholin-1-yl)-2,3,5,6-tetrafluoropyridine.

**PREPARATION 3**

1-[(2,6-Dichloropyridin-4-yl)carbonyl]-4-methylpiperazine, Hydrochloride

To methylene chloride (15 mL) was added 2,6-dichloropyridine-4-carbonyl chloride (1.0 g, 4.8 mmol) and 1-methylpiperazine (0.48 g, 4.8 mmol). After stirring for 1 day, the reaction was poured into ether. The resulting solid was filtered to give 1-[(2,6-dichloropyridin-4-yl)carbonyl]-4-methylpiperazine, hydrochloride.

**PREPARATION 4**

3-(1-Methylimidazolin-2-yl)phenol, Hydrobromide

A. To ethanol (200 mL) was added 3-methoxybenzonitrile (10.9 g, 82 mmol). The solution was cooled in an ice bath and HCl (g) was bubbled into the solution. The reaction was warmed to ambient temperature and stirred for 2 days. The solvent was removed in vacuo and the residue was slurried in ethanol (20 mL). N-methylhexylene--diamine (12 g, 160 mmol) was added and the reaction was refluxed for 7 hours. The solvent was removed in vacuo and the residue was chromatographed on silica gel with methylene chloride/methanol/ammonium hydroxide (20/1/0.1). The resulting oil was dissolved in 48% HBr (20 mL) and refluxed for 19 hours. The mixture was cooled to ambient temperature and the solvent was removed in vacuo to give 3-(1-methylimidazolin-2-yl)phenol, hydrobromide.

B. In a similar manner, the following compound is made:

3-(1-methyltetrahydroxypyrimidin-2-yl)phenol, hydrobromide.
PREPARATION 5

3,3'-[2,6-Pyridinediyl]bis(oxy)bis(benzonitrile)

A. To sodium hydride (0.38 g, 9.5 mmol) in N,N-dimethylformamide (3 mL) was added 3-cyanophenol (1.1 g, 8.9 mmol) and 2,6-difluoropyridine (0.4 mL, 4.4 mmol). After heating in an oil bath at 100°C for 15 hours the reaction was partitioned with ethyl acetate and water. The organic layer was separated, washed with water, dried (Na$_2$SO$_4$), and the solvent was removed in vacuo. The residue was chromatographed on silica gel (50 g) with methylene chloride/hexane (3/1) to give 3,3'-[2,6-pyridinediyl]bis(oxy)bis(benzonitrile). Recrystallization from ethyl acetate/hexane gave pure 3,3'-[2,6-pyridinediyl]bis(oxy)bis(benzonitrile); NMR (CDCl$_3$) 7.79 (t, 1), 7.45 (m, 4), 7.32 (m, 4), 6.72 (d, 2) ppm.

B. In a similar manner, the following compounds were made:

4,4'-[2,6-pyridinediyl]bis(oxy)bis(benzonitrile); NMR (CDCl$_3$) 7.8 (t, 1), 7.6 (d, 4), 7.2 (d, 4), 6.8 (d, 2) ppm;

3,3'-[3,5-dichloro-2,6-pyridinediyl]bis(oxy)bis(benzonitrile); NMR (CDCl$_3$) 7.95 (s, 1), 7.45 (m, 4), 7.2 (m, 4) ppm;

4,4'-[3,5-dichloro-2,6-pyridinediyl]bis(oxy)bis(benzonitrile); NMR (CDCl$_3$) 7.95 (s, 1), 7.6 (d, 4), 7.1 (d, 4) ppm;

2,6-bis(3-cyanophenoxy)pyridine-4-carboxylic acid, ethyl ester; NMR (CDCl$_3$) 7.45 (m, 4), 7.35 (m, 6), 4.45 (q, 2), 1.45 (t, 3) ppm;

2,6-bis(3-cyanophenoxy)pyridine-3-carboxylic acid, ethyl ester; NMR (CDCl$_3$) 8.4 (d, 1), 7.45 (m, 4), 7.25 (m, 4), 6.75 (d, 1), 4.4 (q, 2), 1.45 (t, 3) ppm;

3,3'-[3,5-difluoro-2,6-pyridinediyl]bis(benzonitrile); NMR (CDCl$_3$) 7.55 (t, 1), 7.45 (m, 4), 7.29 (m, 4) ppm;

3,3'-[2,6-pyrazinediyl]bis(oxy)bis(benzonitrile); NMR (CDCl$_3$) 8.2 (s, 2), 7.5 (m, 4), 7.3 (m, 4) ppm;

3,3'-[2,6-pyrimidinediyl]bis(oxy)bis(benzonitrile); NMR (CDCl$_3$) 8.4 (d, 1), 7.5 (m, 4), 7.4 (m, 4), 6.8 (d, 1) ppm;

3,3'-[3,5-difluoro-4-methyl-2,6-pyridinediyl]bis(benzonitrile); NMR (CDCl$_3$) 7.44 (m, 4), 7.27 (m, 4), 2.4 (s, 3) ppm;

3,3'-[4-nitro-1,3-phenylenebis(oxy)]bis(benzonitrile); NMR (CDCl$_3$) 8.13 (d, 1), 7.5 (m, 4), 7.3 (m, 4), 6.84 (dd, 1), 6.69 (d, 1) ppm; and

3,3'-[3-trifluoromethyl-2,6-pyridinediyl]bis(benzonitrile); NMR (CDCl$_3$) 8.05 (t, 1), 7.5 (m, 4), 7.3 (m, 4), 6.8 (d, 1) ppm.

PREPARATION 6

3-{[(3,5,6-Trifluoro-4-methylpyridin-2-yl)oxy]benzonitrile

A. To 2,3,5,6-tetrafluoro-4-methylpyridine (0.71 g, 4.3 mmol) dissolved in acetonitrile (5 mL) was added 3-cyanophenol (0.5 g, 4.2 mmol) and cesium carbonate (1.44 g, 4.4 mmol). The reaction was heated in an oil bath at 45 °C for 16 hours and partitioned with ether and water. The
organic layer was separated, washed with brine, dried (Na$_2$SO$_4$), and the solvent removed in vacuo.

Chromatography on silica gel with methylene chloride/hexane (7/3) gave 3-[(3,5,6-trifluoro-4-methylpyridin-2-yl)-oxy]benzonitrile; NMR (CDCl$_3$) 7.55 (m, 2), 7.45 (m, 2), 2.24 (s, 3) ppm;

B. In a similar manner, the following compounds were made:

4-[(2,3,5,6-tetrafluoropyridin-4-yl)oxy]-3-methoxybenzoic acid, ethyl ester;

3-(4-dimethylamino-3,5,6-trifluoropyridin-2-yl)-4-methoxybenzonitrile; NMR (CDCl$_3$)

7.55 (d, 1), 7.4 (s, 1), 7.05 (d, 1), 4.15 (q, 2), 3.8 (s, 3), 3.7 (m, 2), 2.55 (m, 1), 1.9 (m, 2), 1.15 (t, 3) ppm;

1-[2-(5-cyano-2-methoxyphenoxo)-3,5,6-trifluoropyridin-4-yl]piperidine-4-carboxylic acid, ethyl ester; NMR (CDCl$_3$) 7.5 (d, 1), 7.4 (s, 1), 7.05 (d, 1), 4.15 (q, 2), 3.8 (s, 3), 3.8 (m, 1), 3.55 (m, 1), 3.4 (m, 1), 3.25 (m, 1), 2.7 (m, 1), 2.15 (m, 1), 1.8 (m, 3), 1.15 (t, 3) ppm;

2-chloro-6-[(5-cyano-2-methoxyphenoxo)pyridine-4-carboxylic acid, ethyl ester; NMR (CDCl$_3$) 7.6 (m, 2), 7.4 (m, 2), 7.0 (d, 2), 4.4 (q, 2), 3.8 (s, 3), 1.4 (t, 3) ppm;

2-chloro-6-(3-dimethylaminophenoxo)pyridine-4-carboxylic acid, ethyl ester; NMR (CDCl$_3$) 7.6 (s, 1), 7.2 (m, 2), 6.6 (d, 1), 6.5 (m, 2), 4.4 (q, 2), 3.0 (s, 6), 1.4 (t, 3) ppm;

4-benzoxo-3-[(4-piperidin-1-yl)-3,5,6-trifluoropyridin-2-yl]benzonitrile; NMR (CDCl$_3$)

7.5 (m, 2), 7.35 (m, 3), 7.2 (m, 2), 7.05 (d, 1), 5.1 (s, 2), 3.4 (m, 4), 1.75 (m, 6) ppm;

4-benzoxo-3-[(4-(4-methylpiperazin-1-yl)-3,5,6-trifluoropyridin-2-yl]benzonitrile; NMR (CDCl$_3$) 7.5 (m, 2), 7.35 (m, 3), 7.2 (m, 2), 7.05 (d, 1), 5.1 (s, 2), 3.4 (m, 4), 2.5 (m, 4), 2.35 (s, 3) ppm;

1-[2-(5-cyano-2-methoxyphenoxo)-6-chloropyridin-4-yl]carbonyl-4-methylpiperazine; NMR (CDCl$_3$) 7.44 (dd, 1), 7.3 (d, 1), 6.95 (d, 1), 6.9 (s, 1), 6.74 (s, 1), 3.7 (s, 3), 3.7 (m, 2), 3.3 (s, 2), 2.4 (m, 2), 2.3 (m, 2), 2.2 (s, 3) ppm;

4-[(2-(5-cyano-2-benzoxophenoxo)-3,5,6-trifluoropyridin-4-yl)piperazine-1-acetic acid, ethyl ester; NMR (CDCl$_3$) 7.5 (m, 2), 7.35 (m, 3), 7.2 (m, 2), 7.05 (d, 1), 5.1 (s, 2), 4.2 (q, 2), 3.5 (m, 4), 3.3 (s, 2), 2.75 (m, 4), 1.3 (t, 3) ppm;

3-[(3,5,6-trifluoro-4-methylpyridin-2-yl)oxy]-4-methoxybenzonitrile; NMR (CDCl$_3$)

7.6 (d, 1), 7.4 (s, 1), 7.0 (d, 1), 3.8 (s, 3), 2.4 (s, 3) ppm;

3-[(3,5,6-trifluoro-4-((2,2,2-trifluoroethoxy)pyridin-2-yl)-N,N-dimethylbenzamide; NMR (CDCl$_3$)

7.4 (m, 1), 7.2 (d, 1), 7.3 (m, 1), 7.1-7.2 (m, 2), 4.7 (q, 2), 3.1 (s, 3), 3.0 (s, 3) ppm;

3-[(4-(1,3-difluoroprop-2-oxo)-3,5,6-trifluoropyridin-2-yl)oxy]-N,N-dimethylbenzamide;

N-(2-(5-cyano-2-methoxyphenoxo)-3,5,6-trifluoropyridin-4-yl)-N-methylglycine, ethyl ester;

N-(2-(3-cyanophenoxo)-3,5,6-trifluoropyridin-4-yl)-N-methylglycine, ethyl ester;

3-(4-(morpholin-1-yl)-3,5,6-trifluoropyridin-2-yl)oxy)-4-(benzoxyl)benzonitrile;

2-chloro-6-(3-dimethylaminocarbonylphenoxy)pyridine-4-carboxylic acid, ethyl
ester; NMR (CDCl$_3$) 7.59 (s, 1), 7.46 (t, 1), 7.38 (s, 1), 7.32 (d, 1), 7.21 (s, 1), 7.2 (d, 1), 4.42 (q, 2), 3.05 (s, 3), 2.88 (s, 3), 1.20 (t, 3) ppm;

3-[(6-fluoropyridin-2-yl)oxy]-N,N-dimethylbenzamide; NMR (CDCl$_3$) 7.75 (q, 1), 7.43 (m, 1), 7.27 (m, 1), 7.2 (m, 2), 6.75 (m, 1), 6.62 (d, 1), 3.1 (s, 3), 3.0 (s, 3) ppm;

4-[(2-[(5-cyano-2-benzoxoxyphenoxy)-3,5,6-trifluoropyridin-4-yl]oxy]-3-methoxybenzoic acid, ethyl ester; and

4-[(2-[(5-cyano-2-benzoxoxyphenoxy)-3,5-difluoro-6-[(1-methylimidazolin-2-yl)phenoxy]pyridin-4-yl]oxy]-3-methoxybenzoic acid, ethyl ester.

**PREPARATION 7**

3-[(3,5,6-trifluoro-5-methylamino-2-methylphenoxy)-4-methylpyridin-2-yl]oxy]benzonitrile

A. In a manner similar to preparation 6, reaction of 3-[(3,5,6-trifluoro-4-methylpyridin-2-yl)benzonitrile (1.1 g, 4.4 mmol), 5-dimethylamino-2-methylphenol (0.66 g, 4.4 mmol), and cesium carbonate (1.7 g, 5.2 mmol) in acetonitrile (10 mL) gave

3-[(3,5,6-trifluoro-4-methylamino-2-methylphenoxy)-4-methylpyridin-2-yl]oxy]benzonitrile; NMR (CDCl$_3$) 7.3 (m, 4), 7.0 (d, 1), 6.5 (d, 1), 6.3 (s, 1), 2.8 (s, 6), 2.4 (s, 3), 2.0 (s, 3) ppm;

3,3’-[(3,5-difluoro-4-methoxy-2,6-pyridinediyl)bis(oxy)]bis(benzonitrile); NMR CDCl$_3$

7.45 (m, 4), 7.3 (m, 4), 4.3 (s, 3) ppm;

25 3-[(6-(3-cyanophenoxo)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-4-methoxybenzenecarboxylic acid;

NMR (CDCl$_3$) 7.9 (d, 1), 7.7 (s, 1), 7.2 (m, 4), 6.95 (d, 1), 3.85 (s, 3), 2.4 (s, 3) ppm;

3-[(6-(3-cyanophenoxo)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-4,5-dimethoxybenzencarboxylic acid, ethyl ester; NMR (CDCl$_3$) 7.4 (s, 1), 7.2-7.4 (m, 5), 4.35 (q, 2), 3.9 (s, 3), 3.8 (s, 3), 2.4 (s, 3) ppm;

30 3-[(6-[(3-cyanophenxo)-3,5-difluoro-4-methylpyridin-2-yl]oxy]-4-methylbenzoic acid;

NMR (CDCl$_3$) 7.75 (d, 1), 7.55 (s, 1), 7.1-7.3 (m, 5), 2.4 (s, 3), 2.2 (s, 3) ppm;

5-[(6-[(3-cyanophenoxo)-3,5-difluoro-4-methylpyridin-2-yl]oxy]benzene-1,3-dicarboxylic acid,

diethyl ester; NMR (CDCl$_3$) 8.45 (s, 1), 7.85 (s, 2), 7.25 (m, 4), 4.4 (q, 4), 2.4 (s, 3), 1.4 (t, 6) ppm;

35 4-[(6-[(3-cyanophenoxo)-3,5-difluoro-4-methylpyridin-2-yl]oxy]-3-methoxybenzoic acid;

NMR (CDCl$_3$) 7.65 (dd, 1), 7.62 (d, 1), 7.33 (dt, 1), 7.27 (dt, 1), 7.18 (m, 2), 7.05 (d, 1), 3.8 (s, 3), 2.4 (s, 3) ppm;

3,3’-[(3-nitro-2,6-pyridinediyl)bis(oxy)]bis(benzonitrile); NMR (CDCl$_3$) 8.6 (d, 1),
7.5 (m, 4), 7.2 (m, 4), 6.8 (d, 1) ppm;
3-[(3,5-difluoro-6-(4-dimethylaminomethylphenoxy)-4-methylpyridin-2-yl)oxy]benzonitrile; NMR
(CDCl₃) 7.3 (m, 5), 7.15 (m, 1), 6.9 (m, 2), 3.35 (s, 2), 2.4 (s, 3), 2.15 (s, 6) ppm;
3-[(3,5-difluoro-4-methyl-6-(3-morpholin-4-yl)phenoxy)pyridin-2-yl)oxy]benzonitrile;
NMR (CDCl₃) 7.1-7.4 (m, 5), 6.7 (d, 1), 6.5 (s, 1), 3.8 (m, 4), 3.1 (m, 4), 2.4 (s, 3) ppm;
3-[(3,5-difluoro-6-(3-[2-(1H-imidazol-1-yl)-1-oxoethyl]phenoxy)-4-methylpyridin-2-yl)oxy]benzonitrile; NMR (CDCl₃) 7.8 (d, 1), 7.7 (s, 1), 7.5 (m, 2), 7.3 (m, 5), 7.1 (s, 1), 7.0 (s, 1), 5.45 (s, 2), 2.4 (s, 3) ppm;
4-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzoic acid;
NMR (CDCl₃) 8.05 (d, 2), 7.2-7.5 (m, 4), 7.1 (d, 2), 2.4 (s, 3) ppm;
3-[(3,5-difluoro-4-methyl-6-(3-((phenyl)oxomethyl)phenoxy)pyridin-2-yl)oxy]benzonitrile;
NMR (CDCl₃) 7.75 (d, 2), 7.4-7.6 (m, 6), 7.3 (m, 5), 2.4 (s, 3) ppm;
3-[(3,5-difluoro-6-(3-hydroxyphenoxy)-4-methylpyridin-2-yl)oxy]benzonitrile;
NMR (CDCl₃) 7.35 (m, 4), 7.2 (t, 1), 6.65 (dd, 1), 6.6 (m, 2), 5.65 (s, 1), 2.4 (s, 3) ppm;
5-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl)oxy]-2-methoxy-benzonitrile; NMR (CDCl₃) 7.4 (d, 1), 7.3 (s, 1), 7.03 (t, 1), 6.8 (d, 1), 6.43 (d, 1), 6.25 (s, 1),
6.18 (d, 1), 3.68 (s, 3), 2.85 (s, 6), 2.45 (s, 3) ppm;
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzenepropionic acid;
NMR (CDCl₃) 7.3 (m, 5), 7.05 (d, 1), 6.9 (m, 2), 3.65 (s, 3), 3.6 (s, 2), 2.4 (s, 3) ppm;
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-N,N-dimethylbenzene-
propionamide; NMR (CDCl₃) 7.3 (d, 1), 7.0 (t, 1), 6.55 (d, 1), 6.4 (d, 1), 6.2 (m, 2), 3.9 (s, 3), 3.7 (s, 3), 2.9 (s, 6), 2.4 (s, 3) ppm;
3-[(3,5-difluoro-6-(3-(2-hydroxyethyl)phenoxy)-4-methylpyridin-2-yl)oxy]benzonitrile; NMR (CDCl₃)
7.2-7.4 (m, 5), 7.0 (d, 1), 6.85 (m, 2), 3.75 (t, 2), 2.8 (t, 2), 2.4 (s, 3) ppm;
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-N,N-dimethylbenzene-
propionamide; NMR (CDCl₃) 7.45 (d, 1), 7.1-7.4 (t, 4), 7.0 (d, 1), 6.85 (m, 1), 6.8 (d, 1), 3.9 (s, 3), 3.85 (s, 3), 3.85 (m, 2), 2.5 (t, 2), 2.35 (s, 3) ppm;
3-[(3,5-difluoro-6-(3-(hydroxymethyl)phenoxy)-4-methylpyridin-2-yl)oxy]benzonitrile;
NMR (CDCl₃) 7.3-7.5 (m, 5), 7.2 (d, 1), 7.1 (s, 1), 6.95 (d, 1), 4.7 (s, 2), 2.4 (s, 3) ppm;
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-N,N-dimethylbenzamide;
NMR (CDCl₃) 7.2-7.4 (m, 5), 7.0 (m, 1), 6.9 (m, 2), 3.65 (s, 2), 2.95 (s, 6), 2.35 (s, 3) ppm;
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzonitrile; NMR (CDCl₃) 7.35 (m, 2),
7.25 (m, 2), 7.2 (t, 1), 7.0 (d, 1), 6.85 (m, 2), 2.9 (t, 2), 2.45 (t, 2), 2.4 (s, 3) ppm;
4-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-α-hydroxybenzeneacetic
acid; NMR (CDCl₃) 7.25 (m, 6), 7.15 (s, 1), 6.95 (m, 1), 5.2 (s, 1), 2.4 (s, 3) ppm;
3-[(3,5-difluoro-4-methyl-6-(3-(1-oxoethyl)phenoxy)pyridin-2-yl)oxy]benzonitrile; NMR (CDCl₃) 7.75
(dt, 1), 7.59 (m, 1), 7.44 (t, 1), 7.2-7.4 (m, 5), 2.57 (s, 3), 2.40 (s, 3) ppm;

3-[(3,5-difluoro-4-methyl-6-(3-[(2-methyl-1-oxopropyphenyloxy)pyridin-2-yl]oxy)-benzonitrile; NMR (CDCl₃) 7.75 (d, 1), 7.6 (m, 1), 7.45 (t, 1), 7.2-7.4 (m, 5), 3.45 (m, 1), 2.34 (s, 3), 2.15 (m, 6) ppm;

σ-acetoxy-4-[(6-(3-cyanophenoxo)-3,5-difluoro-4-methylpyridin-2-yl]oxy)-N,N-dimethylbenzeneacetamide; NMR (CDCl₃) 7.3 (m, 6), 7.15 (m, 1), 7.0 (m, 1), 6.1 (s, 1), 2.9 (s, 3), 2.85 (s, 3), 2.40 (s, 3), 2.1 (s, 3) ppm;

4-[(6-(3-cyanophenoxo)-3,5-difluoro-4-methylpyridin-2-yl]oxy]-α-ethoxybenzeneacetic acid, methyl ester; NMR (CDCl₃) 7.0-7.5 (m, 8), 4.75 (s, 1), 3.75 (s, 3), 3.35 (s, 3), 2.4 (s, 3) ppm;

3-[(6-(5-cyano-2-methoxy phenoxo)-3,5-difluoro-4-dimethylaminopyridin-2-yl]oxy)-N,N-dimethylbenzamide; NMR (CDCl₃) 7.4 (m, 2), 7.1 (d, 1), 6.95 (m, 3), 3.8 (s, 3), 3.1 (s, 6), 3.05 (s, 3), 2.9 (s, 3) ppm;

1-[(2-(5-cyano-2-methoxyphenoxo)-3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)pyridin-4-yl)piperidine-4-carboxylic acid, ethyl ester; NMR (CDCl₃) 7.4 (d, 1), 7.2 (m, 2), 7.1 (d, 1), 6.9 (m, 3), 4.15 (q, 2), 3.75 (s, 3), 3.7 (m, 2), 3.25 (m, 2), 3.1 (s, 3), 2.95 (s, 3), 2.55 (m, 1), 2.0 (m, 4), 1.15 (t, 3) ppm;

3-[(6-(5-cyano-2-benzyl oxyphenoxo)-3,5-difluoro-4-(piperidin-1-yl)pyridin-2-yl]oxy)-N,N-dimethylbenzamide; NMR (CDCl₃) 7.4 (m, 5), 7.2 (m, 3), 7.1 (m, 1), 6.95 (m, 3), 5.1 (s, 2), 3.4 (m, 4), 3.1 (s, 3), 2.9 (s, 3), 2.6 (m, 4), 2.4 (s, 3) ppm;

3-[(6-(5-cyano-2-benzyl oxyphenoxo)-3,5-difluoro-4-(4-methylpiperazin-1-yl)pyridin-2-yloxy)-N,N-dimethylbenzamide; NMR (CDCl₃) 7.2 (m, 9), 6.95 (m, 3), 5.1 (s, 2), 3.5 (m, 4), 3.3 (s, 2), 3.1 (s, 3), 2.8 (s, 3), 2.75 (m, 4), 1.3 (t, 3) ppm;

1-[(2-(5-cyano-2-methoxyphenoxo)-6-(3-dimethylaminocarbonylphenoxo)pyridin-4-yl]carbonyl-4-methyl piperazine; NMR (CDCl₃) 7.4 (dd, 1), 7.27 (m, 2), 7.16 (m, 1), 7.0 (m, 2), 6.9 (d, 1), 6.63 (s, 1), 6.55 (s, 1), 3.8 (m, 2), 3.8 (s, 3), 3.5 (m, 2), 3.1 (s, 3), 2.9 (s, 3), 2.5 (m, 2), 2.4 (m, 2), 2.4 (s, 3) ppm;

1-[(2-(5-cyano-2-methoxyphenoxo)-6-chloropyridin-4-yl]carbonyl-4-methyl piperazine; NMR (CDCl₃) 7.44 (dd, 1), 7.3 (d, 1), 6.95 (d, 1), 6.9 (s, 1), 6.74 (s, 1), 3.7 (s, 3), 3.7 (m, 2),
3.3 (m, 2), 2.4 (m, 2), 2.3 (m, 2), 2.2 (s, 3) ppm;
2-(5-cyano-2-methoxyphenoxy)-6-(3-imidazol-1-yl)phenoxy)pyridine-4-carboxylic acid, ethyl ester;
NMR (CDCl₃) 7.8 (s, 1), 7.3 (m, 3), 7.2 (m, 5), 7.0 (m, 2), 6.7 (d, 1), 6.4 (q, 2), 3.7 (s, 3), 1.4 (t, 3) ppm;
5
2-(5-cyano-2-methoxyphenoxy)-6-(3-dimethylaminophenoxy)pyridine-4-carboxylic acid, ethyl ester; NMR (CDCl₃) 7.4 (d, 1), 7.3 (s, 1), 7.2 (s, 1), 7.1 (t, 1), 7.0 (s, 1), 6.8 (d, 1), 6.5 (d, 1), 6.3 (m, 2), 4.4 (q, 2), 3.7 (s, 3), 2.8 (s, 6), 1.4 (t, 3) ppm;
3-{[6-(5-cyano-2-methoxyphenoxy)-3,5-difluoro-4-methyl(pyridin-2-yl)oxy]-N,N-dimethylbenzamide; NMR (CDCl₃) 8.00 (bs, 1), 7.40 (dt, 1), 7.25 (t, 1), 7.21 (dt, 1), 7.08 (bd, 1), 6.91 (bs, 1), 6.87 (td, 1), 3.74 (s, 3), 2.92 (s, 3), 2.85 (s, 3), 2.39 (s, 3) ppm;
10
3-{[6-(2-amino-5-cyanophenoxy)-3,5-difluoro-4-methyl(pyridin-2-yl)oxy]-N,N-dimethylbenzamide; NMR (CDCl₃) 7.5 (t, 1), 7.2-7.0 (m, 5), 6.6 (d, 1), 4.6 (s, 2), 3.1 (s, 3), 2.9 (s, 3), 2.0 (s, 3) ppm;
15
3-{[6-(2-amino-5-cyanophenoxy)-3,5-difluoro-4-(2,2,2-trifluoroethoxy)(pyridin-2-yl)oxy]-N,N-dimethylbenzamide; NMR (CDCl₃) 7.3 (dd, 1), 7.2 (d, 1), 7.1 (m, 2), 7.0-7.1 (m, 2), 6.6 (d, 1), 4.8 (q, 2), 4.6 (s, 2), 3.1 (s, 3), 2.9 (s, 3) ppm;
3-{[6-(5-cyano-2-methoxyphenoxy)-3,5-difluoro-4-(2,2,2-trifluoroethoxy)(pyridin-2-yl)oxy]-N,N-dimethylbenzamide; NMR (CDCl₃) 7.4 (dd, 1), 7.3 (d, 1), 7.2 (t, 1), 7.1 (d, 1), 6.9-7.0 (m, 2), 6.9 (d, 1), 4.7 (q, 2), 3.7 (s, 3), 3.1 (s, 3), 2.9 (s, 3) ppm; and
20
3-{[6-(5-cyano-2-methoxyphenoxy)-4-(1,3-difluoroprop-2-oxy)-3,5-difluoropyridin-2-yl)oxy]-N,N-dimethylbenzamide; NMR (CDCl₃) 7.4 (dd, 1), 7.3 (d, 1), 7.2 (t, 1), 7.1 (d, 1), 6.9-7.0 (m, 2), 6.9 (d, 1), 5.0 (m, 1), 4.9 (d, 2), 4.7 (d, 2), 3.7 (s, 3), 3.1 (s, 3), 2.9 (s, 3) ppm.

PREPARATION 8

4-(6-Fluoropyridin-2-yl)oxy-3-methoxybenzonitrile

A. To 4-hydroxy-3-methoxybenzonitrile (2.6 g, 17 mmol) in DMSO (15 mL) was added sodium hydride (0.44 g, 18 mmol) and 2,6-difluoropyridine (1.0 g, 8.7 mmol). After heating at 100°C for 18 hours the reaction was partitioned with ethyl acetate and water. The organic layer was separated, washed with water, dried (Na₂SO₄), and the solvent was removed in vacuo to give

4-(6-fluoropyridin-2-yl)oxy-3-methoxybenzonitrile (1.3 g); NMR (CDCl₃) 7.8 (q, 1), 7.35 (m, 1), 7.25 (m, 2), 6.85 (d, 1), 6.65 (m, 1), 3.85 (s, 3) ppm.

B. In a similar manner, the following compounds were made:

3-{[4-methyl-3,5,6-trifluoropyridin-2-yl]amino}benzonitrile; NMR (CDCl₃) 8.05 (s, 1), 8.95 (d, 1), 7.6 (d, 1), 7.45 (t, 1), 7.25 (s, 1), 2.3 (s, 3) ppm;

2-chloro-6-(3-cyanophenoxy)pyridine-4-carboxylic acid, ethyl ester, NMR (CDCl₃) 7.80-7.38 (m, 6), 4.41 (q, 2), 1.92 (t, 3) ppm;

2-chloro-6-(5-cyano-2-methoxyphenoxy)-N,N-dimethyl(pyridine-4-carboxamide; NMR (CDCl₃) 7.2 (m, 5), 3.84 (s, 3), 3.13 (s, 3), 2.95 (s, 3) ppm; and
2-chloro-6-(5-cyanophenoxy)-N,N-dimethylpyridine-4-carboxamide; NMR (CDCl₃) 7.45 (m, 3), 7.08 (s, 1), 6.87 (s, 1), 6.67 (s, 1), 3.14 (s, 3), 3.00 (s, 3) ppm.

PREPARATION 9

5 2-Methoxy-3'-4-[2,6-pyridinediylbis(oxyl)]benzonitrile

A. To 4-(6-fluoropyridin-2-yl)oxy-3-methoxybenzonitrile (0.65 g, 2.7 mmol) in DMSO (15 mL) was added 3-cyanophenol (0.32 g, 0.91 mmol) and sodium hydride (0.070 g, 2.9 mmol). After heating at 140 °C for 2 days, the reaction was poured into water and the precipitate was filtered off. The solid was chromatographed to give 2-methoxy-3'-4-[2,6-pyridinediylbis(oxyl)]benzonitrile; NMR (CDCl₃)

10 (CDCl₃) 7.75 (t, 1), 7.2-7.5 (m, 6), 7.1 (d, 1), 6.7 (d, 1), 6.65 (d, 1), 3.8 (s, 3) ppm.

B. In a similar manner, the following compounds were made:

3,3'-bis(methoxy)-4'-[2,6-pyridinediylbis(oxyl)]bis(benzonitrile); NMR (CDCl₃)

15 7.75 (t, 1), 7.2 (d, 2), 7.1 (m, 4), 6.65 (d, 2), 3.75 (s, 6) ppm;

3-[(3,5-difluoro-6-(3-ethylamino-4-methylphenoxyl)-4-methylpyridin-2-yl)oxy]benzonitrile;

NMR (CDCl₃) 7.3 (m, 4), 6.95 (d, 1), 6.25 (m, 2), 3.45 (br s, 1), 3.1 (q, 2), 2.4 (s, 3), 2.1 (s, 3), 1.3 (t, 3) ppm;

3,4'-[2,6-pyridinediylbis(oxyl)]bis(benzonitrile); NMR (CDCl₃) 7.8 (t, 1), 7.6 (d, 2), 7.2-7.5 (m, 4), 7.1 (d, 2), 6.7 (d, 2) ppm;

3-[(6-[(3-cyanophenyl)amino]-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzonitrile;

NMR (CDCl₃) 7.65 (m, 2), 7.5 (m, 2), 7.2-7.4 (m, 4), 2.4 (s, 3) ppm;

3-[(3-aminophenyl)amino-3,5-difluoro-4-methylpyridin-2-yl]benzonitrile; NMR (CDCl₃) 7.1-7.5 (m, 9), 3.4 (s, 3), 2.3 (s, 3) ppm;

3-[(3,5-difluoro-4-methyl-6-(pyridin-3-yl)oxy)pyridin-2-yl]oxy]benzonitrile;

NMR (CDCl₃) 8.4 (m, 2), 7.35 (m, 4), 7.25 (m, 4), 2.4 (s, 3) ppm;

3-[(3,5-difluoro-4-methyl-6-phenoxy)pyridin-2-yl]oxy]benzonitrile; NMR (CDCl₃)

25 7.25-7.5 (m, 6), 7.2 (t, 1), 7.0 (d, 2), 2.4 (s, 3) ppm;

3-[(3,5-difluoro-6-(4-dimethylaminophenoxyl)-4-methylpyridin-2-yl)oxy]benzonitrile;

NMR (CDCl₃) 7.25-7.5 (m, 4), 6.95 (d, 2), 6.65 (d, 2), 2.95 (s, 6), 2.4 (s, 3) ppm;

3-[(6-[(3,5-difluoro-4-methyl-6-[3-(1'H-imidazol-1-yl)phenoxy]-4-methylpyridin-2-yl)oxy]benzonitrile;

NMR (CDCl₃) 7.75 (s, 1), 7.4 (t, 1), 7.1-7.3 (m, 7), 7.03 (m, 2), 2.4 (s, 3) ppm;

3-[(3,5-difluoro-4-methyl-6-[3-nitrophenoxyl]pyridin-2-yl)oxy]benzonitrile;

NMR (CDCl₃) 8.03 (d, 1), 7.85 (s, 1), 7.5 (t, 1), 7.4 (m, 3), 7.3 (m, 2), 2.4 (s, 3) ppm;

3-[(6-[(3-aminophenoxyl)-3,5-difluoro-4-methylpyridin-2-yl)oxy]phenoxy]acetamide;

NMR (CDCl₃) 7.35 (m, 4), 7.05 (t, 1), 6.45 (d, 1), 6.35 (m, 2), 2.4 (s, 3) ppm;

3-[(3,5-difluoro-6-(3-dimethylaminophenoxyl)-4-methylpyridin-2-yl)oxy]benzonitrile;

3-[(3,5-difluoro-6-(3-[dimethylaminol]ethyl)phenoxy)-4-methylpyridin-2-yl)oxy]benzonitrile;
1-3-{[6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yloxy]phenyl}urea;
3-[6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yloxy]benzoic acid, ethyl ester;
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yloxy)-N,N-dimethylbenzamide; 3-[(5,3-difluoro-6-(3-ethylaminophenoxy)-4-methylpyridin-2-yloxy]benzonitrile;
3-[(6-(3-diethylaminophenoxy)-3,5-difluoro-4-methylpyridin-2-yloxy]benzonitrile;
3-[(3,5-difluoro-4-methyl-6-(3-phenylaminophenoxy)pyridin-2-yl]oxy]benzonitrile; NMR (CDCl₃) 7.4 (m,2), 7.2-7.33 (m,3), 7.13 (ddd,1), 7.0 (t,1), 6.91 (ddd,1), 2.4 (s,3) ppm;
3-[(5,3-difluoro-4-methyl-6-(3-trifluoromethylphenoxy)pyridin-2-yl]oxy]benzonitrile;
10 NMR (CDCl₃) 7.42 (m,3), 7.33 (t,1), 7.15-7.3 (m,4), 2.4 (s,3) ppm;
3-[(3,5-difluoro-6-(3-methoxyphenoxy)-4-methylpyridin-2-yl]oxy]benzonitrile; NMR (CDCl₃) 7.25-7.42 (m,5), 6.72 (ddd,1), 6.6 (m,1), 6.58 (m,1), 3.8 (s,3), 2.4 (s,3) ppm;
3-[(3,5-difluoro-6-(3-fluorophenoxy)-4-methylpyridin-2-yl]oxy]benzonitrile;
NMR (CDCl₃) 7.35-7.45 (m,2), 7.2-7.33, (m,3), 6.85 (m,2), 6.73 (dt,1), 2.4 (s,3) ppm;
15 3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl]oxy]-4-methylbenzonitrile; NMR (CDCl₃) 7.28 (m,1), 7.26 (s,1), 7.2 (m,2), 7.12 (t,1), 6.48 (dd,1), 6.28 (m,2), 2.88 (s,6), 2.38 (s,3), 2.21 (s,3) ppm;
4-amino-3-[(6-(3-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl]oxy]benzonitrile; NMR (CDCl₃) 7.2 (m,3), 6.66 (d,1), 6.54 (d,1), 6.35 (m,2), 4.28 (s,2), 2.91 (s,6), 2.37 (s,3) ppm;
20 3-[(6-(5-cyano-2-methoxyphenoxy)pyridin-2-yl]oxy)-N,N-dimethylbenzamide; NMR (CDCl₃) 7.7 (t,1), 7.4 (dd,1), 7.3 (d,1), 7.27 (d,1), 7.15 (dt,1), 7.0 (m,2), 6.9 (d,1), 6.66 (d,1), 6.57 (d,1), 3.8 (s,3), 3.1 (s,3), 2.9 (s,3) ppm;
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yloxy)-5-hydroxybenzoic acid, ethyl ester; NMR (CDCl₃) 7.3 (m,6), 6.7 (s,1), 4.3 (q,2), 2.4 (s,3), 1.5 (t,3) ppm;
3-[(6-(5-cyano-2-methoxyphenoxy)-3,5-difluoro-4-methylpyridin-2-yloxy)-5-hydroxybenzoic acid; NMR (CDCl₃) 7.4 (d,1), 7.3 (m,2), 7.1 (s,1), 6.8 (d,1), 6.6 (s,1), 5.6 (s,1), 4.4 (q,2), 3.8 (s,3), 2.4 (s,3), 1.4 (t,3) ppm;
2-(3-cyanophenoxy)-6-(5-cyano-2-benzylxophenoxy)pyridine-4-carboxylic acid, ethyl ester; NMR (CDCl₃) 7.62-7.02 (m,12), 5.16 (s,2H), 4.42 (q,2), 1.41 (t,3) ppm;
35 \(N\)-[2-(5-cyano-2-methoxyphenoxy)-6-(3-dimethylaminocarbonylphenoxy)pyridin-4-yl]
3,5-difluoropyridin-4-yl-\(N\)-methylglycine, ethyl ester;
\(N\)-[2-(5-cyanophenoxy)-6-(3-dimethylaminophenoxy)-3,5-difluoropyridin-4-yl]-
\(N\)-methylglycine, ethyl ester;
2-(5-cyano-2-methoxyphenoxy)-6-(3-dimethylaminocarbonylphenoxy)pyridine-4-carboxylic acid, methyl ester; NMR (CDCl₃) 7.2 (m,9), 3.92 (s,3), 3.70 (s,3), 3.10 (s,3), 2.88 (s,3) ppm;
2-(5-cyano-2-methoxyphenoxy)-6-(3-dimethylaminocarbonylphenoxy)-
N,N-dimethylpyridine-4-carboxamide; NMR (CDCl$_3$) 7.1 (m, 7), 6.55 (s, 1), 6.48 (s, 1), 3.65 (s, 3), 2.95 (m, 12) ppm;

2-(3-cyanophenoxo)-6-(3-dimethylaminocarbonylphenoxy)-N,N-dimethylpyridine-
4-carboxamide; NMR (CDCl$_3$) 7.16 (m, 8), 6.57 (s, 1), 6.53 (s, 1), 2.95 (m, 12) ppm; and

4-[[2-(3-aminothenoxy)-6-(5-cyano-2-phenylmethoxyphenoxy)-3,5-difluoropyridin-
4-yl]oxy]-3-methoxybenzoic acid, ethyl ester.

**PREPARATION 10**

2,6-Bis(3-cyanophenoxy)-N-methylpyridine-4-carboxamide

A. To 2,6-bis(3-cyanophenoxy)pyridine-4-carboxylic acid, ethyl ester (1.6 g, 4.0 mmol) in tetrahydrofuran/water (50 mL, 1/1) was added lithium hydroxide (0.85 g, 20 mmol). After stirring for 1.5 hours the reaction was partitioned with 1 M HCl and ethyl acetate. The organic layer was separated, dried (MgSO$_4$), and the solvent was removed *in vacuo*. The residue was dissolved in methylene chloride (50 mL) and thionyl chloride (2.4 g, 20 mmol) was added. After stirring for 2 hours the solvent was removed *in vacuo*. The residue was dissolved in methylene chloride/water (30/10 mL) and methylamine hydrochloride (0.090 g, 1.3 mmol) and potassium carbonate (0.46 g, 3.3 mmol) were added. The organic layer was separated, washed with brine, dried (MgSO$_4$), and the solvent removed *in vacuo* to give 2,6-bis(3-cyanophenoxy)-N-methylpyridine-4-carboxamide; NMR (CDCl$_3$) 7.5 (m, 4), 7.3 (m, 4), 7.0 (s, 2), 6.25 (br s, 1), 3.1 (d, 3) ppm.

B. In a similar manner, the following compounds were made:

2,6-bis(3-cyanophenoxy)-N-methylpyridine-3-carboxamide; NMR (CDCl$_3$) 7.8 (d, 1), 7.4-7.6 (m, 5), 7.1-7.3 (m, 4), 6.8 (d, 1), 3.1 (d, 3) ppm;

N-[[2,6-bis(3-cyanophenoxy)pyridin-3-yl]oxomethyl]glycine, ethyl ester; NMR (CDCl$_3$) 8.65 (d, 1), 8.1 (t, 1), 7.2-7.6 (m, 8), 6.8 (d, 1), 4.3 (m, 4), 1.3 (t, 3) ppm; and

2,6-bis(3-cyanophenoxy)-N,N-dimethylpyridine-4-carboxamide; NMR (CDCl$_3$) 7.85 (d, 1), 7.45 (m, 4), 7.25 (m, 4), 6.75 (d, 1), 3.2 (s, 3), 3.1 (s, 3) ppm.

**PREPARATION 11**

3-[[6-(3-Cyanophenyl)methylamino-3,5-difluoro-4-methylpyridin-
2-yl]oxy]benzonitrile

A. To 3-[[6-(3-cyanophenyl)methylamino-3,5-difluoro-4-methylpyridin-2-yl]oxy]-benzonitrile (0.10 g, 0.28 mmol) in acetonitrile (10 mL) was added iodomethane (0.20 g, 1.4 mmol) and sodium hydride (0.055 g, 1.4 mmol). After stirring for 18 hours the reaction was partitioned with water and ethyl acetate. The organic layer was separated, dried (Na$_2$SO$_4$), and the solvent was removed *in vacuo*. Chromatography of the residue on silica gel with ethyl acetate/hexane (1/3) as eluent gave 3-[[6-(3-cyanophenyl)methylamino-3,5-difluoro-4-methylpyridin-2-yl]oxy]-benzonitrile; NMR (CDCl$_3$) 7.4 (m, 5), 7.25 (m, 1), 7.1 (m, 2), 3.25 (s, 3), 2.3 (s, 3) ppm.
B. In a similar manner, the following compounds were made:

3-[(4-methyl-3,5,6-trifluoropyridin-2-yl)methylaminobenzonitrile; NMR (CDCl₃)
7.35 (t, 1), 7.3 (m, 1), 7.2 (m, 2), 3.4 (s, 3), 2.3 (s, 3) ppm; and
3,3’-[3,5-difluoro-4-methyl-2,6-pyridinediyl]bis(methylamino)]bis(benzonitrile);
NMR (CDCl₃) 7.1-7.5 (m, 8), 3.4 (s, 6), 2.3 (s, 3) ppm.

PREPARATION 12
3-[(6-(3-Cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-
5-methoxybenzoic Acid, Ethyl Ester

A. To acetonitrile (5 mL) was added 3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-5-hydroxybenzoic acid, ethyl ester (0.20 g, 0.47 mmol), cesium carbonate (0.31 g, 0.94 mmol), and iodomethane (0.13 g, 0.94 mmol). After stirring for 15 hours the mixture was partitioned with ethyl acetate and water. The organic layer was dried (MgSO₄) and the solvent was removed in vacuo to give 3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-5-methoxybenzoic acid, ethyl ester; NMR (CDCl₃) 7.3 (m, 6), 6.8 (s, 1), 4.4 (q, 2), 3.8 (s, 3), 2.4 (s, 3), 1.4 (t, 3) ppm.

B. In a similar manner, the following compound was made:
3-[(6-(5-cyano-2-methoxyphenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-
5-methoxybenzoic acid, ethyl ester; NMR (CDCl₃) 7.4 (d, 1), 7.3 (m, 2), 7.1 (s, 1), 6.8 (d, 1),
6.6 (s, 1), 4.4 (q, 2), 3.8 (s, 3), 3.7 (s, 3), 2.4 (s, 3), 1.4 (t, 3) ppm.

PREPARATION 13
5-[(6-(3-Cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzene-
1,3-dicarboxylic acid

A. To 5-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzene-
1,3-dicarboxylic acid, diethyl ester (0.97 g, 2.0 mmol) in tetrahydrofuran/water (20 mL, 1/1) was added lithium hydroxide (0.42 g, 10 mmol). After heating at 60°C for 90 minutes, the material was partitioned between ethyl acetate and 2 N HCl. The organic layer was separated, dried (MgSO₄), and the solvent removed in vacuo to give 5-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzene-1,3-dicarboxylic acid; NMR (DMSO-d₆) 8.25 (s, 1), 7.85 (s, 2), 7.4-7.7 (m, 3),
7.3 (m, 3), 2.4 (s, 3) ppm.

B. In a similar manner, the following compounds were made:
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-2,3-dimethoxybenzenecarboxylic acid; NMR (DMSO-d₆) 7.95 (s, 1), 7.1-7.7 (m, 5), 3.85 (s, 3), 3.6 (s, 3), 2.4 (s, 3) ppm;
3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-5-methoxybenzoic acid; and
3-[(6-(5-cyano-2-methoxyphenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-5-methoxybenzoic acid.
PREPARATION 14

3-{(6-(3-Cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-N,N-dimethyl-4-methoxybenzamide

A. To 3-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-4-methoxybenzoic acid (0.47 g, 1.1 mmol) in tetrahydrofuran (12 mL) was added 1,1'-carbonyldimidazole (0.22 g, 1.4 mmol) and stirred at ambient temperature for 3 hours. Then dimethylaniline (aq, 0.077 g, 1.7 mmol) was added. After stirring for 12 hours the solution was partitioned between water and ethyl acetate. The organic layer was separated, dried (MgSO₄), and the solvent was removed in vacuo. Chromatography on silica gel with ethyl acetate/hexane (1/8) as eluent gave 3-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-N,N-dimethyl-4-methoxybenzamide; NMR (CDCl₃) 6.9-7.4 (m, 7), 3.8 (s, 3), 3.0 (br, 6), 2.4 (s, 3) ppm.

B. In a similar manner, the following compounds were made:

3-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-N,N-dimethyl-4-methoxybenzamide; NMR (CDCl₃) 7.3 (m, 2), 7.2 (m, 3), 7.15 (d, 1), 6.95 (s, 1), 3.05 (br, 3), 2.85 (br, 3), 2.4 (s, 3), 2.15 (s, 3) ppm;

5-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-N,N,N',N'-tetraethylbenzene-1,3-dicarboxamide; NMR (CDCl₃) 7.9 (s, 1), 7.65 (s, 2), 7.1-7.5 (m, 4), 3.45 (br, 4), 3.15 (br, 4), 2.4 (s, 3), 1.15 (br, 6), 1.05 (br, 6) ppm;

5-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-2,3-dimethoxy-N,N-dimethylbenzamide; NMR (DMSO-d₆) 7.95 (m, 1), 7.1-7.7 (m, 5), 3.9 (s, 3), 3.65 (s, 3), 3.4 (s, 3), 3.15 (s, 3), 2.4 (s, 3) ppm;

5-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}¹-N,N,N',N'-tetramethylbenzene-1,3-dicarboxamide; NMR (CDCl₃) 7.7 (s, 2), 7.1-7.5 (m, 5), 3.1 (m, 6), 2.9 (s, 3), 2.85 (s, 3), 2.4 (s, 3) ppm;

4-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-3-methoxy-N,N-dimethylbenzamide; NMR (CDCl₃) 7.7 (s, 1), 7.2-7.4 (m, 3), 7.1 (s, 1), 7.05 (m, 1), 6.95 (d, 1), 3.8 (s, 3), 3.1 (s, 3), 3.0 (s, 3), 2.4 (s, 3) ppm;

1-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}benzoylpyrrolidine; NMR (CDCl₃) 7.2-7.5 (m, 6), 7.2 (s, 1), 7.1 (d, 1), 3.65 (m, 2), 3.3 (m, 2), 2.4 (s, 3), 1.8-2.1 (m, 4) ppm;

1-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}benzoylmorpholine;

4-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-N,N-dimethylbenzamide; NMR (CDCl₃) 7.2-7.6 (m, 6), 7.05 (d, 2), 3.2 (br, 3), 3.0 (br, 3), 2.4 (s, 3) ppm;

3-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-N-methylbenzenecarboxamide;

1-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}benzoyl-4-ethylpiperazine;

3-{(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy}-N-methyl-2-(pyridin-
2-(yl)ethyl]benzamide;
3-(1-(3-cyanophenoxy)-3,5-difluoro-4-methyl[pyridin-2-yl]oxy)-N-ethyl-N-methylbenzamide;
3-(1-(3-cyanophenoxy)-3,5-difluoro-4-methyl[pyridin-2-yl]oxy)-N,N-diethylbenzamide;
N-[3-(1-(3-cyanophenoxy)-3,5-difluoro-4-methyl[pyridin-2-yl]oxy)benzoyl]-β-alanine, 5
ethyl ester;
3-(1-(3-cyanophenoxy)-3,5-difluoro-4-methyl[pyridin-2-yl]oxy)-N,N-dimethyl-
5-methoxybenzamide; NMR (CDCl₃) 7.4 (s, 2), 7.3 (m, 2), 6.7 (s, 1), 6.6 (s, 2), 3.8 (s, 3), 3.0 10
(s, 3), 2.8 (s, 3), 2.4 (s, 3) ppm; and
3-(1-(5-cyano-2-methoxyphenoxy)-3,5-difluoro-4-methyl[pyridin-2-yl]oxy)-N,N-dimethyl-
5-methoxybenzamide; NMR (CDCl₃) 7.4 (d, 1), 7.3 (s, 1), 6.9 (d, 1), 6.6 (d, 1), 6.5 (d, 1), 3.8
(s, 3), 2.9 (s, 1), 2.4 (s, 1) ppm.

PREPARATION 15
3,3'-[3-Amino-2,6-pyridinediylbis(oxy)]bis(benzonitrile)

A. To 3,3'-[3-nitro-2,6-pyridinediylbis(oxy)]bis(benzonitrile) (18.5 g, 50 mmol) dissolved 15
in ethanol/ethyl acetate (500 mL, 2/3) was added 10% palladium on carbon (1.8 g). After subjecting
the mixture to hydrogen at 15 psi for 2 hours, the reaction was suction filtered through celite; The
solvent was removed in vacuo to give 3,3'-[3-amino-2,6-pyridinediylbis(oxy)]-bis(benzonitrile); NMR
(CDCl₃) 7.5 (m, 7), 7.2 (m, 2), 6.6 (d, 1), 3.8 (br, 2) ppm.

B. In similar manner, the following compounds were made:

N-[2,6-bis(3-cyanophenoxy)pyridin-3-yl]acetamide; NMR (CDCl₃) 8.65 (d, 1), 7.6 (s, 1),
7.1-7.6 (m, 8), 6.7 (d, 1), 2.3 (s, 3) ppm;
N-[2,6-bis(3-cyanophenoxy)pyridin-3-yl]carboxy] glycine, ethyl ester;
NMR (CDCl₃) 8.5 (d, 1), 7.2-7.5 (m, 8), 7.15 (s, 1), 6.6 (d, 1), 5.7 (m, 1), 4.2 (q, 2), 4.1 (m, 2), 20
1.25 (d, 3) ppm;
N-[2,6-bis(3-cyanophenoxy)pyridin-3-yl]methanesulfonamide; NMR (CDCl₃) 8.0 (d, 1),
7.45 (m, 4), 7.25 (m, 4), 6.75 (d, 1), 6.6 (s, 1), 3.1 (s, 3) ppm; and
N-[3-(1-(3-cyanophenoxy)-3,5-difluoro-4-methyl[pyridin-2-yl]oxy)phenyl]methanesulfonamide; NMR
35
**PREPARATION 17**

**N'-[2,6-Bis(3-cyanophenoxy)pyridin-3-yl]-N'-phenylurea**

A. To 3,3'-[3-amino-2,6-pyridinediylbis(oxy)]bis(benzonitrile) (3.0 g, 8.7 mmol) dissolved in acetonitrile (100 mL) was added phenyl isocyanate (1.1 g, 9.5 mmol). After refluxing for 4 hours, the reaction was partitioned between ether and water. The organic layer was separated, washed with water, saturated aqueous sodium bicarbonate, and brine, dried (MgSO₄), and the solvent was removed in vacuo. Chromatography on silica gel with ethyl acetate/hexane (1/4) as eluent gave material which was crystallized from ethyl acetate/hexane to give N'-[2,6-bis(3-cyanophenoxy)pyridin-3-yl]-N'-phenylurea; NMR (CDCl₃) 8.65 (d,1), 7.4 (m,8), 7.1-7.3 (m,6), 6.8 (s,1), 6.7 (d,1) ppm.

B. In a similar manner, the following compound was made: N'-[2,6-bis(3-cyanophenoxy)pyridin-3-yl]-N'-methylurea; NMR (CDCl₃) 8.65 (d,1), 7.5 (m,4), 7.25 (m,4), 6.8 (s,1), 6.7 (d,1), 2.9 (d,3) ppm.

**PREPARATION 18**

3-{[6-(3-Cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl]oxy}-benzenepropionic Acid, Methyl Ester

To 3-{[6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl]oxy}benzene-propionic acid (0.50 g, 1.2 mmol) in methylene chloride (20 mL) was added methyl iodide (0.26 g, 1.8 mmol) and diazabicycloundecane (2.8 g, 1.8 mmol). After stirring for 15 hours, the solution was concentrated in vacuo and chromatographed on silica gel with ethyl acetate/hexane (1/4) to give 3-{[6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl]oxy}benzenepropionic acid, methyl ester; NMR (CDCl₃) 7.3 (m,5), 7.05 (d,1), 6.85 (m,2), 3.68 (s,3), 2.9 (t,2), 2.55 (t,2), 2.4 (s,3) ppm.

**PREPARATION 19**

4,4'-[1,3-Phenylenbis(oxy)]benzotriazole

To DMSO (6 mL) was added resorcinol (1.1 g, 10 mmol), 4-fluorobenzonitrile (2.4 g, 20 mmol) and potassium carbonate (2.4 g, 17 mmol). After heating in an oil bath at 100°C for 16 hours the reaction mixture was partitioned with water and ethyl acetate. The organic layer was separated, washed with 1 N sodium hydroxide, water, brine, dried (sodium sulfate) and concentrated in vacuo. Chromatography on silica gel with methylene chloride/hexane (20/1) as eluent gave 4,4'-[1,3-phenylenbis(oxy)]benzonitrile; NMR (CDCl₃) 7.64 (d,4), 7.43 (t,1), 7.06 (d,4), 6.82 (dd,2), 6.80 (t,1) ppm.
PREPARATION 20
4-[[2-(3-(Guanidino)phenoxy)-6-(5-cyano-2-benzyloxyphenoxy)-3,5-difluoropyridin-4-yloxy]-3-methoxybenzoic Acid, Ethyl Ester.

To ethanol (15 mL) was added 4-[[2-(3-aminophenoxy)-6-(5-cyano-2-phenylmethoxyphenoxy)-3,5-difluoropyridin-4-yloxy]-3-methoxybenzoic acid, ethyl ester (0.50 g, 0.80 mmol), cyanamide (0.60 g, 14 mmol), and 6 M hydrochloric acid (0.7 mL). After refluxing for 19 hours, cyanamide (0.60 g, 14 mmol) and 6 M hydrochloric acid (0.7 mL) was added and refluxing was continued for 4 hours. The reaction mixture was concentrated in vacuo and purified by HPLC to give 4-[[2-(3-(guanidinophenoxy)-6-(5-cyano-2-benzyloxyphenoxy)-3,5-difluoropyridin-4-yloxy]-3-methoxybenzoic acid, ethyl ester.

EXAMPLE 1
3,3’-[2,6-Pyridinediylbis(oxy)]bis(benzamidine), Dihydrochloride

A. To 3,3’-[2,6-pyridinylbis(oxy)]bis(benzonitrile) (0.2 g, 0.7 mmol) slurred in ethanol (6 mL) cooled in a dry ice/isopropanol bath was bubbled HCl (g). After the solution was saturated the reaction flask was sealed and allowed to warm to ambient temperature and stir for 18 hours. The solvent was removed in vacuo and the residue was triturated with ether. The ether was removed by decantation and the residue was dissolved in ethanol (6 mL). The solution was cooled in a dry ice/isopropanol bath and ammonia (g) was bubbled in. The reaction flask was sealed and heated to 50°C for 2 hours. The solvent was removed in vacuo and the residue was recrystallized from 5 M HCl to give 3,3’-[2,6-pyridinediylbis(oxy)]bis(benzamidine), dihydrochloride as a solid; m.p. 160°C (decom); NMR (DMSO-d6) 9.45 (s,4), 9.3 (s,4), 8.02 (t,1), 7.4-7.8 (m,8), 6.90 (d,2) ppm.

B. In a similar manner, the following compounds were made:

4,4’-[2,6-pyridinediylibis(oxy)]bis(benzamidine), dihydrochloride; NMR (DMSO-d6) 9.4 (s,4), 9.2 (s,4), 8.1 (t,1), 7.95 (d,4), 7.40 (d,4), 6.96 (d,2) ppm;

3,3’-bis(methoxy)-4,4’-[2,6-pyridinediylbis(oxy)]bis(benzamidine), dihydrochloride;
NMR (DMSO-d6) 9.5 (br s,4), 9.2 (br s,4), 7.9 (t,1), 7.7 (s,2), 7.5 (d,2), 7.3 (d,2), 6.7 (d,2), 3.85 (s,6) ppm;

4-[[3-(3-amidinophenoxy)pyridin-2-yloxy]-3-methoxybenzamidine, dihydrochloride;
NMR (DMSO-d6) 9.7 (s,2), 9.55 (s,2), 9.4 (br s,4), 7.95 (t,1), 7.75 (s,1), 7.3-7.7 (m,6), 6.85 (d,1), 6.75 (d,1), 3.9 (s,3) ppm;

3-[[3,5-difluoro-6-[3-ethylamino-4-methylphenoxy]-4-methylpyridin-2-yloxy]-benzamidine, dihydrochloride; NMR (DMSO-d6) 9.4 (s,2), 9.2 (s,2), 7.6 (m,2), 7.55 (t,1), 7.45 (m,1), 7.3 (m,2), 7.15 (dd,1), 3.2 (q,2), 2.4 (s,3), 2.35 (s,3), 1.2 (t,3) ppm;

3,3’-[2,6-pyridinediylbis(oxy)]bis(benzamidine), dihydrochloride; NMR (DMSO-d6) 9.4 (s,4), 9.2 (s,4), 8.3 (d,1), 7.7 (m,4), 7.6 (d,4), 7.0 (m,1) ppm;

3,3’-[2,6-pyridinediylbis(oxy)]bis(benzamidine), dihydrochloride; NMR (DMSO-d6) 9.4 (br s,8), 8.1 (t,1), 7.9 (d,2), 7.5-7.8 (m,4), 7.40 (d,2), 6.95 (m,2) ppm;
3,3’-[3-methylaminocarbonylamino-2,6-pyrindinediylibis(oxy)]bis(benzamidine), dihydrochloride; m.p. 205-206°C;

4-methoxy-3-[(3,5-difluoro-6-(3-dimethylaminocarboxylphenoxy)-4-carboxy-pyridin-2-yl)oxy]benzamidine, hydrochloride; NMR (DMSO-d$_6$) 9.2 (s,2), 9.0 (s,2), 7.9 (t,1), 7.78 (dd,1), 7.68 (m,1), 7.36 (t,1), 7.26 (d,1), 7.15 (d,1), 7.05 (m,1), 7.02 (m,1), 6.75 (d,1), 6.7 (d,1), 3.8 (s,3), 2.95 (s,3), 2.8 (s,3) ppm;

4-methoxy-3-[(3,5-difluoro-6-(3-dimethylaminocarboxylphenoxy)-4-(4-methyl-piperazinoyl)pyridin-2-yl)oxy]benzamidine, dihydrochloride;

3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-((methyl)(ethoxycarbonylmethyl)amino) pyridin-2-yl)oxy]benzamidine, ethyl ester, hydrochloride; NMR (DMSO-d$_6$) 9.3 (s,2), 9.2 (s,2), 7.5 (m,4), 7.2 (t,1), 6.7 (m,2), 6.5 (d,1), 4.2 (s,2), 3.2 (s,3), 2.9 (s,6) ppm;

4-methoxy-3-[(6-(3-dimethylaminocarboxylphenoxy)-4-(dimethylaminocarbonyl)pyridin-2-yl)oxy]benzamidine, hydrochloride;

4-methoxy-3-[(6-(3-dimethylaminocarboxylphenoxy)-4-(aminocarbonyl)-pyridin-2-yl)oxy]benzamidine, hydrochloride; and

4-methoxy-3-[(6-(3-dimethylaminocarboxylphenoxy)-4-(ethoxycarbonyl)pyridin-2-yl)oxy]benzamidine, hydrochloride.

C. In a similar manner, reaction of 3,3’-[3,5-difluoro-4-methyl-2,6-pyrindinediylibis(oxy)]bis(benzonitrile) gave 3,3’-[3,5-difluoro-4-methyl-2,6-pyrindinediylibis(oxy)]bis(benzamidine); which was purified by HPLC on a C18 Dynamax column with a 20-80% acetonitrile in water gradient with 0.1% trifluoroacetic acid to give the compound as a pure trifluoroacetic acid salt; m.p. > 210°C; NMR (DMSO-d$_6$) 9.3 (br s,8), 7.6 (m,4), 7.54 (m,4), 2.4 (m,3) ppm.

D. In a similar manner, the following compounds were made:

3,3’-[3,5-dichloro-2,6-pyrindinediylibis(oxy)]bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.2 (br s,8), 8.6 (s,1), 7.4-7.7 (m,8) ppm;

4,4’-[3,5-dichloro-2,6-pyrindinediylibis(oxy)]bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.25 (s,4), 9.0 (s,4), 8.58 (s,1), 7.8 (d,4) 7.4 (d,4) ppm;

3,3’-[4-ethoxycarboxyl-2,6-pyrindinediylibis(oxy)]bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.55 (br s,4), 9.4 (br s,4), 7.65 (m,4), 7.6 (m,4), 7.2 (s,2), 4.4 (q,2), 1.4 (t,3) ppm;

3,3’-[3-ethoxycarboxyl-2,6-pyrindinediylibis(oxy)]bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.35 (br s,4), 9.1 (br s,4), 8.4 (d,1), 7.6 (m,4), 7.5 (m,4), 6.9 (d,1), 4.3 (q,2), 1.3 (t,3) ppm;

3,3’-[3,5-difluoro-2,6-pyrindinediylibis(oxy)]bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.55 (br s,4), 9.4 (br s,4), 8.5 (t,1), 7.7 (m,4), 7.5 (m,4) ppm;

3,3’-[4-methylaminocarbonyl-2,6-pyrindinediylibis(oxy)]bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.35 (br s,4), 9.2 (br s,4), 8.85 (m,1), 7.5-7.7 (m,8), 7.2 (s,2), 2.9 (d,3) ppm;
3,3'-[(3-methylaminocarbonyl)-2,6-pyridinediyl]bis(benzamide),
trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.6 (m,4), 9.4 (br s,4), 8.65 (d,1), 8.5 (m,1),
7.7-8.0 (m,8), 7.2 (d,1), 2.85 (d,3) ppm.

3,3'-[(3-dimethylaminocarbonyl)-2,6-pyridinediyl]bis(benzamide),
trifluoroacetic acid salt; m.p. 180-183°C;

3,3'-(1-aminocarbonyl)methylaminocarbonyl)-2,6-pyridinediyl]bis(benzamide),
trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.3 (s,2), 9.25 (s,2), 9.05 (s,4), 8.5 (d,1), 7.4-7.7
(l,m,11), 6.85 (d,1), 4.0 (d,2) ppm;

3-[(3,5-difluoro-6-(5-dimethylamino-2-methylphenoxy)-4-methylpyridin-2-yl)oxy]-
benzamide, trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.25 (s,2), 9.1 (s,2), 7.4-7.6 (m,3),
7.2-7.4 (m,4), 3.1 (s,6), 2.4 (s,3), 2.1 (s,3) ppm;

3-[(3,5-difluoro-6-(3-dimethylamino-2-methylphenoxy)-4-methylpyridin-2-yl)oxy]-
benzamide, trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.25 (s,2), 9.1 (s,2), 7.5-7.7 (m,4),
7.4 (m,1), 7.3 (m,1), 7.2 (d,1), 3.1 (s,6), 2.4 (s,3), 2.3 (s,3) ppm;

3-[(3,5-difluoro-6-[(3-aminophenyl)methylamino]-4-methylpyridin-2-yl]oxy]-
benzamide, trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.35 (s,2), 9.3 (s,2), 9.15 (s,2),
9.05 (s,2), 7.6 (m,4), 7.4 (m,3), 7.25 (m,1), 7.2 (d,1), 3.25 (s,3), 2.3 (s,3) ppm;

3-[(3,5-difluoro-6-[(3-aminophenyl)methylamino]-4-methylpyridin-2-yl]oxy]-
benzamide; trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.35 (s,2), 9.2 (s,4), 8.95 (s,2),
7.5-7.8 (m,6), 7.25 (m,2), 2.35 (s,3) ppm;

3,3'-[(3,5-difluoro-4-methoxy-2,6-pyridinediyl]bis(benzamide),
trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.3 (br s,4), 9.2 (br s,4), 7.6 (m,4), 7.5 (m,4), 4.3
(s,3), 2.3 (m,3) ppm;

3,3'-[(3,5-difluoro-4-methyl-2,6-pyridinediyl]bis(methylamino)bis(benzamide),
trifluoroacetic acid salt; m.p. 115-120°C;

3-[(6-(2-methoxy-5-dimethylaminocarbonyl)phenoxy)-3,5-difluoro-4-methylpyridin-2-yl]-
oxy]benzamide, trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.3 (s,2), 9.15 (s,2), 7.5 (m,3),
7.3 (d,1), 7.2 (m,2), 7.1 (d,1), 3.75 (s,3), 2.9 (br,s,6), 2.4 (s,3) ppm;

3-[(6-(2,3-dimethoxy-5-ethoxycarbonylphenoxy)-3,5-difluoro-4-methylpyridin-2-yl]-
oxy]benzamide, trifluoroacetic acid salt; m.p. 200-202°C;

3-[(6-(2,5-dimethylaminocarbonyl)phenoxy)-3,5-difluoro-4-methylpyridin-2-yl]-
oxy]benzamide, trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.35 (s,2), 9.05 (s,2), 7.6 (m,3), 7.45 (m,1), 7.2 (s,2), 7.1 (s,1), 3.45 (br,4), 3.15 (br,4), 2.4 (s,3) 1.2 (br,6), 1.05 (br,6) ppm;

3-[(6-(2,3-dimethoxy-5-dimethylaminocarbonylphenoxy)-3,5-difluoro-4-methylpyridin-
2-yl]oxy]benzamide, trifluoroacetic acid salt; NMR (DMSO-$d_6$) 9.25 (s,2), 9.1 (s,2), 7.95
(s,1), 7.4-7.6 (m,4), 7.3 (s,1), 3.9 (s,3), 3.7 (s,3), 2.5 (s,6), 2.4 (s,3) ppm;

3-{[6-(3,5-dimethylaminocarbonyl)phenoxyl]-3,5-difluoro-4-methylpyridin-2-yl}-oxy)benzamide, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.3 (s,2), 9.05 (s,2), 7.55 (m,4), 7.25 (s,2), 7.2 (s,1), 3.0 (s,6), 2.85 (s,6), 2.4 (s,3) ppm;

5 3-{[6-(2-methoxy-4-dimethylaminocarbonylphenoxyl)-3,5-difluoro-4-methylpyridin-2-yl]oxy}-benzamide, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.3 (s,2), 9.15 (s,2), 7.5 (m,3), 7.35 (m,1), 7.15 (d,1), 7.1 (s,1), 6.9 (d,1), 3.7 (s,3), 3.05 (br,3), 2.9 (br,3), 2.4 (s,3) ppm;

3,3’-(4-phenylcarbamoylamino-2,6-pyridinediylbis(oxy))bis(benzamide), trifluoroacetic acid salt; m.p. 269-271°C;

10 3,3’-(3-phenylaminocarbonylamino-2,6-pyridinediylbis(oxy))bis(benzamide), trifluoroacetic acid salt; m.p. 159-160°C;

3,3’-(3-(aminocarbonylmethyl)aminocarbonylamino-2,6-pyridinediylbis(oxy))-bis(benzamide), trifluoroacetic acid salt; m.p. 129-130°C;

3,3’-(3-amino-2,6-pyridinediylbis(oxy))bis(benzamide), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.6 (s,1), 9.4 (m,8), 8.4 (d,1), 7.95 (d,1), 7.5-7.7 (m,8), 6.9 (d,1), 3.1 (s,3) ppm;

15 3,3’-(3-methylsulfonylamino-2,6-pyridinediylbis(oxy))bis(benzamide), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.8 (s,1), 9.3 (m,4), 9.25 (m,4), 8.4 (d,1), 7.4-7.7 (m,8), 6.9 (d,1), 2.15 (s,3) ppm;

3-[(6-(3-aminophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.35 (s,2), 9.2 (s,2), 7.6 (m,3), 7.55 (m,1), 7.0 (t,1), 6.45 (d,1), 6.35 (m,2), 2.4 (s,3) ppm;

25 3-[(3,5-difluoro-6-[3-(1H-imidazol-1-yl)-1-oxoethylphenoxyl]-4-methylpyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.4 (s,2), 9.3 (s,2), 9.0 (s,1), 7.4-7.9 (m,10), 6.0 (s,2), 2.4 (s,3) ppm;

3-[(6-(3-(dimethylaminocarbonyl)ethyl)phenoxyl)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-benzamide, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.3 (s,2), 9.25 (s,2), 7.6 (m,4), 7.2 (t,1), 7.0 (m,2), 6.9 (d,1), 2.9 (s,3), 2.8 (s,3), 2.75 (t,2), 2.5 (m,2), 2.4 (s,3) ppm;

3-[(3,5-difluoro-6-[3-(hydroxymethyl)phenoxyl]-4-methylpyridin-2-yl)oxy]-benzamide, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.4 (br,4), 7.6 (m,4), 7.25 (t,1), 7.1 (d,1), 7.05 (m,1), 7.0 (d,1), 4.45 (s,2), 2.4 (s,3) ppm;

3-[(6-(3-(dimethylaminocarbonyl)methyl)phenoxyl]-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.3 (s,4), 7.6 (m,3), 7.55 (m,1), 7.2 (t,1), 7.0 (m,2), 3.6 (s,2), 2.95 (s,3), 2.8 (s,3), 2.4 (s,3) ppm;

3-[(6-(3-aminocarbonylmethyl)phenoxyl)-3,5-difluoro-4-methylpyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt; m.p. 189-192°C;
3-{[6-{3-(aminomethyl)phenoxyl}-3,5-difluoro-4-methylpyridin-2-yl]oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.3 (br, 4), 8.2 (br, 3), 7.6 (m, 3), 7.55 (m, 1), 7.35 (t, 1), 7.2 (m, 2), 7.15 (d, 1), 4.0 (m, 2), 2.4 (s, 3) ppm;

3-[[3,5-difluoro-4-methyl-6-[3-(prop-2-oxymethyl)phenoxyl]pyridin-2-yl]oxy]-benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.3 (s, 2), 9.1 (s, 2), 7.6 (m, 4), 7.2 (t, 1), 6.65 (m, 3), 4.55 (m, 1), 2.4 (s, 3), 1.15 (m, 6) ppm;

4,4'-(1,3-phenylenebis(oxy))bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.4 (br, 4), 9.2 (br, 4), 7.96 (d, 4), 7.6 (t, 1), 7.3 (d, 4), 7.05 (dd, 2), 6.97 (m, 1) ppm;

3,3'-(4-nitro-1,3-phenylenebis(oxy))bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.4 (s, 4), 9.2 (m, 4), 8.25 (d, 1), 7.6 (m, 8), 7.0 (dd, 1), 6.9 (m, 1) ppm;

3-[[6-{3-methoxy-5-dimethylaminocarbonylphenoxyl}-3,5-difluoro-4-methylpyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.3 (s, 2), 9.1 (s, 2), 7.6 (m, 4), 6.8 (s, 1), 6.7 (d, 2), 3.7 (s, 3), 3.0 (s, 3), 2.8 (s, 3), 2.4 (s, 3) ppm;

4-methoxy-3-[[6-{3-methoxy-5-dimethylaminocarbonylphenoxyl}-3,5-difluoro-4-methylpyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.1 (s, 2), 8.9 (s, 2), 8.0 (s, 1), 7.6 (m, 7), 7.2 (m, 4), 4.4 (q, 2), 3.7 (s, 3), 1.3 (t, 3) ppm;

4-methoxy-3-[[(6-{3-dimethylaminocarbonylphenoxyl}-3,5-difluoro-4-methylpyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt, NMR (CDCl$_3$) 9.10 (s, 2), 8.94 (s, 2), 7.71 (d, 1), 7.66 (s, 1), 7.32 (t, 1), 7.25 (d, 1), 7.09 (d, 1), 7.01 (d, 1), 6.95 (s, 1), 3.77 (s, 3), 2.95 (s, 3), 2.75 (s, 3), 2.37 (s, 3);

4-amino-3-[[6-{3-dimethylaminocarbonylphenoxyl}-3,5-difluoro-4-methylpyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; NMR (CDCl$_3$) 8.8 (s, 4), 7.71 (d, 1), 7.5 (d, 1), 7.4 (s, 1), 7.3 (t, 1), 7.1-7.2 (m, 2), 7.1 (s, 1), 6.6 (d, 1), 6.2 (s, 2), 3.0 (s, 3), 2.8 (s, 3), 2.4 (s, 3) ppm;

4-amino-3-[[6-{3-dimethylaminocarbonylphenoxyl}-3,5-difluoro-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; NMR (CDCl$_3$) 8.7 (s, 2), 8.5 (s, 2), 7.4-7.5 (m, 2), 7.3 (t, 1), 7.1-7.2 (m, 3), 6.7 (d, 1), 6.2 (br s, 2), 5.2 (q, 2), 3.0 (s, 3), 2.8 (s, 3) ppm;

4-methoxy-3-[[6-{3-dimethylaminocarbonylphenoxyl}-3,5-difluoro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

3,3'-(2,6-pyrazinediylbis(oxy))bis(benzamidine), trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.4 (m, 8), 8.6 (d, 1), 7.7 (m, 8), 7.05 (d, 1) ppm;

4-hydroxy-3-[[6-{3-dimethylaminocarbonylphenoxyl}-3,5-difluoro-2-methoxypyridin-4-yl]-
4-amino-3-[[3,5-difluoro-6-{3-dimethylaminophenoxy}-4-(methyl)-
(aminocarbonylmethyl)amino]pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-amino-3-[[3,5-difluoro-6-{3-dimethylaminophenoxy}-4-(methyl)-
(ethoxycarbonylmethyl)amino]pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-amino-3-[[3,5-difluoro-6-{3-dimethylaminophenoxy}-4-(methyl)-
(phenyl)aminocarbonyl]pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-methoxy-3-[[6-(3-dimethylaminocarbonyl)phenoxy]-3,5-difluoro-4-{1,3-difluoroprop-2-oy]pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

3-[[6-(3-dimethylaminocarbonyl)phenoxy]-4-dimethylaminocarbonyl]pyridin-
2-yl]oxy]benzamide, trifluoroacetic acid salt; NMR (DMSO-\text{d}_6) 9.31 (s, 2), 9.24 (s, 2), 7.35 (m, 8), 6.81 (s, 1), 6.78 (s, 1), 2.95 (m, 12) ppm;

3-[[3,5-difluoro-6-{3-dimethylaminophenoxy}-4-{4-ethoxycarbonyl-
2-methoxyphenoxy}]pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

3-[[3,5-difluoro-6-{3-dimethylaminophenoxy}-4-{4-ethoxycarbonyl-
2-(morpholin-4-yl)methyl]phenoxy}]pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt; and
3-[[3-(3-aminophenoxy)phen-1-yl]oxy]benzamide, trifluoroacetic acid salt.

### EXAMPLE 2

3-[[6-(3-Aminophenoxy)-4-carboxy]pyridin-2-yl]oxy]benzamide,

Dihydrochloride

2,6-Bis[3-aminophenoxy]pyridine-4-carboxamide (5 g, 11 mmol) was dissolved in 5 M HCl
and heated. The solid that precipitated on cooling was collected by filtration to give 3-[[6-(3-
amidophenoxy)-4-carboxy]pyridin-2-yl]oxy]benzamide, dihydrochloride; NMR (DMSO-\text{d}_6) 9.4 (br
s, 4), 9.2 (br s, 4), 7.4 (m, 4), 7.3 (m, 4), 7.2 (s, 2) ppm.

### EXAMPLE 3

3-[[3,5-Difluoro-4-methyl-6-{[pyridin-3-yl]oxy}pyridin-2-yl]oxy]benzamide,

Acetic Acid Salt

A. In a manner similar to Example 1 above, 3-[[3,5-difluoro-4-methyl-
6-[[pyridin-3-yl]oxy]pyridin-2-yl]oxy]benzonitrile was reacted with HCl and ammonia (g). The solvent
was removed \text{in vacuo} and the material was partitioned with methylene chloride and 2 N aqueous
potassium hydroxide. The organic layer was separated, acetic acid added, and the solvent was
removed \text{in vacuo}. The residue was triturated with ether and the resulting solid was filtered to give
3-[[3,5-difluoro-4-methyl-6-[[pyridin-3-yl]oxy]pyridin-2-yl]oxy]benzamide, acetic acid salt;
m.p. 213-214°C.

B. In a similar manner, the following compounds were made:
3-[[3,5-difluoro-4-methyl-6-phenoxy]pyridin-2-yl]oxy]benzamidine, acetic acid salt; m.p. 122-123°C;
3-[[3,5-difluoro-6-(4-dimethylaminophenoxy)-4-methyl]pyridin-2-yl]oxy]benzamidine, acetic acid salt; m.p. 106-107°C;
3-[[3,5-difluoro-6-[3-{1H-imidazol-1-yl}phenoxy]-4-methyl]pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 9.9 (br, s), 8.3 (s, 1), 7.8 (s, 1), 7.65 (m, 6), 7.3 (t, 1), 7.15 (m, 2), 2.4 (s, 3) ppm;
3-[[3,5-difluoro-4-methyl-6-(3-nitrophenoxy)pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10.1 (br, s), 8.05 (m, 2), 7.7 (m, 2), 7.6 (m, 2), 7.5 (m, 2), 2.45 (s, 3) ppm;
3-[[3,5-difluoro-4-methyl-6-[3-[[methylsulfonyl]amino]phenoxy]pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10 (br, s), 7.5 (m, 3), 7.4 (d, 1), 7.15 (t, 1), 6.85 (d, 1), 6.8 (t, 1), 6.66 (dd, 1), 2.83 (s, 3), 2.36 (s, 3) 1.74 (s, 3) ppm;
3-[[3,5-difluoro-6-(3-methylcarbonylaminophenoxy)-4-methyl]pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10.3 (br, s), 10.1 (s, 1), 7.4-7.7 (m, 5), 7.25 (m, 2), 6.8 (m, 1), 2.4 (s, 3), 2.1 (s, 3), 1.8 (s, 3) ppm;
3-[[3,5-difluoro-4-methyl-6-[3-{(morpholin-4-yl)phenoxy}pyridin-2-yl]oxy]benzamidine, acetic acid salt; m.p. 194-196°C;
3-[[3,5-difluoro-4-methyl-6-[3-{1-pyrrolidinoyl}phenoxy]pyridin-2-yl]oxy]benzamidine, acetic acid salt; m.p. 162-164°C;
3-[[3,5-difluoro-4-methyl-6-[3-{4-morpholinoyl}phenoxy]pyridin-2-yl]oxy]benzamidine, acetic acid salt; m.p. 123-126°C;
3-[[3,5-difluoro-4-methyl-6-[3-{3-dimethylaminocarbonylphenoxy}pyridin-2-yl]oxy]benzamidine, acetic acid salt; m.p. 198-200°C;
3-[[3,5-difluoro-4-methyl-6-[3-(carboxy)phenoxy]pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10 (br, s), 7.4-7.7 (m, 6), 7.25 (m, 3), 7.15 (m, 1), 7.05 (m, 1), 4.82 (s, 1), 2.4 (s, 3), 1.8 (s, 3) ppm;
3-[[3,5-difluoro-4-methyl-6-[3-{1-oxoethyl}phenoxy]pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (CDCl$_3$) 10.2 (br, s), 7.7 (m, 1), 7.2-7.6 (m, 7), 3.45 (m, 1), 2.39 (s, 3), 1.88 (s, 3), 1.14 (m, 6) ppm;
3-[[3,5-difluoro-4-methyl-6-[3-(dimethylaminocarbonyl)phenoxy)methylphenoxy]pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10 (br, s), 7.55 (m, 3), 7.4 (m, 1), 7.3 (t, 1), 7.1 (m, 3), 5.35 (s, 1), 2.82 (s, 6), 2.40 (s, 3), 1.78 (s, 3) ppm;
3-[[3,5-difluoro-4-methyl]-6-[3-(dimethylaminocarbonyl)(methoxy)methyl]phenoxyl]pyridin-2-yl]oxy]benzamide, acetic acid salt; NMR (DMSO-d$_6$) 10 (br, 4), 7.5 (m, 4), 7.4 (m, 1), 7.3 (m, 2), 7.15 (d, 1), 7.05 (m, 2), 4.5 (s, 1), 3.3 (s, 3), 2.4 (s, 3), 1.78 (s, 3) ppm; and

4-methoxy-3-[[3,5-difluoro-4-(ethoxycarbonylmethyl)amino-6-[3(dimethylaminocarbonyl)phenoxy]-pyridin-2-yl]oxy]benzamide, acetic acid salt.

**EXAMPLE 4**

3-[[3,5-Difluoro-6-[3-dimethylaminophenoxy]-4-methylpyridin-2-yl]oxy]benzamide, Acetic Acid Salt

A. T$_8$-[[3,5-difluoro-6-[3-dimethylaminophenoxy]-4-methylpyridin-2-yl]oxy]benzonitrile (1.4 g, 3.7 mmol) dissolved in ethanol (100 mL) and cooled to -10°C was bubbled hydrochloric acid (g) until saturated. The mixture was allowed to warm to ambient temperature and the solvent was removed in vacuo. The residue was dissolved in ethanol (50 mL) and heated at reflux while ammonia (g) was bubbled through the reaction mixture for 2 hours. The solvent was removed in vacuo and the residue was partitioned with 2 N aqueous potassium hydroxide and methylene chloride. The organic layer was separated and dried (MgSO$_4$). Acetic acid (1 mL) was added and the solvent was removed in vacuo. Crystallization from ether gave 3-[[3,5-difluoro-6-[3-dimethylaminophenoxy]-4-methylpyridin-2-yl]oxy]benzamide, acetic acid salt; m.p. 176-179°C.

B. In a similar manner, the following compounds were made:

3-[[3,5-difluoro-6-[3-(2-dimethylamino)ethyl]phenoxy]-4-methylpyridin-2-yl]oxy]benzamide, acetic acid salt; m.p. 214-216°C;

3-[[3,5-difluoro-6-[3-aminocarbonylaminophenoxy]-4-methylpyridin-2-yl]oxy]benzamide, hydrochloride; NMR (DMSO-d$_6$) 9.4 (s, 2), 9.25 (s, 2), 9.1 (s, 1), 7.6 (m, 2), 7.55 (m, 2), 7.4 (s, 1), 7.2 (t, 1), 7.05 (d, 1), 6.6 (d, 1), 6.1 (s, 2), 2.4 (s, 3), 2.1 (s, 3), 1.8 (s, 3) ppm;

3-[[3,5-difluoro-6-[3-ethoxycarbonylphenoxy]-4-methylpyridin-2-yl]oxy]benzamide, acetic acid salt; m.p. 198-199°C;

3-[[3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-methylpyridin-2-yl]oxy]benzamide, acetic acid salt; m.p. 160-163°C;

3-[[3,5-difluoro-6-[3-(ethylamino)phenoxy]-4-methylpyridin-2-yl]oxy]benzamide, acetic acid salt; m.p. 193-196°C;

3-[[6-(3-diethylaminophenoxy)-3,5-difluoro-4-methylpyridin-2-yl]oxy]benzamide, acetic acid salt; m.p. 196-197°C;

3-[[3,5-difluoro-4-methyl]-6-[3-(phenylamino)phenoxy]pyridin-2-yl]oxy]benzamide, acetic acid salt; NMR (DMSO-d$_6$) 10.0 (br, 4), 8.4 (s, 1), 7.4-7.7 (m, 4), 7.3 (t, 2), 7.2 (t, 1), 7.1 (d, 2), 6.9 (m, 2), 6.8 (s, 1), 6.5 (d, 1), 2.4 (s, 3), 1.8 (s, 3) ppm;

3-[[3,5-difluoro-6-[3-methylaminocarbonylphenoxy]-4-methylpyridin-2-yl]oxy]benzamide, acetic acid salt; NMR (DMSO-d$_6$) 10.3 (br, 4), 8.5 (s, 1), 7.6 (d, 1), 7.55
3-[[3,5-difluoro-6-[[3-(4-methylpiperazin-1-yl)phenoxy]-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10.3 (br, 4), 7.6 (m, 3), 7.45 (m, 2), 7.25 (m, 1), 7.1 (m, 2), 3.6 (br, 2), 3.2 (br, 2), 2.4 (s, 3), 2.35 (br, 2), 2.2 (br, 2), 2.2 (s, 3), 1.8 (s, 3) ppm;

3-[[3,5-difluoro-6-[[3-(piperidin-1-yl)phenoxy]-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10.3 (br, 4), 7.6 (m, 3), 7.45 (m, 2), 7.2 (d, 1), 7.15 (m, 2), 3.6 (br, 2), 3.2 (br, 2), 2.4 (s, 3), 1.8 (s, 3) 1.3-1.6 (m, 6) ppm;

3-[[3,5-difluoro-6-[[3-(methyl)benzyl]aminocarbonylphenoxy]-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; m.p. 167-169°C;

3-[[3,5-difluoro-6-[[3-(2-pyridin-1-yl)ethyl]aminocarbonylphenoxy]-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; m.p. 145-150°C;

3-[[3,5-difluoro-6-[[3-(methyl)ethyl]aminocarbonylphenoxy]-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10.2 (br, 4), 8.5 (m, 1), 7.1-7.7 (m, 8), 3.4 (br, 1), 3.05 (br, 1), 1.8 (m, 3), 2.4 (s, 3), 1.75 (s, 3) 1.1 (m, 1.5), 1.0 (m, 1.5) ppm;

3-[[3,5-difluoro-6-[[3-diethylaminocarbonylphenoxy]-4-methylpyridin-2-yloxy]benzamidine, ethyl ester, acetic acid salt;

3-[[6-(3-chlorophenoxy)-3,5-difluoro-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; m.p. 200-202°C;

3-[[3,5-difluoro-4-methyl-6-[[3-trifluoromethylphenoxy]pyridin-2-yloxy]benzamidine, acetic acid salt; m.p. 192-193°C;

3-[[3,5-difluoro-6-[[3-methoxyphenoxy]-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; m.p. 182-185°C;

3-[[3,5-difluoro-6-[[3-fluorophenoxy]-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; m.p. 208-209°C;

3-[[3,5-difluoro-6-[[3-dimethylaminophenoxy]-4-methylpyridin-2-yloxy]-4-methyl benzamidine, acetic acid salt; m.p. 192-193°C;

3-[[3,5-difluoro-4-methyl-6-[[3-(phenyl)oxomethylphenoxy]pyridin-2-yloxy]benzamidine, acetic acid salt; m.p. 162-165°C;

3-[[3,5-difluoro-6-[[3-hydroxyphenoxy]-4-methylpyridin-2-yloxy]benzamidine, acetic acid salt; m.p. 114-117°C;

5-[[3,5-difluoro-6-[[3-dimethylaminophenoxy]-4-methylpyridin-2-yloxy]-2-methoxy benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 9.8 (br, 4), 7.75 (d, 1), 7.7 (s, 1), 7.3 (d, 1), 7.05 (t, 1), 6.45 (d, 1), 6.3 (s, 1), 6.15 (d, 1), 3.8 (s, 3), 2.85 (s, 6), 2.4 (s, 3), 1.8 (s, 3) ppm;

3-[[6-(3-ethoxycarbonylmethylphenoxy)-3,5-difluoro-4-methylpyridin-2-yloxy]-
benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10.0 (br, 4), 7.55 (m, 3), 7.45 (m, 1), 7.25 (m, 1), 7.05 (m, 3), 4.05 (q, 2), 3.65 (s, 2), 2.4 (s, 3), 1.8 (s, 3), 1.2 (t, 3) ppm;

3-[(6-ethoxycarbonylmethylphenoxy)-3,5-difluoro-4-methylpyridin-2-yl]oxy]benzamidine;

3-[(6-[(2-ethoxycarbonyl)ethyl]phenoxy)-3,5-difluoro-4-methylpyridin-2-yl]oxy]benzene propionic acid, ethyl ester, acetic acid salt; NMR (DMSO-d$_6$) 10.2 (br, 4), 7.55 (m, 3), 7.45 (m, 1), 7.25 (t, 1), 7.0 (m, 3), 4.05 (q, 4), 2.8 (t, 2), 2.6 (m, 2), 2.4 (s, 3), 1.8 (s, 3), 1.2 (t, 3) ppm;

3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl]oxy]-2,6-dimethoxybenzamidine, acetic acid salt; m.p. 109-111°C;

3-[(3,5-difluoro-6-(2-hydroxyethyl)phenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, acetic acid salt; m.p. 179-182°C;

4-methoxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 9.6 (br, 4), 7.7 (d, 1), 7.6 (s, 1), 7.3 (t, 1), 7.2 (d, 1), 7.05 (d, 1), 7.0 (d, 1), 6.9 (s, 1), 3.8 (s, 3), 3.1 (s, 6), 2.95 (s, 3), 2.8 (s, 3), 1.75 (s, 3) ppm;

4-methoxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(ethoxycarbonylpip eridin-1-yl)pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10.0 (br, 4), 7.65 (m, 2), 7.3 (m, 1), 7.2 (m, 1), 7.0 (m, 3), 4.1 (q, 2), 3.8 (s, 3), 3.7 (m, 2), 3.3 (m, 2), 3.0 (s, 3), 2.8 (s, 3), 2.7 (m, 1), 2.0 (m, 2), 1.75 (s, 3), 1.25 (t, 3) ppm; and

4-methoxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(ethoxycarbonylpiperidin-1-yl)pyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 9.2 (br, 4), 7.8 (d, 1), 7.7 (s, 1), 7.3 (m, 2), 7.0 (m, 3), 4.1 (q, 2), 3.8 (s, 3), 3.7 (m, 1), 3.4 (m, 5), 3.0 (s, 3), 2.8 (s, 3), 2.7 (m, 1), 2.0 (s, 3), 1.8 (m, 4), 1.1 (t, 3) ppm.

**EXAMPLE 5**

4-Amino-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, Acetic Acid Salt

A. In a manner similar to Example 1 above, 4-amino-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl]oxy]benzene carbonitrile was reacted with hydrogen chloride and ammonia. The resulting residue was purified by HPLC on a C18 Dynamax column with a 20-80% acetonitrile in water gradient with 0.1% trifluoroacetic acid and the material was partitioned with ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried (MgSO$_4$), and the solvent was removed in vacuo. The residue was dissolved in water, acidified with acetic acid, and the solvent removed to give 4-amino-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 10 (br, 4), 7.45 (m, 2), 7.03 (t, 1), 6.79 (d, 1), 6.44 (dd, 1), 6.33 (t, 1), 6.29 (d, 1), 6.16 (s, 1), 3.36 (s, 2), 2.84 (s, 6), 2.38 (s, 3), 1.76 (s, 3) ppm.

B. In a similar manner, the following compound was made:

4-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl]amino]-3-hydroxy-
EXAMPLE 6

4-Hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl)oxy]-benzamidin, Trifluoroacetic Acid Salt

A. To 5-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl)oxy]-4-methoxybenzamidine, trifluoroacetic acid salt (0.80 g, 1.9 mmol) in methylene chloride (70 mL) at -78°C was added boron tribromide (1 M in methylene chloride, 9 mL, 9 mmol). The reaction was warmed to ambient temperature. After stirring for 16 hours, the reaction was concentrated and purified by HPLC as described above in Example 5 to give 4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-methylpyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.06 (s,2), 8.88 (s,2), 7.67 (m,1), 7.62 (d,1), 7.1 (d,1), 7.04 (t,1), 6.45 (d,1), 6.32 (m,1), 6.23 (d,1), 2.85 (s,6), 2.4 (s,3) ppm.

B. In a similar manner, the following compounds were made:

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-dimethylaminopyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 11.0 (s,1), 9.0 (s,2), 8.8 (s,2), 7.6 (m,2), 7.3 (t,1), 7.0 (m,4), 3.1 (s,6), 2.95 (s,3), 2.8 (s,3) ppm;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-ethoxy carbonyl-piperidin-1-yl)pyridin-2-yl)oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 11.0 (s,1), 9.0 (s,2), 8.9 (s,2), 7.55 (m,2), 7.3 (t,1), 7.0 (m,4), 4.1 (q,2), 3.6 (m,2), 3.3 (m,2), 3.0 (s,3), 2.8 (s,3), 2.6 (m,1), 2.0 (m,2), 1.1 (s,2), 1.15 (t,3) ppm;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(3-ethoxy carbonyl-piperidin-1-yl)pyridin-2-yl)oxy]benzamidine, acetic acid salt; NMR (DMSO-d$_6$) 9.2 (br,4), 7.6 (m,2), 7.3 (t,1), 7.0 (m,4), 4.1 (q,2), 3.8 (s,3), 3.2-3.7 (m,4), 3.0 (s,3), 2.8 (s,3), 2.7 (m,1), 2.0 (s,3), 1.8 (m,4), 1.1 (t,3) ppm;

4-hydroxy-3-[(6-(3-dimethylaminocarbonylphenoxy)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 11.0 (s,1), 9.1 (s,2), 8.85 (s,2), 7.9 (t,1), 7.6 (m,2), 7.4 (t,1), 7.15 (m,2), 7.05 (m,2), 6.75 (d,1), 6.7 (d,1), 2.95(s,3), 2.8 (s,3) ppm;

4-hydroxy-3-[(6-(3-dimethylaminocarbonylphenoxy)-4-(4-methylpiperazin-1-yl)-pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 11.0 (s,1), 10.1 (br,1), 9.05 (s,2), 8.85 (s,2), 7.6 (m,2), 7.4 (t,1), 7.2 (m,2), 7.05 (m,2), 6.8 (s,1), 6.7 (s,1), 3.5 (m,8), 2.95 (s,3), 2.8 (s,3) ppm;
4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-methylpyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (CDCl₃) 11.20 (bs, 1), 8.98 (s, 2), 8.66 (s, 2), 7.59 (s, 1), 7.53 (d, 1), 7.29 (t, 1), 7.18-6.92 (m, 4), 2.96 (s, 3), 2.78 (s, 3), 2.36 (s, 3), 1.91 (s, 1.5) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2,2,2-trifluoromethyl)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-δ₆) 11.1 (s, 1), 9.0 (s, 2), 8.8 (s, 2), 7.6 (m, 2), 7.3 (t, 1), 7.0-7.1 (m, 4), 5.2 (q, 2), 3.0 (s, 3), 2.8 (s, 3) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-hydroxy-pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (CD₃CN) 8.7 (s, 2), 7.5 (s, 2), 7.3-7.4 (m, 4), 7.2 (dt, 1), 7.1 (dd, 1), 7.0 (t, 1), 6.8 (d, 1), 3.1 (s, 3), 3.0 (s, 3) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1,3-difluoroprop-2-oxypyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (CD₃CN) 9.8 (s, 2), 7.3-7.4 (m, 4), 7.2 (d, 1), 7.1 (d, 1), 7.0 (s, 1), 6.8 (d, 1), 5.1 (t, 1), 4.8 (d, 4), 3.1 (s, 3), 3.0 (s, 3) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1-bromo-3-fluoroprop-2-oxypyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (CD₃CN) 10.8 (s, 2), 7.3-7.4 (m, 4), 7.2 (d, 1), 7.1 (d, 1), 7.0 (s, 1), 6.8 (d, 1), 5.1 (m, 1), 4.9 (d, 1), 4.7 (d, 1), 3.8 (d, 1), 3.1 (s, 3), 3.0 (s, 3) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1,3-dibromoprop-2-oxypyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-δ₆) 11.1 (s, 1), 9.0 (s, 2), 8.8 (s, 2), 7.5-7.6 (m, 2), 7.3 (t, 1), 7.1 (m, 2), 7.0 (m, 2), 5.1 (t, 1), 3.9 (d, 4), 3.0 (s, 3), 2.8 (s, 3) ppm;

4-hydroxy-3-{(6-(3-dimethylaminocarbonylphenoxy)-4-carboxy-3-pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-δ₆) 11.12 (s, 2), 9.16 (s, 2), 9.03 (s, 2), 7.3 (m, 9), 2.99 (s, 3), 2.87 (s, 3) ppm;

4-hydroxy-3-{(6-(3-dimethylaminocarbonylphenoxy)-4-(aminocarbonyl)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-δ₆) 11.0 (s, 1), 9.06 (s, 2), 8.76 (s, 2), 8.3 (s, 1), 7.85 (s, 1), 7.3 (m, 9), 2.98 (s, 3), 2.86 (s, 3) ppm;

4-hydroxy-3-{(6-(3-dimethylaminocarbonylphenoxy)-4-(dimethylaminocarbonyl)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-δ₆) 10.95 (s, 1), 9.08 (s, 2), 8.72 (s, 2), 7.3 (m, 7), 6.72 (s, 1), 6.66 (s, 1), 2.95 (m, 12) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(3-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-
4-(2-hydroxy-4-carboxyphenoxy)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt; and
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-hydroxy-
4-methoxycarbonylphenoxy)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt.

C. In a similar manner, the following compounds are made:

5
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2-hydroxy-
4-methoxycarbonylphenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidinophenoxy)-4-(2-hydroxy-
4-methoxycarbonylphenoxy)pyridin-2-yl)oxy]benzamidine; and

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(2-hydroxy-
4-methoxycarbonylphenoxy)pyridin-2-yl)oxy]benzamidine.

EXAMPLE 7
4-Hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(piperidin-1-yl)-pyridin-2-yl)oxy]benzamidine, Trifluoroacetic Acid Salt

A. In a manner similar to Example 1, 3-[(6-(5-cyano-2-(benzyloxy)phenoxy)-3,5-difluoro-4-(piperidin-1-yl)pyridin-2-yl)oxy]-N,N-dimethylbenzamide was reacted with HCl and ammonia. The solvent was removed in vacuo. The material was dissolved in methanol and Pd(C) was added. The reaction was placed under an atmosphere of hydrogen at 50 psi for 2 hours. The reaction was filtered through celite and the solvent was removed in vacuo. The material was partially dissolved in 0.25 N aqueous potassium hydroxide and the solid was removed by filtration. The solid was purified by HPLC as described above in Example 5 to give 4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(piperidin-1-yl)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt, as the final product; NMR (DMSO-d$_6$) 11.0 (s,1), 9.0 (s,2), 8.7 (s,2), 7.6 (m,2), 7.3 (t,1), 7.0 (m,4), 3.4 (m,4), 2.95 (s,3), 2.8 (s,3), 1.65 (m,6) ppm.

B. In a similar manner, the following compounds were made:

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-methylpiperazin-1-yl)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 11.2 (s,1), 10.3 (br,1), 9.0 (s,4), 7.6 (m,2), 7.3 (m,2), 7.0 (m,4), 3.6 (m,8), 3.0 (s,3), 2.9 (s,3), 2.8 (s,3), 1.65 (m,6) ppm;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-ethoxy-
carbonylmethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine, acetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-aminophenoxy)-4-(ethoxycarbonyl)pyridin-
2-yl)oxy]benzamidine, trifluoroacetic acid salt; NMR (CDCl$_3$) 11.14 (s,1), 9.37-8.88 (m,8 ), 7.76-7.06 (m,9), 4.35 (q,2), 1.32 (t,3) ppm;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(morpholin-4-yl)-
pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 9.0 (s,2), 8.6 (s,2), 7.5 (m,2), 7.3 (t,1), 7.0 (m,4), 3.7 (m,4), 3.4 (m,4), 2.9 (s,3), 2.8 (s,3) ppm;
4-hydroxy-3-[(3,5-difluoro-6-[(3-((guanidino)phenox)yl)-4-(methyl)(phenyl)amino-
carbonyl]pyridin-2-yl)oxy]benzamide;

4-hydroxy-3-[(3,5-difluoro-6-[(3-dimethylaminocarbonyl)phenox)yl]-4-methoxy(pyridin-
2-yl)oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(2-methoxy-4-ethoxy-
carbonyl]phenox)ylpyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-methyl)aminocarbonyl]phenox)yl]-4-(2-methoxy-4-ethoxy-
carbonyl]phenox)ylpyridin-2-yl)oxy]benzamide;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(2-methoxy-4-ethoxy-
carbonyl]phenox)ylpyridin-2-yl)oxy]benzamide;

4-hydroxy-3-[(3,5-difluoro-6-[(3-dimethylaminophenox)yl]-4-(4-ethoxy-
carbonyl]phenox)ylpyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(1-prop-2-oxycarbonyl)methylpyridin-4-ylox)pyridin-2-yl)oxy]benzamidinar trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(2,6-dimethoxy-4-methoxy carbonyl-
phenox)ylpyridin-2-yl)oxy]benzamide;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(2,6-dimethoxy-
4-ethoxy carbonyl]phenox)ylpyridin-2-yl)oxy]benzamide;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(1-ethoxy carbonyl]methylpyridin-4-ylox)pyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(4-1-ethoxy-
carbonyl]ethyl)methylpiperazin-1-ylox)pyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(4-1-ethoxy-
carbonyl]ethyl)methylpiperazin-1-ylox)pyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-ethyl)(2-methylimidazolin-2-yl)phenox)yl]-4-(5-ethoxy carbonyl-
pyrrolidin-3-ylox)pyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt; NMR (DMSO-d$_6$)

11.35 (s, 1), 10.41 (s, 1), 9.03 (d, 4), 7.35-7.62 (m, 6), 7.0 (d, 1), 5.57 (s, 1), 4.64 (dd, 1),
4.22 (q, 2), 4.05 (dd, 2), 3.95 (dd, 1), 3.78 (d, 1), 3.65 (d, 1), 2.96 (s, 3), 2.75 (m, 1), 2.55
(m, 1), 1.23 (t, 3) ppm;

4-hydroxy-3-[(3,5-difluoro-6-[(3-((guanidino)phenox)yl)-4-(5-ethoxycarbonylpyrrolidin-3-yl)oxy]-
pyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-dimethylaminophenox)yl]-4-(1-methoxycarbonyl-
methylpiperidin-4-ylox)pyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(pyrrolidin-3-yloxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1-ethoxycarbonylmethylpyrrolidin-3-yloxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-aminocarbonylmethylpyrrolidin-3-yloxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-2-(3,5-dihydroxycarboxyl)phenoxy)pyridin-4-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazolin-2-yl)phenoxy)-4-(4-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-dichloro-6-(3-dimethylaminocarbonylphenoxy)-4-(1-benzylpyrrolidin-3-yloxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-5-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(4-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(3-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-1-yl)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2,3-dimethoxy-5-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(3-arylimidazolin-2-yl)phenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2,6-dimethoxy-4-ethoxycarboxylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2,6-dimethoxy-4-ethoxycarboxylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-guanidino)phenoxy)-4-(2,6-dimethoxy-4-aminocarbonylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-amidinophenoxy)-4-(2-methoxy-4-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-\{(6-\{3-amidinophenoxy\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-\{1-methylimidazolin-2-yl\}phenoxy\}4-\{(2-chloro-
4-ethoxy carbonyl phenoxy\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-\{1-methylimidazolin-2-yl\}phenoxy\}4-\{(2,6-dimethyl-
4-ethoxy carbonyl phenoxy\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-\{1-methylimidazolin-2-yl\}phenoxy\}4-\{(3-(2-ethoxy-
carbonyl ethyl)phenoxy\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-\{1-methylimidazolin-2-yl\}phenoxy\}4-\{(2-methoxy-
4-ethoxy carbonylmethyl phenoxy\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-\{1-methylimidazolin-2-yl\}phenoxy\}4-\{(2-methoxy-
5-(tetrazol-5-yl)pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-\{1-methylimidazolin-2-yl\}phenoxy\}4-\{(2-methoxy-
phenoxy\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-dimethylaminocarboxylphenoxy\}4-methoxy-
pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-dimethylaminocarboxylphenoxy\}4-propoxy-
pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-dimethylaminocarboxylphenoxy\}4-\{(4-ethoxy carbonyl-
methyl)piperazinyl\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-\{1-methylimidazolin-2-yl\}phenoxy\}4-(\{methyl-
ethoxy carbonyl methyl\}amino)pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-dichloro-6-\{3-dimethylaminocarboxylphenoxy\}-
4-\{(tetrahydrofuran-3-oxyl\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-dichloro-6-\{3-dimethylaminocarboxylphenoxy\}-
4-\{piperidin-4-yl\}oxy\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-dimethylaminocarboxylphenoxy\}-
4-\{laminocarboxyl methyl\}ethoxy\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-dichloro-6-\{3-dimethylaminocarboxylphenoxy\}-
4-\{(1-carboxymethyl)pyrrolidin-3-oxyl\}pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-dimethylaminocarboxylphenoxy\}-
pyridin-2-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-dimethylaminocarboxylphenoxy\}-2-\{methyl-
5-ethoxycarbonyl phenoxy\}pyridin-4-yl\}oxy\}benzamide, trifluoroacetic acid salt;
4-hydroxy-3-\{(3,5-difluoro-6-\{3-dimethylaminocarboxylphenoxy\}-2-\{methyl-
5-ethoxycarbonyl phenoxy\}pyridin-4-yl\}oxy\}benzamide, trifluoroacetic acid salt;
aminophen-1-yloxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3-(3-dimethylaminocarbonyl)phenoxy)-2,4,6-trichloro-5-fluoro-
phen-1-yloxy)benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(piperidin-4-
yl)amino)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(1-benzyl-
piperidin-4-yl)amino)pyridin-2-yl)oxy)benzamidine;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(piperidin-4-yl)-
(methyl)amino)pyridin-2-yl)oxy)benzamidine;

4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(1-benzyl-
piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy)benzamidine;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(1-(1-methoxy-
carbonyl)ethyl)piperidin-4-yl)amino)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-
4-aminocarbonyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-
(1-hydroxymethyl)ethoxycarbonyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-
(prop-2-oxycarbonyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-
(2-methoxyethoxy)carbonyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-
(2-2-hydroxyethoxy)ethoxy)carbonyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-
(2-(2-methoxyethoxy)ethoxy)carbonyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-
(2-(methoxycarbonyl)ethenyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-
(2-methoxycarbonyl)ethenyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-
(2-chloro-1-methylthoxycarbonyl)phenoxy)pyridin-2-yl)oxy)benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-[(3,5-difluoro-6-[(3-[(1-methylimidazolin-2-yl)phenoxy]-4-3-
(2-ethoxycarbonyl)ethenyl]phenoxy)pyridin-2-yl]oxy]benzamidine, trifuoroacetic acid salt;
4-hydroxy-3-[(3,5-difluoro-6-[(3-[(1-methylimidazolin-2-yl)phenoxy]-4-4-
(2-ethoxycarbonyl)phenoxy)pyridin-2-yl]oxy]benzamidine, trifuoroacetic acid salt; and
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxy]-4-[(2-methoxy-4-ethoxycarbonyl-
phenoxy)pyridin-2-yl]oxy]benzamidine, trifuoroacetic acid salt.

C. In a similar manner, the following compounds are made:

4-hydroxy-3-[(3,5-difluoro-6-[(3-[(1-methylimidazolin-2-yl)phenoxy]-4-4-
(4-[(1-methyl-1-ethoxycarbonyl)ethyl]piperazin-1-yl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-dimethylaminocarbonyl)phenoxy]-4-4-
(4-[(1-methyl-1-ethoxycarbonyl)ethyl]piperazin-1-yl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxy]-4-4-
(4-[(1-methyl-1-ethoxycarbonyl)ethyl]piperazin-1-yl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-[(1-methylimidazolin-2-yl)phenoxy]-4-4-
(5-aminocarbonyl-
pyrroldin-3-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-dimethylaminocarbonyl)phenoxy]-4-4-
(5-aminocarbonyl-
pyrroldin-3-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-[(1-methylimidazolin-2-yl)phenoxy]-4-4-
(5-aminocarbonyl-
pyrroldin-3-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-guanidino)phenoxy]-4-4-
(5-aminocarbonyl-
pyrroldin-3-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-[(1-methylimidazolin-2-yl)phenoxy]-4-4-
(5-aminocarbonyl-
pyrroldin-3-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[(3-[(1-methylimidazolin-2-yl)phenoxy]-4-4-
(5-aminocarbonyl-
pyrroldin-3-yloxy)pyridin-2-yl]oxy]benzamidine;
methoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-[(ethoxycarbonyl)methoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(ethoxycarbonyl)methoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(1-ethyl-5-ethoxycarbonyl)pyrrolidin-3-yl]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy)-4-[(1-ethyl-5-ethoxycarbonyl)pyrrolidin-3-yl]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(tetrazol-5-yl)methyl]piperidin-4-yl]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy)-4-[(1-tetrazol-5-yl)methyl]piperidin-4-yl]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(1-tetrazol-5-yl)methyl]piperidin-4-yl]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(2-methoxy-4-(tetrazol-5-yl)]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(2-methoxy-4-(tetrazol-5-yl)]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(2-chloro-4-(tetrazol-5-yl)]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(2-chloro-4-(tetrazol-5-yl)]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(2-chloro-4-(tetrazol-5-yl)]oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-[(2-chloro-4-(tetrazol-5-yl)]oxy]pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[2-chlorophenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(guanidino)phenoxy]-4-[2-chlorophenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[2-chlorophenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(guanidino)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-(1-methylimidazolin-2-yl)phenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[3-dimethylaminocarbonylphenoxy]-4-[1-ethoxycarbonyl-1-methylthiopiperidine-4-yloxy]pyridin-2-yl)oxy]benzamidine;
pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(piperidin-1-yl)-pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-methoxypyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)-4-methoxypyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-methoxypyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(1-prop-2-oxycarbonyl)methyl]piperidin-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(1-prop-2-oxycarbonyl)methyl]piperidin-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(1-ethoxycarbonyl)ethyl]piperidin-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(1-ethoxycarbonyl)ethyl]piperidin-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(1-ethoxycarbonyl)ethyl]piperidin-4-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(1-ethoxycarbonyl)methyl]piperazin-1-yl]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(4-(1-ethoxycarbonyl)methyl]piperazin-1-yl]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(5-ethoxycarbonyl)pyrrolidin-3-yloxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(4-(1-ethoxycarbonyl)methyl]piperazin-1-yl]pyridin-2-yl)oxy]benzamidine;
4-(5-ethoxycarbonylpyrrolidin-3-yl)oxy)pyridin-2-yl)oxy)benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)4-(pyrrolidin-
3-yl)oxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{guanidino}-4-(pyrrolidin-3-yl)oxy]pyridin-
2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-(pyrrolidin-
3-yl)oxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)4-(1-ethoxycarbonyl-
methylpyrrolidin-3-yl)oxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{guanidino}-4-(1-ethoxycarbonylmethylpyrrolidin-
3-yl)oxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-(1-ethoxycarbonyl-
methylpyrrolidin-3-yl)oxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-
4-(4-ethoxycarbonyl)phenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{guanidino})phenoxy)-4-(4-ethoxycarbonyl)phenoxy)-
pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)4-(4-ethoxycarbonyl-
phenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)4-(1-ethoxycarbonyl-
methylpyrrolidin-3-yl)oxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-dichloro-6-(3-{1-methylimidazol-2-yl)phenoxy)-
4-(1-benzyl)pyrrolidin-3-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-dichloro-6-(3-{1-methylimidazol-2-yl)phenoxy)-
4-(1-benzyl)pyrrolidin-3-yloxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-
4-(2-methoxy-5-ethoxy)carbonylphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{guanidino})phenoxy)-
4-(2-methoxy-5-ethoxy)carbonylphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)4-(2-methoxy-5-
ethoxy)carbonylphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{guanidino})phenoxy)-
4-(4-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-
4-(4-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)4-(3-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl]oxy]benzamidine;
4-(3-ethoxy carbonyl piperidin-1-yl) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino] phenoxy)
4-(2,3-dimethoxy-5-ethoxy carbonyl phenoxo) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy)
4-(2,3-dimethoxy-5-ethoxy carbonyl phenoxo) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)
4-(3-aminocarbonyl-5-ethoxy carbonyl phenoxo) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino] phenoxy)
4-(3-aminocarbonyl-5-ethoxy carbonyl phenoxo) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy)
4-(3-aminocarbonyl-5-ethoxy carbonyl phenoxo) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino] phenoxy) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy) pyridin-2-yl)oxy] benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methyl imidazol-2-yl] phenoxy) pyridin-2-yl)oxy] benzamide;
4-ethoxycarbonylphenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-guanidino)phenoxy]-4-(2-chloro-
4-ethoxycarbonylphenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-1-methylimidazol-2-yl)phenoxy]-4-(2-chloro-
4-ethoxycarbonylphenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-dimethylaminocarbonylphenoxy)-4-(2,6-dimethyl-
4-ethoxycarbonylphenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-guanidino)phenoxy]-4-(2,6-dimethyl-
4-ethoxycarbonylphenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-1-methylimidazol-2-yl)phenoxy]-4-(2,6-dimethyl-
4-ethoxycarbonylphenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-dimethylaminocarbonylphenoxy)-4-(3'-2-ethoxy-
carbonyl|ethyl|phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-guanidino)phenoxy]-4-(3'-2-ethoxy-
carbonyl|ethyl|phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-1-methylimidazol-2-yl)phenoxy]-4-(3'-2-ethoxy-
carbonyl|ethyl|phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-dimethylaminocarbonylphenoxy)-4-(3'-2-methoxy-
4-ethoxycarbonyl|ethyl|phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-guanidino)phenoxy]-4-(3'-2-methoxy-
4-ethoxycarbonyl|ethyl|phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-1-methylimidazol-2-yl)phenoxy]-4-(3'-2-methoxy-
4-ethoxycarbonyl|ethyl|phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-dimethylaminocarbonylphenoxy)-4-(3'-2-methoxy-
5-(tetrazol-5-yl)phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-guanidino)phenoxy]-4-(2-methoxy-
5-(tetrazol-5-yl)phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-1-methylimidazol-2-yl)phenoxy]-4-(2-methoxy-
5-(tetrazol-5-yl)phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-dimethylaminocarbonylphenoxy)-4-(2-methoxy-
phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-1-methylimidazol-2-yl)phenoxy]-4-(2-methoxy-
phenoxy|pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-1-methylimidazol-2-yl)phenoxy]-4-propoxy-
pyridin-2-yl|oxy|bentamidine;
4-hydroxy-3-{[3,5-difluoro-6-(3'-guanidino)phenoxy]-4-propoxy-
pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-(1-methylimidazol-2-yl)phenoxy)]-4-propoxy-
pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-dimethylaminocarbonylphenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{guanidino}-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-[(3-{1-methylimidazol-2-yl}phenoxy)]-4-((methyl)-
(ethoxycarbonylmethyl)amino)pyridin-2-yl)oxy]benzamidine;
(methyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-4-[[1-benzyl-
piperidin-4-yl](methyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-guanidino)phenoxy]-4-[[1-benzyl-
piperidin-4-yl](methyl)amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-methylimidazol-2-yl)phenoxy]-4-[[1-benzyl-
piperidin-4-yl]amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-4-[[1-(1-methoxy-
carbonyl)ethyl]piperidin-4-yl]amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-guanidino)phenoxy]-4-[[1-(1-methoxy-
carbonyl)ethyl]piperidin-4-yl]amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-methylimidazol-2-yl)phenoxy]-4-[[1-(1-methoxy-
carbonyl)ethyl]piperidin-4-yl]amino)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-guanidino)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-methylimidazol-2-yl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-methylimidazol-2-yl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-methylimidazol-2-yl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-methylimidazol-2-yl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-methylimidazol-2-yl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonyl)phenoxy]-4-[[2-methoxy-
4-aminocarbonyl]phenoxy]pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-<sup>1</sup>-methylimidazol-2-yl)phenoxy]-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-
4-hydroxy-3-[[3,5-difluoro-6-(3-{1-methylimidazol-2-yl)phenoxy)-4-{2-methoxy-4-

1-methylethoxycarbonyl[phenoxy]pyridin-2-yl]oxy]benzamidin;
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(2-methoxy-
4-(2-chloro-1-methylethoxycarbonyl]phenoxy)pyridin-2-yl]oxy]benzamidin;
4-hydroxy-3-[(3,5-difluoro-6-[(dimethylaminocarbonylphenoxy)-4-(3-
4-hydroxy-3-[(3,5-difluoro-6-[(guanidino]phenoxy)-4-(3-
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(3-
4-hydroxy-3-[(3,5-difluoro-6-[(guanidino]phenoxy)-4-(4-
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(4-
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(2,6-dimethoxy-
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(2,6-dimethoxy-
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(4-methylpiperezin-
1-yl]pyridin-2-yl]oxy]benzamidin;
4-hydroxy-3-[(3,5-difluoro-6-[(guanidino]phenoxy)-4-(4-methylpiperezin-
1-yl]pyridin-2-yl]oxy]benzamidin;
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(4-methylpiperezin-
1-yl]pyridin-2-yl]oxy]benzamidin;
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(dimethylamin-
pyridin-2-yl]oxy]benzamidin;
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-(dimethylamin-
pyridin-2-yl]oxy]benzamidin;
4-hydroxy-3-[(3,5-difluoro-6-[(1-methylimidazol-2-yl]phenoxy)-4-methylpyridin-
2-yl]oxy]benzamidin;
4-hydroxy-3-[(3,5-difluoro-6-[(guanidino]phenoxy)-4-methylpyridin-
2-yl]oxy]benzamidin;
2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-{1-methylimidazol-2-yl}phenoxy)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-{guanidino}phenoxy)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-{1-methylimidazol-2-yl}phenoxy)-4-(1,3-difluorophenyl)2-oxopyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-{guanidino}phenoxy)-4-(1,3-difluorophenyl)2-oxopyridin-2-yl]oxy]benzamidine; and
4-hydroxy-3-[(3,5-difluoro-6-(3-{1-methylimidazol-2-yl}phenoxy)-4-(1,3-difluorophenyl)2-oxopyridin-2-yl]oxy]benzamidine.

EXAMPLE 8
4-Hydroxy-3-[(3,5-difluoro-6-(3-{imidazol-1-yl}phenoxy)-4-(carboxy)pyridin-2-yl]oxy]benzamidine, Trifluoroacetic Acid Salt
A. In a manner similar to Example 6, 2-(5-amidino-2-hydroxyphenoxy)-6-(3-{imidazol-1-yl}phenoxy)pyridine-4-carboxylic acid, ethyl ester was reacted with boron tribromide. The resulting oil was dissolved in 6 N HCl and heated at reflux for 2 hours. Concentration of the mixture in vacuo and purification by HPLC as described above in Example 5 gave 4-hydroxy-3-[(3,5-difluoro-6-(3-{imidazol-1-yl}phenoxy)-4-(carboxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d6, TFA) 9.7 (s, 1), 9.0 (s, 2), 8.8 (s, 2), 8.3 (s, 1), 7.9 (s, 1), 7.6 (m, 5), 7.3 (m, 1), 7.1 (m, 2), 7.0 (m, 1) ppm.

B. In a similar manner, the following compound was made:
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(carboxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d6) 11.0 (s, 1), 9.1 (s, 2), 8.7 (s, 2), 7.7 (m, 2), 7.2 (m, 2), 7.0 (s, 1), 6.8 (s, 1), 6.6 (d, 1), 6.4 (m, 2), 2.8 (s, 6) ppm.

EXAMPLE 9
3,3′-[4-Aminocarbonyl-2,6-pyridinediyl]bis(oxyl)bis(benzamidine), Trifluoroacetic Acid Salt
A. In a manner similar to Example 1 above, reaction of 3,3′-[4-ethoxy-carbonyl-2,6-pyridinediyl]bis(benzonitrile) gave 3,3′-[4-aminocarbonyl-2,6-pyridinediyl]bis(oxyl)bis(benzamidine), which was purified by HPLC as described above in Example 5 to give the trifluoroacetic acid salt, m.p. >210°C; NMR (DMSO-d6) 9.3 (s, 4), 9.1 (s, 4), 8.3 (s, 1), 7.8 (s, 1), 7.65 (m, 4), 7.55 (m, 4), 7.2 (s, 2) ppm.

B. In a similar manner, the following compounds were made:
EXAMPLE 10

2,6-bis(3-Aminophenoxy)pyridine-3-carboxylic acid, Dihydrochloride

A. In a manner similar to Example 2 above, 2,6-bis(3-aminophenoxy)pyridine-3-carboxylic acid, ethyl ester (0.20 g, 0.31 mmol) was dissolved in 5 M HCl and heated for 2 hours at 80 °C. The solvent was removed in vacuo to give 2,6-bis(3-aminophenoxy)pyridine-3-carboxylic acid, dihydrochloride; NMR (DMSO-d$_6$) 9.5 (br s, 4), 9.35 (br s, 4), 8.45 (d, 1), 7.7 (m, 2), 7.6 (m, 2), 7.5 (m, 4), 6.95 (d, 1) ppm.

B. In a similar manner, the following compounds were made and purified by HPLC as described above in Example 5:

4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy))-4-(2-methoxy-5-carboxyphenoxy)pyridin-2-y]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy))-4-(2-methoxy-5-carboxyphenoxy)pyridin-2-y]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy))-4-(2-methoxy-5-carboxyphenoxy)pyridin-2-y]oxy]benzamide, trifluoroacetic acid salt;
4-hydroxy-3-[(3,5-difluoro-6-[(3-[[1-methylimidazolin-2-yl]phenoxy]-4-[(3-[2-carboxy-ethenyl]phenoxy)]pyridin-2-yl]oxy)benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-[[1-methylimidazolin-2-yl]phenoxy]-4-[(4-[2-carboxy-ethenyl]phenoxy)]pyridin-2-yl]oxy)benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-[(3-[dimethylaminomethyl]phenoxy)-4-[(2-methoxy-4-carboxy-phenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(3-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(3,5-dicarboxyphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(3-carboxy-5-ethoxy-carbonylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(2,6-dimethoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[guanidino]phenoxy)-4-[(2,6-dimethoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(2-methoxy-4-carboxymethylphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[3-amidinophenoxy]-4-[(2-methoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(2-chloro-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(2,6-dimethyl-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(2-dimethyl-aminoethyl)(carboxymethyl)amino]pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(2-dimethyl-aminoethyl)(carboxymethyl)amino]pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(1-carboxy-methyl)piperidin-4-yl(methyl)amino]pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d6) 11.25 (s, 1), 10.30 (s, 1), 9.03 (br s, 4), 7.58-7.55 (m, 2), 7.50 (t, 1), 7.38-7.31 (m, 3), 7.03 (d, 1), 4.10 (s, 2), 4.08-3.88 (m, 4), 3.66 (m, 2), 3.16 (m, 2), 2.95 (s, 6), 2.26 (m, 2), 1.93(m, 2) ppm;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(1-carboxy-methyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-3-[1-methylimidazolin-2-yl]phenoxy)-4-[(methyl)(carboxymethyl)amino]pyridin-2-yl]oxy]benzamidine, hydrochloride salt; NMR (DMSO-d6) 11.25 (s, 1), 10.45 (s, 1), 9.1 (d, 4), 7.35 (m, 7), 4.18 (s, 2), 4.05 (m, 4), 3.2 (s, 3), 2.95 (s, 3)
ppm;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(2-methoxy-4-carboxyphenoxy)-pyridin-2-yl)oxy]benzamide, trifluoroacetic acid salt.

C. In a similar manner, the following compounds are made:

5 4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(4-(1-methyl-1-(carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-(1-methyl-1-(carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(4-(1-methyl-1-(carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(4-(1-methyl-1-(carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-(1-carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(4-(1-carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(4-(1-carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(4-(1-carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(4-(1-carboxy)ethyl)piperazin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(2-carboxyethylphenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(2-carboxyethylphenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(2-carboxyethylphenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(2-carboxyethylphenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(1-(1-carboxy)ethyl)piperazin-4-yl)oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1-(1-carboxy)ethyl)piperazin-4-yl)oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(1-(1-carboxy)ethyl)piperazin-4-yl)oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(1-(1-carboxy)ethyl)piperazin-4-yl)oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(1-(1-carboxy)ethyl)piperazin-4-yl)oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(1-(1-carboxy)ethyl)piperazin-4-yl)oxy]pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolizin-2-yl)phenoxy)-4-(1-(1-carboxy)ethyl)piperazin-4-yl)oxy]pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)]
4-(1-carboxy-1-methylethyl)piperidin-4-yloxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-guanidino)phenoxy)]
4-(1-carboxy-1-methylethyl)piperidin-4-yloxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(1-carboxy-1-methylethyl)piperidin-4-yloxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(1-carboxymethylpiperidin-4-yloxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(6-(3-dimethylaminocarbonylphenoxy)]
4-(1-carboxymethylpiperidin-4-yloxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(6-(3-guanidino)phenoxy)]
4-(1-carboxymethylpiperidin-4-yloxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(1-carboxymethylpiperidin-4-yloxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(carboxymethoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)]
4-(carboxymethoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-guanidino)phenoxy)]
4-(carboxymethoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(carboxymethoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-guanidino)phenoxy)]
4-(2-methoxy-5-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(2-methoxy-5-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-guanidino)phenoxy)]
4-(2,3-dimethoxy-5-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-1-methylimidazol-2-yl)phenoxy)]
4-(2,3-dimethoxy-5-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-guanidino)phenoxy)]
4-(3-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-{(3,5-difluoro-6-(3-(guanidino)phenoxy)-
4-(3,5-dicarboxyphenoxy)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(3,5-dicarboxyphenoxy)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-
4-(3-carboxy-5-ethoxycarbonylphenoxy)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(3-carboxy-5-ethoxycarbonylphenoxy)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(2,6-dimethoxy-4-carboxyphenoxy)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(2-chloro-4-carboxyphenoxy)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(2,6-dimethyl-4-carboxyphenoxy)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(2,6-dimethyl-4-carboxyphenoxy)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-carboxy-
methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl)oxy}benzamide;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(2,6-dimethoxy-4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(3-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(2,6-dimethoxy-4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(2,6-dimethoxy-4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-
4-(3-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-
4-(2,6-dimethoxy-4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-
4-(3-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-
4-(2,6-dimethoxy-4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-
4-(3-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-
4-(2,6-dimethoxy-4-(2-carboxyethyl)phenoxy)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-(carboxymethyl)-pyrroldin-3-yloxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-(carboxymethyl)-pyrroldin-3-yloxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-(carboxymethyl)-pyrroldin-3-yloxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-(carboxymethyl)-pyrroldin-3-yloxy)pyridin-2-yl)oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-
4-(1-(carboxymethyl)-pyrroldin-3-yloxy)pyridin-2-yl)oxy]benzamidine; and
4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-
4-(1-(carboxymethyl)-pyrroldin-3-yloxy)pyridin-2-yl)oxy]benzamidine.

**EXAMPLE 11**

4-Hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-(ethoxycarbonyl)-
methyl)pyrroldin-3-yloxy)pyridin-2-yloxy]benzamidine, Trifluoroacetic Acid Salt

A. To ethanol (40 mL) was added 4-hydroxy-3-[(3,5-difluoro-6-(3-dimethyl-
aminophenoxy)-4-(pyrroldin-3-yloxy)pyridin-2-yloxy]benzamidine (0.44 g, 0.90 mmol), ethyl bromoacetate (0.15 g, 0.9 mmol), and triethylamine (0.11 g, 1.1 mmol). After stirring for 19 hours, the reaction mixture was concentrated and purified by HPLC as described above in Example 5 to give 4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylamino-phenoxy)-4-(1-(ethoxycarbonylmethyl)-pyrroldin-3
yloxy)pyridin-2-yl)-oxy]benzamidine, trifluoroacetic acid salt.

B. In a similar manner, the following compounds were made:

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1-ethoxycarbonylmethyl)piperridin-4-yl]oxygen]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxo)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)(methyl)amino]pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; and

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxo)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)amino]pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt.

C. In a similar manner, the following compounds are made:

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(1-ethoxycarbonylmethyl)piperridin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(guanidino)phenoxy)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxo)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)(methyl)amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxo)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)amino]pyridin-2-yl]oxy]benzamidine; and

4-hydroxy-3-[[3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxo)-4-((1-ethoxycarbonylmethyl)piperidin-4-yl)amino]pyridin-2-yl]oxy]benzamidine.

EXAMPLE 12

3-[[3,5-Difluoro-6-(3-carboxyphenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, Hydrochloride Salt

A. To 3-[[3,5-difluoro-6-(3-ethoxycarbonylphenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, acetic acid salt (1.0 g, 2.0 mmol) dissolved in methanol (40 mL) was added 5N potassium hydroxide (20 mL). After stirring for 4 hours, the solvent was removed in vacuo. The residue was dissolved in water (50 mL) and acidified with 12 N HCl. The resulting solid was filtered and washed with ether to give 3-[[3,5-difluoro-6-(3-carboxyphenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, hydrochloride salt; NMR (DMSO-d6) 9.3 (s,2), 9.1 (s,2), 7.7 (d,1), 7.65 (s,1), 7.3-7.6 (m,6), 2.4 (s,3) ppm. If necessary the material can be further purified by HPLC as described above in Example 5.

B. In a similar manner, the following compounds were made:

3-[[3,5-difluoro-6-(3-(2-carboxyethyl)aminocarbonylphenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, m.p. 145-150°C;

3-[[3,5-difluoro-6-(3-(2-carboxyethyl)phenoxy)-4-methylpyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt; NMR (DMSO-d6) 9.3 (s,2), 9.2 (s,2), 7.6 (m,4), 7.25 (t,1), 7.0 (m,2),
6.95 (m, 1), 2.8 (t, 2), 2.6 (m, 2), 2.4 (s, 3) ppm;

3-{(3,5-difluoro-6-(3-carboxyethylphenoxy)-4-methylpyridin-2-yl)oxy}benzamidine, NMR (DMSO-d$_6$) 9.3 (s, 2), 9.2 (s, 2), 7.6 (m, 4), 7.25 (t, 1), 7.0 (m, 3), 3.4 (s, 2), 2.4 (s, 3) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-carboxypiperidin-1-yl)pyridin-2-yl)oxy}benzamidine; NMR (DMSO-d$_6$) 9.75 (br, 2), 8.5 (br, 2), 7.5 (m, 2), 7.3 (t, 1), 7.0 (m, 3), 6.65 (d, 1), 3.6 (m, 2), 3.2 (m, 2), 2.95 (s, 3), 2.8 (s, 3), 2.3 (m, 1), 1.9 (m, 2), 1.7 (m, 2) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(3-carboxypiperidin-1-yl)pyridin-2-yl)oxy}benzamidine; NMR (DMSO-d$_6$) 9.75 (br, 2), 8.7 (br, 2), 7.5 (m, 2), 7.3 (t, 1), 7.0 (m, 3), 6.8 (d, 1), 3.2-3.68 (m, 4), 2.95 (s, 3), 2.8 (s, 3), 2.4 (m, 1), 2.0 (m, 1), 1.8 (m, 1), 1.6 (m, 2) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-carboxymethylpiperazin-1-yl)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 11.1 (s, 1), 9.0 (br, 2), 8.9 (br, 2), 7.65 (m, 2), 7.3 (m, 1), 7.0 (m, 4), 4.1 (s, 2), 3.6 (m, 8), 3.0 (s, 3), 2.8 (s, 3), ppm;

4-hydroxy-3-{(6-(3-amidinophenoxy)-4-(carboxy)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (CDCl$_3$) 11.16 (s, 1), 9.38-8.95 (m, 8), 7.68-7.04 (m, 9) ppm;

3-{(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(N-methyl-N-carboxymethylamino)pyridin-2-yl)oxy}benzamidine; NMR (DMSO-d$_6$) 9.3 (s, 2), 9.2 (s, 2), 7.5 (m, 4), 7.2 (t, 1), 6.7 (m, 2), 6.5 (d, 1), 4.2 (s, 2), 3.2 (s, 3), 2.9 (s, 6) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(methyl)-(carboxymethylamino)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(3-carboxypiperidin-1-yl)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(5-carboxypyridazin-3-yl)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 11.30 (s, 1), 10.37 (s, 1), 9.00 (s, 2), 8.99 (s, 2), 7.61 (d, 1), 7.57 (dd, 1), 7.52-7.32 (m, 4), 7.04 (d, 1), 6.55 (s, 1), 4.52 (dd, 1), 4.02 (dd, 2), 3.88 (dd, 2), 3.72 (dd, 1), 3.58 (d, 1), 2.92 (s, 3), 2.63 (dd, 1), 2.44 (dd, 1);

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(1-carboxymethylpiperidin-4-yl)oxy)pyridin-2-yl)oxy}benzamidine, trifluoroacetic acid salt; NMR (DMSO-d$_6$) 11.29 (s, 1), 10.31 (s, 1), 9.05 (s, 2), 9.02 (s, 2), 7.63-7.57 (m, 2), 7.52 (t, 1), 7.42-7.37 (m, 3), 7.04 (d, 1), 4.92 (br s, 1), 4.15 (s, 2), 4.09-3.92 (m, 4), 3.60-3.40 (m, 4), 2.95 (s, 3), 2.32-2.10 (m, 4) ppm;

4-hydroxy-3-{(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(1-carboxy-1-methylethyl)piperidin-4-yl)oxy}pyridin-2-yl)oxy}benzamidine; NMR (DMSO-d$_6$) 11.34 (s, 1), 10.46 (s, 1), 9.21 (s, 2), 8.99(s, 2), 7.70 (s, 1), 7.63 (d, 1), 7.54 (t, 1), 7.43-
7.40 (m, 2), 7.15 (d, 1), 4.96 (br s, 1), 4.12-4.09 (m, 2), 3.96-3.90 (m, 2), 3.40-3.20 (m, 4),
2.97 (s, 3), 2.40-2.30 (m, 2), 2.28-2.14 (m, 2), 1.54 (s, 6) ppm;

4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidinophenoxy)-4-(1-carboxymethyl)piperidin-4-yloxy)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenox)-4-(2-methoxy-4-carboxyphenox)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenox)-4-(carboxymethyl)(methyl)aminocarbonylpyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-carboxymethyl)piperidin-4-yloxy)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenox)-4-(4-carboxy piperidin-1-yl)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenox)-4-(4-carboxypent-1-oxypyrindin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-(methyl)carboxymethyl)aminocarbonyl)methyl ammethylpyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenox)-4-(4-carboxymethyl)piperazin-1-yl)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-carboxy)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(6-(3-(2,4-dimethylimidazol-1-yl)phenox)-4-(carboxy)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(6-(3-(2-methylimidazol-1-yl)phenox)-4-(carboxy)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(6-(3-(4-methylimidazol-1-yl)phenox)-4-(carboxy)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-carboxymethyl)piperazin-1-yl)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-carboxy 2-methoxyphenox)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;

4-hydroxy-3-[(6-(3-(1-methylimidazolin-2-yl)phenox)-4-(carboxy)pyridin-2-yl]oxy]benzamide, trifluoroacetic acid salt;
4-hydroxy-3-[(6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(carboxy)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt;
4-amino-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-((methyl)carboxymethyl)amino)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt;
3-hydroxy-4-[(6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(carboxy)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt;
3-hydroxy-4-[(6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(carboxy)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-[(6-(3-dimethylaminocarbonylphenoxy)-4-((carboxymethyl)(methyl)amino)pyridin-2-yl)oxy]benzamidine, trifluoroacetic acid salt;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazol-2-yl)phenoxy)-4-(3-amino-5-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine, trifluoroacetic acid salt.

C. In a similar manner, the following compounds are made:
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2-methoxy-5-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2,3-dimethoxy-5-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(3,5-dicarboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2,6-dimethoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2-chloro-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2,6-dimethyl-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-((1-carboxy-methyl)piperidin-4-yl)(methyl)amino)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-((1-carboxy-methyl)piperidin-4-yl)amino)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-(2-methoxy-
4-carboxymethyl[phenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxyl)-
4-(2,6-dimethoxy-4-(2-carboxyethenyl)phenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxyl)-
4-(2-carboxyethenyl)phenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxyl)-
4-(2,6-dimethoxy-4-(2-carboxyethenyl)phenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxyl)
4-(2-carboxyethyl)phenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxyl)
4-(1-carboxymethyl)piperidin-4-yl][oxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[(1-methylimidazol-2-yl)phenoxyl-
4-(1-carboxymethyl)piperidin-4-yl][oxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl)-4-(2-hydroxy-4-
4-carboxyphenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl)-4-(3-carboxypiperidin-
4-carboxyphenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl]-4-(4-carboxypiperidin-
4-carboxyphenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl]-4-(4-carboxypiperidin-
4-carboxyphenoxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl]-4-(5-carboxypent-1-oxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl]-4-(5-carboxypent-1-oxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl]-4-(5-carboxypent-1-oxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl]-4-(5-carboxypent-1-oxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl]-4-(5-carboxypent-1-oxyl]pyridin-2-yl][oxyl]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxyl]-4-(5-carboxypent-1-oxyl]pyridin-2-yl][oxyl]benzamidine;
5-carboxyphenoxy)pyridin-2-yl)oxy benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-3-(guanidino)phenoxy)-4-(3-aminocarbonyl)-
5-carboxyphenoxy)pyridin-2-yl)oxy benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-3-(1-methylimidazol-2-yl)phenoxy)-4-(3-aminocarbonyl)-
5-carboxyphenoxy)pyridin-2-yl)oxy benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-3-dimethylaminocarbonylphenoxy)-
4-(5-carboxy pyrrolidin-3-yl)oxy)pyridin-2-yl)oxy benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-3-(guanidino)phenoxy)-4-(5-carboxy pyrrolidin-
3-yl)oxy)pyridin-2-yl)oxy benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-3-(1-methylimidazol-2-yl)phenoxy)-
4-(5-carboxy pyrrolidin-3-yl)oxy)pyridin-2-yl)oxy benzamidine;

EXAMPLE 13

3-[(3,5-Difluoro-6-3-(phenyl)hydroxymethyl)phenoxy)-4-methylpyridin-2-yl)oxy]-
benzamidine, Trifluoroacetic Acid Salt

A. To 3-[(3,5-difluoro-4-methyl-6-3-(phenyl)oxomethyl)phenoxy]-
pyridin-2-yl)oxy benzamidine, acetic acid salt, (0.10 g, 0.19 mmol) in methanol was added Pd-C (75
mg). After stirring under hydrogen for 2.5 hours, the reaction was filtered, concentrated in vacuo,
and purified by HPLC as described above in Example 5 to give 3-[(3,5-difluoro-
6-3-(phenyl)hydroxymethyl)phenoxy]-4-methylpyridin-2-yl)oxy benzamidine, trifluoroacetic acid salt;
NMR (DMSO-d6) 9.45 (s,2), 9.35 (s,2), 7.55 (m,4), 7.1-7.4 (m,8), 6.95 (m,1), 5.64 (s,1), 2.4 (s,3)
ppm.

EXAMPLE 14

4-Hydroxy-3-[(3,5-dichloro-6-3(dimethylaminocarbonylphenoxy)-4-(1-imino-
edethyl)pyrrolidin-3-yl)oxy)pyridin-2-yl)oxy benzamidine,
Trifluoroacetic Acid Salt

A. To ethanol (8 mL) was added 4-hydroxy-3-[(3,5-dichloro-6-3(dimethyl-
aminocarbonylphenoxy)-4-(pyrrolidin-3-yl)oxy)pyridin-2-yl)oxy benzamidine (0.16 g, 0.20 mmol),
ethylacetimidate hydrochloride (74 mg, 0.6 mmol), and triethylamine (0.10 g, 1.0 mmol). After
stirring for 2 hours, the reaction mixture was concentrated and purified by HPLC as described above in
Example 5 to give 4-hydroxy-3-[(3,5-dichloro-6-3(dimethylaminocarbonyl-phenoxy)-4-(1-imino-
edethyl)pyrrolidin-3-yl)oxy)pyridin-2-yl)oxy benzamidine, trifluoroacetic acid salt.
B. In a similar manner, the following compounds were made:

4-hydroxy-3-[(3,5-difluoro-6-3(dimethylaminophenoxy)-4-(1-iminoethyl)pyrrolidin-
3-yl)oxy)pyridin-2-yl)oxy benzamidine, trifluoroacetic acid salt; and
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxo)-4-(1-iminoethyl)-pyrrolidin-3-yl)oxy]pyridin-2-y]oxy]benzamidine, trifluoroacetic acid salt 6922.

C. In a similar manner, the following compounds are made:

4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxo)-4-(1-[1-iminoethyl]-pyrrolidin-3-yl)oxy]pyridin-2-y]oxy]benzamidine, trifluoroacetic acid salt;

4-hydroxy-3-[(3,5-difluoro-6-(3-[guanidino]phenoxo)-4-(1-[1-iminoethyl]-pyrrolidin-3-yl)oxy]pyridin-2-y]oxy]benzamidine, trifluoroacetic acid salt; and


EXAMPLE 15

This example illustrates the preparation of representative pharmaceutical compositions for oral administration containing a compound of the invention, or a pharmaceutically acceptable salt thereof, e.g., 4-hydroxy-3-[(3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxo)-4-(2,3-dimethoxy-5-carboxyphenoxo)pyridin-2-y]oxy]benzamidine:

A. **Ingredients**

<table>
<thead>
<tr>
<th></th>
<th>% wt./wt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of the invention</td>
<td>20.0%</td>
</tr>
<tr>
<td>Lactose</td>
<td>79.5%</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

The above ingredients are mixed and dispensed into hard-shell gelatin capsules containing 100 mg each.

B. **Ingredients**

<table>
<thead>
<tr>
<th></th>
<th>% wt./wt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of the invention</td>
<td>20.0%</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>0.9%</td>
</tr>
<tr>
<td>Starch</td>
<td>8.6%</td>
</tr>
<tr>
<td>Lactose</td>
<td>79.6%</td>
</tr>
<tr>
<td>PVP (polyvinylpyrrolidine)</td>
<td>0.9%</td>
</tr>
</tbody>
</table>

The above ingredients with the exception of the magnesium stearate are combined and granulated using water as a granulating liquid. The formulation is then dried, mixed with the magnesium stearate and formed into tablets with an appropriate tableting machine.

C. **Ingredients**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of the invention</td>
<td>0.1 g</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>20.0 g</td>
</tr>
<tr>
<td>Polyethylene glycol 400</td>
<td>20.0 g</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>1.0 g</td>
</tr>
<tr>
<td>Water</td>
<td>q.s. 100 mL</td>
</tr>
</tbody>
</table>

The compound of the invention is dissolved in propylene glycol, polyethylene glycol 400 and polysorbate 80. A sufficient quantity of water is then added with stirring to provide 100 mL of the
The above ingredients are melted, mixed and filled into soft elastic capsules.

The compound of the invention is dissolved in the cellulose/saline solution, filtered and bottled for use.

EXAMPLE 16

This example illustrates the preparation of a representative pharmaceutical formulation for parenteral administration containing a compound of the invention, or a pharmaceutically acceptable salt thereof, e.g., 4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(1-carboxymethylpiperidin-4-yloxy)pyridin-2-yl)oxy]-benzamidine:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>% wt./wt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of the invention</td>
<td>0.02 g</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>20.0 g</td>
</tr>
<tr>
<td>Polyethylene glycol 400</td>
<td>20.0 g</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>1.0 g</td>
</tr>
<tr>
<td>0.9% Saline solution</td>
<td>q.s. 100 mL</td>
</tr>
</tbody>
</table>

The compound of the invention is dissolved in propylene glycol, polyethylene glycol 400 and polysorbate 80. A sufficient quantity of 0.9% saline solution is then added with stirring to provide 100 mL of the I.V. solution which is filtered through a 0.2 \( \mu \) membrane filter and packaged under sterile conditions.

EXAMPLE 17

This example illustrates the preparation of a representative pharmaceutical composition in suppository form containing a compound of the invention, or a pharmaceutically acceptable salt thereof, e.g., 4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(4-ethoxycarbonylmethylpiperazin-1-yl)pyridin-2-yl)oxy]benzamidine:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>% wt./wt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of the invention</td>
<td>1.0%</td>
</tr>
<tr>
<td>Polyethylene glycol 1000</td>
<td>74.5%</td>
</tr>
<tr>
<td>Polyethylene glycol 4000</td>
<td>24.5%</td>
</tr>
</tbody>
</table>
The ingredients are melted together and mixed on a steam bath, and poured into molds containing 2.5 g total weight.

EXAMPLE 18
This example illustrates the preparation of a representative pharmaceutical formulation for insufflation containing a compound of the invention, or a pharmaceutically acceptable salt thereof, e.g., 4-hydroxy-3-[(3,5-difluoro-6-(3-{guanidino}phenoxy)-4-(2-methoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>% wt./wt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Micronized compound of the invention</td>
<td>1.0%</td>
</tr>
<tr>
<td>Micronized lactose</td>
<td>99.0%</td>
</tr>
</tbody>
</table>

The ingredients are milled, mixed, and packaged in an insufflator equipped with a dosing pump.

EXAMPLE 19
This example illustrates the preparation of a representative pharmaceutical formulation in nebulized form containing a compound of the invention, or a pharmaceutically acceptable salt thereof, e.g., 4-hydroxy-3-[(3,5-difluoro-6-(3-{1-methylimidazolin-2-yl}phenoxy)-4-(2-methoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>% wt./wt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of the invention</td>
<td>0.005%</td>
</tr>
<tr>
<td>Water</td>
<td>89.995%</td>
</tr>
<tr>
<td>Ethanol</td>
<td>10.000%</td>
</tr>
</tbody>
</table>

The compound of the invention is dissolved in ethanol and blended with water. The formulation is then packaged in a nebulizer equipped with a dosing pump.

EXAMPLE 20
This example illustrates the preparation of a representative pharmaceutical formulation in aerosol form containing a compound of the invention, or a pharmaceutically acceptable salt thereof, e.g., 4-hydroxy-3-[(3,5-difluoro-6-(3-{1-methylimidazolin-2-yl}phenoxy)-4-(2-methoxy-5-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>% wt./wt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of the invention</td>
<td>0.10%</td>
</tr>
<tr>
<td>Propellant 11/12</td>
<td>98.90%</td>
</tr>
<tr>
<td>Oleic acid</td>
<td>1.00%</td>
</tr>
</tbody>
</table>

The compound of the invention is dispersed in oleic acid and the propellants. The resulting mixture is then poured into an aerosol container fitted with a metering valve.
EXAMPLE 21
(In vitro assay for Factor Xa, Thrombin and Tissue Plasminogen Activator)

This assay demonstrates the activity of the compounds of the invention towards factor Xa, thrombin and tissue plasminogen activator. The activities were determined as an initial rate of cleavage of the peptide p-nitroanilide by the enzyme. The cleavage product, p-nitroaniline, absorbs at 405 nm with a molar extinction coefficient of 9920 M\(^{-1}\)cm\(^{-1}\).

Reagents and Solutions:

Dimethyl sulfoxide (DMSO) (Baker analyzed grade).

Assay buffer:

- 50 mM TrisHCl, 150 mM NaCl, 2.5 mM CaCl\(_2\), and 0.1% polyethylene glycol 6000, pH 7.5.

Enzymes (Enzyme Research Lab.):

1. Human factor Xa stock solution: 0.281 mg/mL in assay buffer, stored at -80°C (working solution (2X): 106 ng/mL or 2 nM in assay buffer, prepare prior to use).

2. Human thrombin stock solution: Stored at -80°C (working solution (2X): 1200 ng/mL or 40 nM in assay buffer, prepare prior to use).

3. Human tissue plasminogen activator (tPA) (Two chains, Sigma) stock solution: 1 mg/mL, stored at -80°C (working solution (2X): 1361 ng/mL in assay buffer, prepare prior to use).

Chromogenic substrates (Pharmacia Hepar Inc.):

- S2222 (FXa assay) stock solution: 6 mM in dH\(_2\)O, store at 4°C (working solution (4X): 656 \(\mu\)M in assay buffer).
- S2302 (Thrombin assay) stock solution: 10 mM in dH\(_2\)O, stored at 4°C (working solution (4X): 1200 \(\mu\)M in assay buffer).
- S2288 (tPA assay) stock solution: 10 mM in dH\(_2\)O, stored at 4°C (working solution (4X): 1484 \(\mu\)M in assay buffer).

(All substrate working solutions were prepared on assay day 5.)

Standard inhibitor compound stock solution:

- 5 mM in DMSO, stored at -20°C.

Test compounds (compounds of the invention) stock solutions:

- 10 mM in DMSO, stored at -20°C.

Assay procedure:

Assays were performed in 96-well microtiter plates in a total volume of 200 \(\mu\)L. Assay components were in final concentration of 50 mM TrisHCl, 150 mM NaCl, 2.5 mM CaCl\(_2\), 0.1% polyethylene glycol 6000, pH 7.5, in the absence or presence of the standard inhibitor or the test compounds and enzyme and substrate at following concentrations: (1) 1 nM factor Xa and 164 \(\mu\)M S2222; (2) 20 nM thrombin and 300 \(\mu\)M S2302; and (3) 10 nM tPA and 371 \(\mu\)M S2288. Concentrations of the standard inhibitor compound in the assay were from 5 \(\mu\)M to 0.021 \(\mu\)M in 1 to 3 dilution. Concentration of the test compounds in the assay typically were from 10 \(\mu\)M to 0.041
µM in 1 to 3 dilution. For potent test compounds, the concentrations used in the factor Xa assay were further diluted 100 fold (100 nM to 0.41 nM) or 1000 fold (10 nM to 0.041 nM). All substrate concentrations used are equal to their \( K_m \) values under the present assay conditions. Assays were performed at ambient temperature.

The first step in the assay was the preparation of 10 mM test compound stock solutions in DMSO (for potent test compounds, 10 mM stock solutions were further diluted to 0.1 or 0.01 mM for the factor Xa assay), followed by the preparation of test compound working solutions (4X) by a serial dilutions of 10 mM stock solutions with Biomek 1000 (or Multiprobe 204) in 96 deep well plates as follows:

(a) Prepare a 40 µM working solution by diluting the 10 mM stock 1 to 250 in assay buffer in 2 steps: 1 to 100, and 1 to 2.5.

(b) Make another five serial dilutions (1:3) of the 40 µM solution (600 µl for each concentration). A total of six diluted test compound solutions were used in the assay.

Standard inhibitor compound (5 mM stock) or DMSO (control) went through the same dilution steps as those described above for test compounds.

The next step in the assay was to dispense 50 µl of the test compound working solutions (4X) (from 40 uM to 0.164 uM) in duplicate to microtiter plates with Biomek or MP204. To this was added 100 µl of enzyme working solution (2X) with Biomek or MP204. The resulting solutions were incubated at ambient temperature for 10 minutes.

To the solutions was added 50 µl of substrate working solution (4X) with Biomek or MP204.

The enzyme kinetics were measured at 405 nm at 10 seconds intervals for five minutes in a THERMOMax plate reader at ambient temperature.

**Calculation of \( K_i \) of the test compounds:**

Enzyme rates were calculated as mOD/min based on the first two minutes readings. The IC\(_{50}\) values were determined by fitting the data to the log-logit equation (linear) or the Morrison equation (non-linear) with an EXCEL spread-sheet. \( K_i \) values were then obtained by dividing the IC\(_{50}\) by 2. Routinely, \( K_i \) (factor Xa) values less than 3 nM were calculated from the Morrison equation.

Compounds of the invention, when tested in this assay, demonstrated the selective ability to inhibit human factor Xa and human thrombin.

**EXAMPLE 22**

*(In vitro assay for Human Prothrombinase)*

This assay demonstrates the ability of the compounds of the invention to inhibit prothrombinase. Prothrombinase (PTase) catalyzes the activation of prothrombin to yield fragment 1.2 plus thrombin with mezothrombin as the intermediate. This assay is an end point assay. Activity of the prothrombinase is measured by activity of thrombin (one of the reaction products) or by the amount of thrombin formed/time based on a thrombin standard curve (nM vs mOD/min). For determination of IC\(_{50}\) (PTase) of the compounds of the invention, PTase activity was expressed by
thrombin activity (mOD/min).

Materials:

Enzymes:

1. Human factor Va (Haematologic Technologies Inc., Cat# HCVA-0110) working solution: 1.0 mg/mL in 50% glycerol, 2 mM CaCl₂, stored at -20°C.

2. Human factor Xa (Enzyme Res. Lab. cat# HFXa1011) working solution: 0.281 mg/mL in assay buffer (without BSA), stored at -80°C.

3. Human prothrombin (FII) (Enzyme Res. Lab., Cat# HP1002) working solution: Diluted FII to 4.85 mg/mL in assay buffer (without BSA), stored at -80°C.

10 Phospholipid (PCPS) vesicles:

PCPS vesicles (80%PC, 20%PS) were prepared by modification of the method reported by Barenholz et al., Biochemistry (1977), Vol. 16, pp. 2806-2810.

Phosphatidyl serine (Avanti Polar Lipids, Inc., Cat#840032):

10 mg/mL in chloroform, purified from brain, stored -20°C under nitrogen or argon.

15 Phosphatidyl Choline (Avanti Polar Lipids, Inc., Cat# 850457):

50 mg/mL in chloroform, synthetic 16:0-18:1 Palmitoyl-Oleoyl, stored at -20°C under nitrogen or argon.

Spectrozyme-TH (American Diagnostica Inc., Cat# 238L, 50 μmoles, stored at room temperature) working solution: Dissolved 50 μmoles in 10 mL dH₂O.

20 BSA (Sigma Chem Co., Cat# A-7888, FractionV, RIA grade).

Assay buffer: 50 mM TrisHCl, pH 7.5, 150 mM NaCl, 2.5 mM CaCl₂, 0.1% PEG 6000 (BDH), 0.05% BSA (Sigma, Fr.V, RIA grade).

For one plate assay, prepare the following working solutions:

1. Prothrombinase complex:

(a) 100 μM PCPS (27.5 μl of PCPS stock (4.36 mM) diluted to final 1200 μl with assay buffer.

(b) 25 nM Human factor Va: 5.08 μl of Va stock (1 mg/mL) was diluted to final 1200 μl with assay buffer.

(c) 5 pM Human factor Xa: Dilute Xa stock (0.281 mg/mL) 1:1,220,000 with assay buffer. Prepare at least 1200 μl.

Combine equal volumes (1100 μl) of each component in the order of PCPS, Va and Xa. Let stand at ambient temperature for 5 to 10 minutes and use immediately or store in ice (bring to ambient temperature before use).

2. 6 μM Human prothrombin (FII): dilute 124 μL of FII stock (4.85 mg/mL) to final 1400 μL with assay buffer.

3. 20 mM EDTA/Assay buffer: 0.8 mL of 0.5 M EDTA (pH 8.5) plus 19.2 mL assay buffer.

4. 0.2 mM Spectrozyme-TH/EDTA buffer: 0.44 mL of SPTH stock (5 mM) plus 10.56 mL of 20 mM EDTA/assay buffer.
5. Test compounds (compounds of the invention):

Prepare a working solution (5X) from 10 mM stock (DMSO) and make a series of 1:3 dilution. Compounds were assayed at 6 concentrations in duplicate.

5 Assay conditions and procedure:

Prothrombinase reaction was performed in final 50 μL of mixture containing PTase (20 μM PCPS, 5 mM hFVa, and 1 mM hFXa), 1.2 μM human factor II and varied concentration of the test compounds (5 μM to 0.021 μM or lower concentration range). Reaction was started by addition of PTase and incubated for 6 minutes at room temperature. Reaction was stopped by addition of EDTA-buffer to final 10 mM. Activity of thrombin (product) was then measured in the presence of 0.1 mM of Spectrozyme-TH as substrate at 405 nm for 5 minutes (10 seconds intervals) at ambient temperature in a THEROmax microplate reader. Reactions were performed in 96-well microtiter plates.

In the first step of the assay, 10 μl of diluted test compound (5X) or buffer was added to the plates in duplicate. Then 10 μl of prothrombin (hFII) (5X) was added to each well. Next 30 μl PTase was added to each well, mix for about 30 seconds. The plates were then incubated at ambient temperature for 6 minutes.

In the next step, 50 μl of 20 mM EDTA (in assay buffer) was added to each well to stop the reaction. The resulting solutions were then mixed for about 10 seconds. Then 100 μl of 0.2 mM spectrozyme was added to each well. The thrombin reaction rate was then measured at 405 nm for 5 minutes at 10 seconds intervals in a Molecular Devices microplate reader.

Calculations:

Thrombin reaction rate was expressed as mOD/min. using OD readings from the five minute reaction. IC_{50} values were calculated with the log-logit curve fit program.

The compounds of the invention demonstrated the ability to inhibit pro-thrombinase when tested in this assay.

EXAMPLE 23

(In vivo assay)

The following assay demonstrates the ability of the compounds to act as anti-coagulants.

Male rats (250-330 g) were anesthetized with sodium pentobarbital (90 mg/kg, i.p.) and prepared for surgery. The left carotid artery was cannulated for the measurement of blood pressure as well as for taking blood samples to monitor clotting variables (prothrombin time (PT) and activated partial thromboplastin time (aPTTI)). The tail vein was cannulated for the purpose of administering the test compounds (i.e., the compounds of the invention and standards) and the thromboplastin infusion. The abdomen was opened via a mid-line incision and the abdominal vena cava was isolated for 2-3 cm distal to the renal vein. All venous branches in this 2-3 cm segment of the abdominal vena cava were ligated. Following all surgery, the animals were allowed to stabilize prior to beginning
the experiment. Test compounds were administered as an intravenous bolus ($t = 0$). Three minutes later ($t = 3$), a 5-minute infusion of thromboplastin was begun. Two minutes into the infusion ($t = 5$), the abdominal vena cava was ligated at both the proximal and distal ends. The vessel was left in place for 60 minutes, after which it was excised from the animal, slit open, the clot (if any) carefully removed, and weighed. Statistical analysis on the results was performed using a Wilcoxin-matched-pairs signed rank test.

The compounds of the invention, when tested in this assay, demonstrated the ability to clot the blood and to inhibit the clotting of the blood.

• • • •

While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.
WHAT IS CLAIMED IS:

1. A compound selected from the group consisting of the following formulae:

   ![Diagram of chemical structures](image)

   (I), (II), (III), (IV), (V), (VI), (VII), (VIII);

wherein
A is -C(R^11)= or -N=;
Z^1 and Z^2 are independently -O-, -N(R^8)-, -S-, or -OCH_2-;
R^1 and R^3 are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro,
-N(R^8)R^9, -C(O)OR^8, -C(O)N(R^8)R^9, -C(O)N(R^6)CH_2C(O)N(R^6)R^9, -N(R^8)C(O)N(R^8)R^9,
-N(R^8)C(O)R^9, -N(R^8)S(O)_2R^{12}, or -N(R^8)C(O)N(R^8)CH_2C(O)N(R^8)R^9;
R² is hydrogen; halo; alkyl; haloalkoxy; -OR⁸; -C(O)OR⁸; -C(O)N(R⁸)R⁹;
-N(R⁸)R⁹; -C(O)N[R⁸(H₂)ₘC(O)OR⁸ (where m is 0 to 3); -N(R⁸)(CH₂)ₙC(O)OR⁸ (where n is
1 to 3); -N[(CH₂)ₙN[R⁸(R⁹)R⁹(CH₂)ₙC(O)OR⁸ (where each n is 1 to 3); -O(CH₂)ₙC(O)N[R⁸(R⁹)R⁹
(where n is 1 to 3); -O(CH₂)ₚC(O)OR⁸ (where p is 1 to 6);
-N[R⁸(CH₂)ₙC(O)N[R⁸(R⁹)(CH₂)ₙC(O)OR⁸ (where each n is independently 1 to 3); morpholin-4-yl;
3-tetrahydrofuranoxyl;
or R² is aryloxy (optionally substituted by one or more substituents independently
selected from the group consisting of -OR⁸, -C(O)N(R⁸)R⁹, halo, alkyl, carboxy,
alkoxycarbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxy carbonylalkyl, carboxyalkyl,
aminocarbonylalkyl, (alkylaminocarbonylalkyl, (dialkylaminocarbonylalkyl, (arylaminocarbonylalkyl, (arylaminocarbonylalkenyl, alkoxy carbonylalkenyl, carboxyalkenyl,
aminocarbonylalkenyl, (alkylaminocarbonylalkenyl, (dialkylaminocarbonylalkenyl, (arylaminocarbonylalkenyl, (arylaminocarbonylalkenyl, (hydroxyalkoxy)carbonyl, (alkoxy)alkoxycarbonyl, (hydroxyalkoxy)alkoxycarbonyl, (alkoxy)alkoxycarbonyl, tetrazo-1,yl, morpholin-4-ylalkyl, and (1,2)-imidazolinyl (optionally substituted by alkyl));
or R² is piperazin-1-yl (optionally substituted by one or more substituents independently
selected from the group consisting of alkyl, carboxy, -C(O)N[R⁸(R⁹)R⁹, carboxyalkyl,
alkoxycarbonyl, and alkoxycarbonylalkyl); or R² is 1-piperazin 1-yl (optionally substituted by one or more substituents selected from
the group consisting of alkyl, carboxy, -C(O)N[R⁸(R⁹)R⁹, carboxyalkyl, alkoxy carbonyl, and
alkoxycarbonylalkyl); or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from
the group consisting of carboxy, -C(O)N[R⁸(R⁹)R⁹, carboxyalkyl, alkoxy carbonyl, and
alkoxycarbonylalkyl); or R² is (3,4)-piperidinoxy (optionally substituted by one or more substituents selected
from the group consisting of alkyl carbonyl, carboxy, -C(O)N[R⁸(R⁹)R⁹, a lkoxycarbonyl,
carboxyalkyl, alkoxy carbonylalkyl, and tetrazolylalkyl); or R² is piperidin-4-yl (wherein the amino is optionally substituted by alkyl and the
piperidinyl group is optionally substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy carbonyl, carboxyalkyl, -C(O)N[R⁸(R⁹)R⁹, alkoxy carbonylalkyl and
aralkyl); or R² is 3-pyrrrolidinyloxy (optionally substituted by one or more substituents selected
from the group consisting of alkyl, aralkyl, amidino, 1-iminoethyl, carboxy, carboxyalkyl,
-C(O)N[R⁸(R⁹)R⁹, alkoxy carbonyl and alkoxy carbonylalkyl); R⁴ and R⁷ are independently hydrogen, halo, alkyl, nitro, -OR⁸, -C(O)OR⁸,
-C(O)N[R⁸(R⁹)R⁹, N[R⁸(R⁹)R⁹, N[HC(O)OR⁸, or -N[HS(O)₂R¹²;
R⁵ is -C(NH)NH₂, -C(NH)NH[HIOR⁸, -C(NH)NH[HI(C)OR¹², -C(NH)NH[HI[SI(O)₂R¹²,
-C(NH)NH[HI(C)N[R⁸(R⁹)R⁹, or -C(NH)NH[HI(C)OR⁸;
R⁶ is halo, alkyl, haloalkyl, haloalkoxy, nitro, amino, ureido, guanidino, -OR⁸, -C(NH)NH₂, -C(NH)NHOH, -C(O)R¹⁰, -(CH₂)ₘC(O)N(R⁸)R⁹ (where m is 0 to 3), -CH(OH)C(O)N(R⁸)R⁹, -(CH₂)ₘN(R⁸)R⁹ (where m is 0 to 3), -(CH₂)ₘC(O)OR⁸ (where m is 0 to 3), -N(H)C(O)R⁸, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazoliny1 (optionally substituted by alkyl);

each R⁸ and R⁹ are independently hydrogen, alkyl, aryl, or aralkyl;

R¹⁰ is hydrogen, alkyl, aryl, aralkyl, 1-pyrrolidinyl, 4-morpholino,

4-piperazinyl, 4-(N-methyl)piperazinyl, or piperidin-1-yl;

R¹¹ is hydrogen, alkyl or halo; and

R¹² is alkyl, aryl or aralkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound selected from formula (I):

![Chemical Structure](image)

wherein

A is -N=;

Z¹ and Z² are independently -O-, -N(R⁸)- or -OCH₂-;

R¹ and R³ are independently hydrogen, fluoro, chloro, haloalkyl, -N(R⁸)R⁹, -C(O)OR⁸, -C(O)N(R⁸)R⁹, -N(R⁸)C(O)N(R⁸)R⁹, -N(R⁸)C(O)R⁸, or -N(R⁸)S(O)₂R¹²;

R² is hydrogen; halo; alkyl; haloalkoxy; -OR⁸; -C(O)OR⁸; -C(O)N(R⁸)R⁹;

-N(R⁸)R⁹; -C(O)N(R⁸)(CH₂)ₘC(O)OR⁸ (where m is 0 to 3); -N(R⁸)(CH₂)ₘC(O)OR⁸ (where n is 1 to 3); -N((CH₂)ₘN(R⁸)R⁹)(CH₂)ₘC(O)OR⁸ (where each n is 1 to 3); -O((CH₂)ₘC(O)N(R⁸)R⁹ (where n is 1 to 3); -O((CH₂)ₘC(O)OR⁸ (where p is 1 to 6);

-N(R⁸)(CH₂)ₘC(O)N(R⁸)(CH₂)ₘC(O)OR⁸ (where each n is independently 1 to 3); morpholin-4-yl;

3-tetrahydrofuranoxyl;

or R² is aryloxy (optionally substituted by one or more substituents independently selected from the group consisting of -OR⁸, -C(O)N(R⁸)R⁹, halo, alkyl, carboxy, alkoxycarbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxycarbonylalkyl, carboxylalkyl, aminocarbonylalkyl, (alkylamino)carbonylalkyl, (dialkylamino)carbonylalkyl,
(arylamino)carbonylalkyl, (aralkylamino)carbonylalkyl, alkoxy carbonylalkeny, carboxyalkeny, amine carbonylalkeny, (alkylamino)carbonylalkeny, (dialkylamino)carbonylalkeny, (arylamino)carbonylalkeny, (aralkylamino)carbonylalkeny, (hydroxyalkoxy)carbonyl, (alkoxy)alkoxy carbonyl, (hydroxyalkoxy)alkoxy carbonyl, (alkoxy)alkoxy alkoxycarbonyl, (alkoxy)carbonylalkoxy alkoxycarbonyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazolyl (optionally substituted by alkyl);  

or \( R^2 \) is piperazin-1-yl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, carboxy, \(-C(O)N(R^8)R^9\), carboxyalkyl, alkoxy carbonyl, and alkoxy carbonylalkyl);  

or \( R^2 \) is 1-piperazinoyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, carboxy, \(-C(O)N(R^8)R^9\), carboxyalkyl, alkoxy carbonyl, and alkoxy carbonylalkyl);  

or \( R^2 \) is piperidin-1-yl (optionally substituted by one or more substituents selected from the group consisting of carboxy, \(-C(O)N(R^8)R^9\), carboxyalkyl, alkoxy carbonyl, or alkoxy carbonylalkyl);  

or \( R^2 \) is (3,4)-piperidinylxoy (optionally substituted by one or more substituents selected from the group consisting of alkylcarbonyl, carboxy, \(-C(O)N(R^8)R^9\), alkoxy carbonyl, carboxyalkyl, alkoxy carbonylalkyl, or tetrazolylalkyl);  

or \( R^2 \) is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy carbonyl, carboxyalkyl, \(-C(O)N(R^8)R^9\), alkoxy carbonylalkyl or alkoxy carbonylalkyl);  

or \( R^2 \) is \( \gamma \)-pyrrolidinylxoy (optionally substituted by one or more substituents selected from the group consisting of alkyl, aralkyl, amidino, 1-iminoethyl, carboxy, carboxyalkyl, \(-C(O)N(R^8)R^9\), alkoxy carbonyl or alkoxy carbonylalkyl);  

\( R^4 \) is hydrogen, \(-OR^8 \) or \(-N(R^8)R^9\);  

\( R^5 \) is \(-CNH\)NH\(_2\);  

\( R^6 \) is guanidino, \(-CNH(NH)\)NH\(_2\), \(-C(O)N(R^8)R^9\), \(-CH(O)C(O)N(R^8)R^9\), \(-CH_2\)\(_m\)N(R\(_8\))R\(_9\)  

(where \( m \) is 0 to 3), 1-piperidinoyl, 1-pyrrolidinoyl, (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolyl (optionally substituted by alkyl);  

\( R^7 \) is hydrogen, halo, alkyl, \(-OR^8\), \(-C(O)N(R^8)R^9\);  

\( R^8 \) and \( R^9 \) are independently hydrogen, methyl, ethyl or phenyl; and  

\( R^{12} \) is methyl, ethyl, phenyl or benzyl.  

3. The compound of Claim 2 wherein  

35 \( Z^1 \) and \( Z^2 \) are independently \(-O- \) or \(-NCH_3-\);  

\( R^1 \) and \( R^3 \) are independently hydrogen, fluoro, chloro, trifluoromethyl, amino, \(-C(O)N(R^8)R^9\), or \(-NHC(O)NHR^9\);  

\( R^2 \) is hydrogen; halo; alkyl; haloalkoxy; \(-OR^8\); \(-C(O)OR^8\); \(-N(R^8)R^9\);
or R² is aryloxy (optionally substituted by one or more substituents independently selected from the group consisting of -OR⁸, -C(O)N(R⁸)R⁹, halo, alkyl, carboxy, alkoxy carbonyl, alkoxy carbonylalkyl, carboxyalkyl, alkoxy carbonylalkenyl, carboxyalkenyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazoliny (optionally substituted by alkyl));

or R² is piperazin-1-yl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, carboxyalkyl, and alkoxy carbonylalkyl);

or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from the group consisting of carboxy and alkoxy carbonyl);

or R² is (3,4)-piperidinyloxy (optionally substituted by one or more substituents selected from the group consisting of carboxyalkyl and alkoxy carbonylalkyl);

or R² is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of carboxyalkyl, alkoxy carbonylalkyl and aralkyl);

or R² is 3-pyrolidinyloxy (optionally substituted by one or more substituents selected from the group consisting of 1-iminoethyl, carboxy, carboxyalkyl, alkoxy carbonyl and alkoxy carbonylalkyl);

R⁴ is hydrogen, amino, hydroxy, or methoxy;

R⁵ is -C(NH)NH₂;

R⁶ is guanidino, -C(NH)NH₂, -C(O)N(R⁸)R⁹, -(CH₂)mN(R⁸)R⁹ (where m is 0 to 1), (1,2)-imidazolyl substituted by alkyl, or 2-imidazoliny substituted by alkyl;

R⁷ is hydrogen, methoxy, or hydroxy; and

R⁸ and R⁹ are independently hydrogen, methyl, ethyl, or phenyl.

4. The compound of Claim 3 wherein

Z¹ and Z² are both -O-;

R¹ and R³ are independently hydrogen, fluoro, or chloro;

R⁴ is amino, hydrogen, hydroxy or methoxy;

R⁶ is guanidino, -C(NH)NH₂, -C(O)N(R⁸)R⁹, -(CH₂)mN(R⁸)R⁹ (where m is 0 or 1), (1,2)-imidazolyl substituted by methyl, or 2-imidazoliny substituted by methyl; and

R⁷ is hydrogen or hydroxy.

5. The compound of Claim 4 wherein

R⁴ is hydroxy;

R⁶ is dimethylamino or dimethylaminocarbonyl; and
6. The compound of Claim 5 selected from the group consisting of the following:

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-(2-methoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;


4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-propoxy-pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-(4-carboxypiperidin-1-yl)pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-dimethylaminopyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-[[2,2,2-trifluoroethoxy]pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-[1,3-difluoroprop-2-oxo]pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-methylpyrindin-2-yl]oxy]benzamidine;


4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-methoxy-pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-(3-carboxypiperidin-1-yl)pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-(4-carboxymethylpiperazin-1-yl)pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-(piperidin-1-yl)pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-(4-methylpiperazin-1-yl)pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminocarbonyl]phenoxy]-4-(morpholin-4-yl)pyrindin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-[3-dimethylaminophenoxy]-4-(4-carboxymethyl-
piperazinyl)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-ethoxycarbonyl- 
methyl)piperazinyl]pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-carboxy-2- 
methoxyphenoxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(4-carboxy-2-{morpholi- 
4-ylmethyl}phenoxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-((methyl)- 
(carboxymethyl)amino)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)- 
4-(aminocarbonylmethoxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)- 
pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-((1-carboxy- 
methyl)piperidin-4-yl)oxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difuoro-6-(3-dimethylaminophenoxy)- 
4-carboxymethoxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-((2-dimethyl-
aminooethyl)carboxymethyl)amino)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-(1-(1-iminoethyl)pyrrolidin-
3-yloxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-((pyrrolidin-3-
 yloxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-((1-ethoxycarbonyl-
methyl)pyrrolidin-3-yloxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-((1-
iminoethyl)pyrrolidin-3-yloxy)pyridin-2-yl)oxy]benzamidine;  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminocarbonylphenoxy)-4-((1-
carboxymethyl)pyrrolidin-3-yloxy)pyridin-2-yl)oxy]benzamidine; and  
4-hydroxy-3-[(3,5-difluoro-6-(3-dimethylaminophenoxy)-4-((methyl)- 
(carboxymethyl)aminocarbonyl(methyl)amino)pyridin-2-yl)oxy]benzamidine.

7. The compound of Claim 4 wherein  
R⁴ is hydroxy;  
R⁶ is (1,2)-imidazolyl substituted by methyl or 2-imidazolyl substituted by methyl; and  
R⁷ is hydrogen.  

8. The compound of Claim 7 selected from the group consisting of the following:
4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-(2-methoxyphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-(2-methoxyphenoxyl)pyridin-2-yl]oxy]benzamidine;

5

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((methyl)-(carboxymethyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((methyl)-(ethoxycarbonylmethyl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((1-(methoxy-carbonyl)ethyl)piperidin-4-yl)amino)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2,6-dimethoxy-4-(2-(ethoxycarbonyl)ethenyl)phenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2,6-dimethoxy-4(2-carboxyethenyl)phenoxyl)pyridin-2-yl]oxy]benzamidine;

10

4-hydroxy-3-[[3,5-difluoro-6-(3-[[1-methylimidazolin-2-yl]phenoxy]-4-((5-carboxypyrrolidin-3-yl)oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((4-(1-(ethoxycarbonyl)ethyl)piperazin-1-yl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2,6-dimethoxy-4-ethoxycarbonylphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2-methoxy-4-ethoxycarbonylphenoxyl)pyridin-2-yl]oxy]benzamidine;

20

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2-methoxy-4-carboxyphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((4-ethoxycarbonylphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2-hydroxy-4-carboxyphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((4-carboxyphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2-methoxy-5-ethoxycarbonylphenoxyl)pyridin-2-yl]oxy]benzamidine;

30

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2-methoxy-5-carboxyphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2,3-dimethoxy-5-ethoxycarbonylphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((2,3-dimethoxy-5-carboxyphenoxyl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[(1-methylimidazolin-2-yl)phenoxy]-4-((3-aminocarbonyl-5-ethoxycarbonylphenoxyl)pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-[3-ethoxycarbonylphenoxy]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(2,6-dimethoxy-4-methoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-[2,6-dimethoxy-4-ethoxycarbonylphenoxy]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(3-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(3,5-dicarboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-4-(3-[1-methylimidazolin-2-yl]phenoxy)]-
6-(3,5-dicarboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(3-carboxy-5-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(2,6-dimethoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(2-hydroxy-4-methoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(2-methoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(2-chloro-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(2,6-dimethyl-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(1-ethoxycarbonylmethyl)piperidin-4-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-[4-(ethoxycarbonylmethyl)piperazin-1-yl]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(5-ethoxycarbonylpyrrolidin-3-yl]oxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(1-carboxymethyl)piperidin-4-yl]oxy]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[[3,5-difluoro-6-(3-[1-methylimidazolin-2-yl]phenoxy)]-
4-(1-carboxy-1-methylethyl)piperidin-4-yl]oxy]pyridin-2-yl]oxy]benzamidine;
4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(4-ethoxycarbonylpiperidin-1-yl)pyridin-2-yl)oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(3-carboxy)piperidin-1-yl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(4-carboxypiperidin-1-yl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(3-tetrazol-5-yl)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-ethoxycarbonylmethylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-4-carboxymethylphenoxy)pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2-methoxy-5-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-carboxymethyl)piperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-benzylpiperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-benzylpiperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-benzylpiperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-benzylpiperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-benzylpiperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine;

4-hydroxy-3-[(3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[(1-benzylpiperidin-4-yl]amino]pyridin-2-yl]oxy]benzamidine; and

9. The compound of Claim 4 wherein
\( R^4 \) is hydroxy;
\( R^5 \) is guanidino; and
\( R^7 \) is hydrogen.

10. The compound of Claim 9 selected from the group consisting of the following:
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(1-ethoxycarbonylmethylpiperidin-4-yloxy)pyridin-2-yl)oxy]benzamidine;
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(1-carboxymethylpiperidin-4-yloxy)pyridin-2-yl]oxy]benzamidine;
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(2,6-dimethoxy-4-methoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(2,6-dimethoxy-4-ethoxycarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(2,6-dimethoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(2,6-dimethoxy-4-aminocarbonylphenoxy)pyridin-2-yl]oxy]benzamidine;
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(2-methoxy-4-carboxyphenoxy)pyridin-2-yl]oxy]benzamidine;
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(methyl)phenylamino-carbonylpyridin-2-yl]oxy]benzamidine; and
- 4-hydroxy-3-[(3,5-difluoro-6-(3-(guanidino)phenoxy)-4-(4-carboxymethylpiperazin-1-yl)pyridin-2-yl]oxy]benzamidine.

11. The compound of Claim 1 which is selected from formula (VII):

![Chemical Structure](image)

wherein
\( Z^1 \) and \( Z^2 \) are independently -O-, -N(\( R^6 \))- or -OCH\(_2\)-;
R¹ and R³ are independently hydrogen, fluoro, chloro, haloalkyl, -N(R⁸)R⁹, -C(O)OR⁶,
-C(O)N(R⁸)R⁹, -N(R⁸)C(O)N(R⁸)R⁹, -N(R⁸)C(O)R⁹, or -N(R⁸)S(O)₂R¹²;

R² is hydrogen; halo; alkyl; haloalkoxy; -OR⁶; -C(O)OR⁶; -C(O)N(R⁸)R⁹;
-N(R⁸)R⁹; -C(O)N(R⁸)(CH₂)mC(O)OR⁸ (where m is 0 to 3); -N(R⁸)(CH₂)nC(O)OR⁸ (where n is
1 to 3); -N((CH₂)nN(R⁸)R⁹)(CH₂)mC(O)OR⁸ (where each n is 1 to 3); -O(CH₂)nC(O)N(R⁸)R⁹
(where n is 1 to 3); -O(CH₂)pC(O)OR⁸ (where p is 1 to 6);
-N(R⁸)(CH₂)nC(O)N(R⁸)(CH₂)mC(O)OR⁸ (where each n is independently 1 to 3); morpholin-4-yl;
3-tetrahydrofuranoyl;

or R² is arylxoy (optionally substituted by one or more substituents independently
selected from the group consisting of -OR⁶, -C(O)N(R⁸)R⁹, halo, alkyl, carboxy,
alkoxycarbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxy carbonyl alkyl, carboxy alkyl,
amino carbonyl alkyl, (alkyl amino) carbonyl alkyl, (dialkyl amino) carbonyl alkyl,
(aryl amino) carbonyl alkyl, (alkyl amino) carbonyl alkyl, alkoxy carbonyl alkyl,
(aryl amino) carbonyl alkyl, alkoxy carbonyl alkyl, (hydroxy) carbonyl,
(alkoxy) alkoxycarbonyl, (hydroxy) alkoxycarbonyl, (alkoxy) alkoxycarbonyl,
tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazoliny (optionally substituted by alkyl));

or R² is piperazin-1-yl (optionally substituted by one or more substituents independently
selected from the group consisting of alkyl, carboxy, -C(O)N(R⁸)R⁹, carboxy alkyl,
alcoxy carbonyl, and alkoxy carbonyl alkyl);

or R² is 1-piperazinoyl (optionally substituted by one or more substituents selected from
the group consisting of alkyl, carboxy, -C(O)N(R⁸)R⁹, carboxy alkyl, alkoxy carbonyl, and
alkoxy carbonyl alkyl);

or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from
the group consisting of carboxy, -C(O)N(R⁸)R⁹, carboxy alkyl, alkoxy carbonyl, or
alkoxy carbonyl alkyl);

or R² is (3,4)-piperidinyloxy (optionally substituted by one or more substituents selected
from the group consisting of alkyl carbonyl, carboxy, -C(O)N(R⁸)R⁹, alkoxy carbonyl,
carboxy alkyl, alkoxy carbonyl alkyl, or tetrazolyl alkyl);

or R² is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the
piperidiny group is optionally substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy carbonyl, carboxy alkyl, -C(O)N(R⁸)R⁹, alkoxy carbonyl alkyl or
aralkyl);

or R² is 3-pyrrolidinyloxy (optionally substituted by one or more substituents selected
from the group consisting of alkyl, aralkyl, amidino, 1-iminoethyl, carboxy, carboxy alkyl,
-C(O)N(R⁸)R⁹, alkoxy carbonyl or alkoxy carbonyl alkyl);

R⁴ is hydrogen, -OR⁶ or -N(R⁸)R⁹;
R⁵ is -C(NH)NH₂;
R^6 is guanidino, -C(NH)NH_2, -C(O)N(R^8)R^9, -CH(OH)C(O)N(R^8)R^9, -(CH_2)_mN(R^8)R^9 (where m is 0 to 3), 1-piperidinoyl, 1-pyrrolidinoyl, (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazoliny1 (optionally substituted by alkyl);

R^7 is hydrogen, halo, alkyl, -OR^8, -C(O)N(R^8)R^9;

R^8 and R^9 are independently hydrogen, methyl, ethyl or phenyl; and

R^{12} is methyl, ethyl, phenyl or benzyl.

12. The compound of Claim 11 wherein

Z^1 and Z^2 are independently -O- or -NCH_3-;

R^1 and R^3 are independently hydrogen, fluoro, chloro, trifluoromethyl, amino,
-C(O)N(R^8)R^9, or -NHC(O)NHR^9;

R^2 is hydrogen; halo; alkyl; haloalkoxy; -OR^8; -C(O)OR^8; -N(R^8)R^9;
-N(R^8)(CH_2)_nC(O)OR^8 (where n is 1 to 3); -N((CH_2)_nN(R^8)R^9)(CH_2)_nC(O)OR^8 (where each n is 1 to 3); -O(CH_2)_nC(O)N(R^8)R^9 (where n is 1 to 3); -O(CH_2)_pC(O)OR^8 (where p is 1 to 6);
-N(R^8)(CH_2)_nC(O)N(R^8)(CH_2)_nC(O)OR^8 (where each n is independently 1 to 3); morpholin-4-yl;
3-tetrahydrofuranoyl;

or R^2 is aryloxy (optionally substituted by one or more substituents independently selected from the group consisting of -OR^8, -C(O)N(R^8)R^9, halo, alkyl, carboxy, alkoxyacarbonyl, alkoxyacarbonylalkyl, carboxyalkyl, alkoxyacarbonylalkenyl, carboxyalkenyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazoliny1 (optionally substituted by alkyl));

or R^2 is piperazin-1-yl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, carboxyalkyl, and alkoxyacarbonylalkyl);

or R^2 is piperidin-1-yl (optionally substituted by one or more substituents selected from the group consisting of carboxy and alkoxyacarbonyl);

or R^2 is (3,4)-piperidinoyloxy (optionally substituted by one or more substituents selected from the group consisting of carboxyalkyl and alkoxyacarbonylalkyl);

or R^2 is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of carboxyalkyl, alkoxyacarbonylalkyl and aralkyl);

or R^2 is 3-pyrrolidinoyloxy (optionally substituted by one or more substituents selected from the group consisting of 1-iminoethyl, carboxy, carboxyalkyl, alkoxyacarbonyl and alkoxyacarbonylalkyl);

R^4 is hydrogen, amino, hydroxy, or methoxy;

R^5 is -C(NH)NH_2;

R^6 is guanidino, -C(NH)NH_2, -C(O)N(R^8)R^9, -(CH_2)_mN(R^8)R^9 (where m is 0 to 1), (1,2)-imidazolyl substituted by alkyl, or 2-imidazoliny1 substituted by alkyl;

R^7 is hydrogen, methoxy, or hydroxy; and

R^8 and R^9 are independently hydrogen, methyl, ethyl, or phenyl.
13. The compound of Claim 12 wherein
Z¹ and Z² are both -O-;
R¹ and R³ are independently hydrogen, fluoro, or chloro;
R⁴ is hydrogen, amino, hydroxy or methoxy;
R⁶ is guanidino, -C(NH)NH₂, -C(O)N(R⁸)R⁹, -[CH₂]ₘN(R⁸)R⁹ (where m is 0 or 1),
(1,2)-imidazolyl substituted by methyl, or 2-imidazoliny1 optionally substituted by methyl; and
R⁷ is hydrogen or hydroxy.

14. The compound of Claim 13 wherein
R⁴ is hydroxy;
R⁶ is dimethylamino or dimethylaminocarbonyl; and
R⁷ is hydrogen.

15. The compound of Claim 14 selected from the group consisting of the following:
4-hydroxy-3-[(3,5-difluoro-6-[(3-dimethylaminocarbonyl)phenoxy]-2-methoxy-
pyridin-4-yl]oxy]benzamidine; and
4-hydroxy-3-[(3,5-difluoro-6-[(3-dimethylaminocarbonyl)phenoxy]-2-(2-methoxy-
5-ethoxycarbonyl)phenoxy]pyridin-4-yl]oxy]benzamidine.

16. A pharmaceutical composition useful in treating a human having a disease-state
characterized by thrombotic activity, which composition comprises a therapeutically effective amount
of a compound selected from the group consisting of the following formulae:
wherein

A is -C(R^{11})= or -N-;

Z^1 and Z^2 are independently -O-, -N(R^8)-, -S-, or -OCH_2-;

R^1 and R^3 are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro,

\[-(R^8)R^9, -(C(O)OR^8, -(C(O)N(R^8)R^9, -(C(O)N(R^8)CH_2C(O)N(R^8)R^9, -(N(R^8)C(O)N(R^8)R^9, \]
\[-(N(R^8)C(O)R^9, -(N(R^8)S(O)R^9, -(N(R^8)C(O)N(R^8)CH_2C(O)N(R^8)R^9, \]

R^2 is hydrogen; halo; alkyl; haloalkoxy; -OR^9; -(C(O)OR^9; -(C(O)N(R^8)R^9;

\[-(N(R^8))R^9, -(C(O)N(R^8)(CH_2)mC(O)OR^8 \text{ (where } m \text{ is } 0 \text{ to } 3); -(N(R^8))CH_2nC(O)OR^8 \text{ (where } n \text{ is} \]
5 or R² is aryloxy (optionally substituted by one or more substituents independently
selected from the group consisting of -OR⁸, -C(O)N(R⁸)R⁹, halo, alkyl, carboxy,
alkoxycarbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxycarbonylalkyl, carboxyalkyl,
aminocarbonylalkyl, (alkylamino)carbonylalkyl, (dialkylamino)carbonylalkyl,
(arylamino)carbonylalkyl, (aralkylamino)carbonylalkyl, alkoxycarbonylalkenyl, carboxyalkenyl,
aminocarbonylalkenyl, (alkylamino)carbonylalkenyl, (dialkylamino)carbonylalkenyl,
(arylamino)carbonylalkenyl, (aralkylamino)carbonylalkenyl, (hydroxyalkoxy)carbonyl,
(alkoxy)alkoxycarbonyl, (hydroxyalkoxy)alkoxycarbonyl, (alkoxy)alkoxycarbonylalkenyl,
tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazoliny1 (optionally substituted by alkyl));
or R² is piperazin-1-yl (optionally substituted by one or more substituents independently
selected from the group consisting of alkyl, carboxy, -C(O)N(R⁸)R⁹, carboxyalkyl,
alkoxycarbonyl, and alkoxycarbonylalkyl);
or R² is 1-piperazinyl (optionally substituted by one or more substituents selected from
the group consisting of alkyl, carboxy, -C(O)N(R⁸)R⁹, carboxyalkyl, alkoxycarbonyl, and
alkoxycarbonylalkyl);
or R² is piperidin-1-yl (optionally substituted by one or more substituents selected from
the group consisting of carboxy, -C(O)N(R⁸)R⁹, carboxyalkyl, alkoxycarbonyl, and
alkoxycarbonylalkyl);
or R² is (3,4)-piperidinoxy (optionally substituted by one or more substituents selected from
the group consisting of alkylcarbonyl, carboxy, -C(O)N(R⁸)R⁹, alkoxycarbonyl,
carboxyalkyl, alkoxycarbonylalkyl, and tetrazolylalkyl);
or R² is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the
piperidiny1 group is optionally substituted by one or more substituents selected from the group
consisting of alkyl, alkoxycarbonyl, carboxyalkyl, -C(O)N(R⁸)R⁹, alkoxycarbonylalkyl and
aralkyl));
or R² is 3-pyrrolidinylx0xy (optionally substituted by one or more substituents selected from
the group consisting of alkyl, aralkyl, amidino, 1-iminoethyl, carboxy, carboxyalkyl,
-C(O)N(R⁸)R⁹, alkoxycarbonyl and alkoxycarbonylalkyl);
R⁴ and R⁷ are independently hydrogen, halo, alkyl, nitro, -OR⁸, -C(O)OR⁸,
-C(O)N(R⁸)R⁹, -N(R⁸)R⁹, -N(H)C(O)R⁸, or -N(H)S(O)₂R¹²;
35 R⁵ is -C(NH)NH₂, -C(NH)N(H)OR⁸, -C(NH)N(H)C(O)OR¹², -C(NH)N(H)S(O)₂R¹²,
-C(NH)N(H)C(O)N(R⁸)R⁹, or -C(NH)N(H)C(O)R⁸;
R⁸ is halo, alkyl, haloalkyl, haloalkoxy, nitro, amino, ureido,
guanidino, -OR⁸, -C(NH)NH₂, -C(NH)NOH, -C(O)R¹⁰, -(CH₂)ₘC(O)N(R⁸)R⁹ (where m is 0 to
3), -CH(OH)C(O)N(R^8)R^9, -(CH_2)_mN(R^8)R^9 (where m is 0 to 3), -(CH_2)_mC(O)OR^8 (where m is 0 to 3), -NH(C(O)R^8, (1,2)-tetrahydro-pyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazoliny1 (optionally substituted by alkyl); each R^8 and R^9 are independently hydrogen, alkyl, aryl, or aralkyl; R^{10} is hydrogen, alkyl, aryl, aralkyl, 1-pyrrolidinyl, 4-morpholiny1, 4-piperaziny1, 4-(N-methyl)piperaziny1, or piperidin-1-yl; R^{11} is hydrogen, alkyl or halo; and R^{12} is alkyl, aryl or aralkyl; or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient thereof.

17. A method of treating a human having a disease-state characterized by thrombotic activity, which method comprises administering to a human in need thereof a therapeutically effective amount of a compound selected from the group consisting of the following formulae:
wherein

A is \(-C(R^{11})=\) or \(-N=\);

\(Z^1\) and \(Z^2\) are independently \(-O-,\) \(-N(R^8)-,\) \(-S-,\) or \(-OCH_2-;\)

\(R^1\) and \(R^3\) are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro,

\(-N(R^8)R^9,\) \(-C(O)OR^8,\) \(-C(O)N(R^8)R^9,\) \(-C(O)N(R^8)CH_2C(O)N(R^8)R^9,\) \(-N(R^8)C(O)N(R^8)R^9,\)

\(-N(R^8)C(O)R^8,\) \(-N(R^8)S(O)R^9\) or \(-N(R^8)C(O)N(R^8)CH_2C(O)N(R^8)R^9;\)

\(R^2\) is hydrogen; halo; alkyl; haloalkoxy; \(-OR^8,\) \(-C(O)OR^8,\) \(-C(O)N(R^8)R^9;\)

\(-N(R^8)R^9,\) \(-C(O)N(R^8)\(\text{CH}_2\)\(\text{C}(O)\)OR\(^8\) \text{ where } m \text{ is 0 to 3); -N(R^8)\(\text{CH}_2\)\(n\)C(O)OR\(^8\) \text{ where } n \text{ is}
1 to 3: \(\text{-N}(\text{CH}_2)_n\text{N}(\text{R}^8)\text{R}^9\)(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^8\) (where each \(n\) is 1 to 3); \(\text{-O}(\text{CH}_2)_p\text{C}(\text{O})\text{N}(\text{R}^8)\text{R}^9\) (where \(p\) is 1 to 6); \(\text{-N}(\text{R}^8)\text{(CH}_2)_n\text{C}(\text{O})\text{N}(\text{R}^8)\)(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^8\) (where each \(n\) is independently 1 to 3); morpholin-4-yl; 3-tetrahydrofuranoyl;

5 or \(R^2\) is aryloxy (optionally substituted by one or more substituents independently selected from the group consisting of -OR^8, -C(O)N(R^8)R^9, halo, alkyl, carboxy, alkoxy carbonyl, haloalkoxy, haloalkoxy carbonyl, alkoxy carbonylalkyl, carboxyalkyl, aminocarbonylalkyl, (alkylamino)carbonylalkyl, (dialkylamino)carbonylalkyl, (arylamino)carbonylalkyl, (aralkylamino)carbonylalkyl, alkoxy carbonylalkeny, carboxyalkeny, aminocarbonylalkeny, (alkylamino)carbonylalkeny, (dialkylamino)carbonylalkeny, (arylamino)carbonylalkeny, (aralkylamino)carbonylalkeny, (hydroxyalkoxy)carbonyl, (alkoxy)alcohol, (hydroxyalkoxy)alcohol, (alkoxy)alkoxyalcohol, (alkoxy)alkoxycarbonyl, (alkoxy)alcohol, haloalkoxy, and (1,2)-imidazolyl (optionally substituted by alkyl));

or \(R^2\) is piperazin-1-yl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, carboxy, -C(O)N(R^8)R^9, carboxyalkyl, alkoxy carbonyl, and alkoxycarbonylalkyl);

10 or \(R^2\) is 1-piperazinoyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, carboxy, -C(O)N(R^8)R^9, carboxyalkyl, alkoxy carbonyl, and alkoxycarbonylalkyl);

or \(R^2\) is (3,4)-piperidinyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, carboxy, -C(O)N(R^8)R^9, carboxyalkyl, alkoxy carbonyl, and alkoxycarbonylalkyl);

or \(R^2\) is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy carbonyl, carboxyalkyl, -C(O)N(R^8)R^9, alkoxy carbonyl alkyl and aralkyl);

20 or \(R^2\) is 3-pyrrolidinyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, aralkyl, amidino, 1-imino ethyl, carboxy, carboxyalkyl, -C(O)N(R^8)R^9, alkoxy carbonyl and alkoxycarbonylalkyl);

or \(R^4\) and \(R^7\) are independently hydrogen, halo, alkyl, nitro, -OR^8, -C(O)OR^8, -C(O)N(R^8)R^9, -N(R^8)R^9, -N(H)C(O)R^8, or -N(H)S(O)_2R^12;

35 \(R^5\) is -C(NH)NH_2, -C(NH)N(H)OR^8, -C(NH)N(H)C(O)OR^12, -C(NH)N(H)S(O)_2R^12, -C(NH)N(H)C(O)N(R^8)R^9, or -C(NH)N(H)C(O)R^8;

or \(R^6\) is halo, alkyl, haloalkyl, haloalkoxy, nitro, amino, ureido, guanidino, -OR^8, -C(NH)NH_2, -C(NH)NHOH, -C(O)R^10, -(CH_2)_mC(O)N(R^8)R^9 (where \(m\) is 0 to
-118-

3), \(-\text{CH(OH)C(O)N(R^8)R^9}\), \(-\text{(CH}_2\text{)}_m\text{N(R^8)R^9}\) (where m is 0 to 3), \(-\text{(CH}_2\text{)}_m\text{C(O)OR^8}\) (where m is 0 to 3), \(-\text{N(H)C(O)R^8}\), \((1,2)\)-tetrahydropyrimidinyl (optionally substituted by alkyl), \((1,2)\)-imidazolyl (optionally substituted by alkyl), or \((1,2)\)-imidazolinyl (optionally substituted by alkyl);

5 each \(R^8\) and \(R^9\) are independently hydrogen, alkyl, aryl, or aralkyl;

\(R^{10}\) is hydrogen, alkyl, aryl, aralkyl, 1-pyrrolidinyl, 4-morpholinyl,

4-piperazinyl, 4-(\(N\)-methyl)piperazinyl, or piperidin-1-yl;

\(R^{11}\) is hydrogen, alkyl or halo; and

\(R^{12}\) is alkyl, aryl or aralkyl;

10 or a pharmaceutically acceptable salt thereof.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

<table>
<thead>
<tr>
<th>IPC 6</th>
<th>C07D213/69</th>
<th>A61K31/44</th>
<th>C07D213/79</th>
<th>C07D213/74</th>
<th>C07D213/81</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C07D213/80</td>
<td>C07D213/82</td>
<td>C07D213/73</td>
<td>C07D401/12</td>
<td>C07D401/04</td>
</tr>
<tr>
<td></td>
<td>C07D241/18</td>
<td>A61K31/50</td>
<td>C07D239/52</td>
<td>A61K31/505</td>
<td>C07D401/14</td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>GB. A. 824 908 (MAY &amp; BAKER LIMITED) 9 December 1959 see the whole document</td>
<td>1</td>
</tr>
<tr>
<td>X</td>
<td>JOURNAL OF THE CHEMICAL SOCIETY, no. IV, 1960, pages 4525-4532, XP000573907 ASHLEY J.N. ET AL.: &quot;876. The search for chemotherapeutic amidines. Part XVI. Amidinoanilino-1,3,5-triazines and related compounds&quot; see compounds III, Vg and Vh see page 4531; table 2</td>
<td>1</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Date of the actual completion of the international search

28 June 1996

Date of mailing of the international search report

16.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2060, Tx. 31 651 epo nl, Fax (+31-70) 340-3016

Authorized officer

Hartmann, G
### INTERNATIONAL SEARCH REPORT

<table>
<thead>
<tr>
<th>Classification of Subject Matter</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPC 6</td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC

### FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>THROMBOSIS ET DIATHESIS HAEMORRHAGIC (TDHAAT), vol. 33, no. 2, 30 April 1975, pages 230-243, XP000574202 GERATZ J.D. ET AL.: &quot;Inhibition of urokinase by aromatic diamidines&quot; see page 235; table 2</td>
<td>1,16</td>
</tr>
</tbody>
</table>

---

| X        | JOURNAL OF MEDICINAL CHEMISTRY (JMCMAR), vol. 19, no. 5, May 1976, pages 634-639, XP000573915 GERATZ J.D. ET AL.: "Novel bis(benzamidino) compounds with an aromatic central link. Inhibitors of thrombin, pancreatic kallikrein, trypsin, and complement" see compounds 3, 4, 7 and 9 see page 636; table 1 | 1,16 |

---

**Special categories of cited documents:**

- **A** document defining the general state of the art which is not considered to be of particular relevance
- **E** earlier document but published on or after the international filing date
- **L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- **O** document referring to an oral disclosure, use, exhibition or other means
- **P** document published prior to the international filing date but later than the priority date claimed

**Date of the actual completion of the international search:**

**Date of mailing of the international search report:**

---

**Name and mailing address of the ISA**

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

**Authorized officer**

---

Form PCT/ISA/218 (second sheet) (July 1993)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US, A, 4 064 169 (HAMANO S. ET AL.) 20 December 1977 see claims 1, 4, 5; examples 3, 6</td>
<td>1</td>
</tr>
<tr>
<td>X</td>
<td>INDIAN JOURNAL OF CHEMISTRY, SECTION B (IJSDB, 037574699), vol. 27b, no. 1, January 1988, pages 38-42, XP000573780 CHAUHAN P.M.S. ET AL: &quot;Antiparasitic agents. Part VI. Synthesis of 1,2-, 1,3-, and 1,4-bis[4-substituted (aryloxy)]benzenes and their biological activities&quot; see compounds 9, 15 and 18 see page 39</td>
<td>1</td>
</tr>
<tr>
<td>X</td>
<td>EP, A, 0 518 818 (CIBA-GEIGY AG) 16 December 1992 see page 6, line 8 - line 27; claim 1</td>
<td>1</td>
</tr>
<tr>
<td>X</td>
<td>INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY (IJEBA, 00195189), vol. 31, no. 2, February 1993, pages 196-198, XP0000573781 CHAUHAN P.M.S &amp; IYER R.N.: &quot;Effect of new diamidines against Leishmania donovani infection&quot; see compounds 10, 13 and 16 see page 197</td>
<td>1</td>
</tr>
</tbody>
</table>
# INTERNATIONAL SEARCH REPORT

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
   because they relate to subject matter not required to be searched by this Authority, namely:  
   Although claim 17 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.:  
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:  
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:  

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  

### Remark on Protest

☐ The additional search fees were accompanied by the applicant’s protest.  
☐ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>GB-A-824908</td>
<td></td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-A- 52087135</td>
<td>20-07-77</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-B- 59022697</td>
<td>28-05-84</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE-A- 2643090</td>
<td>21-07-77</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR-A, B 2338039</td>
<td>12-08-77</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB-A- 1559983</td>
<td>30-01-80</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US-A- 4034010</td>
<td>05-07-77</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 2070796</td>
<td>12-12-92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU-A- 61977</td>
<td>29-03-93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-A- 5239008</td>
<td>17-09-93</td>
</tr>
</tbody>
</table>